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Abstract 
Bone tissue engineering is an interdisciplinary field which combines expertise 
from cell biology, material science, medicine and engineering and can help 
accelerate the process of developing scaffolds for bone repair. Furthermore, the rapid 
advancement of additive manufacturing (AM) technologies over the last decade, 
especially in the field of tissue engineering, has provided a platform for the 
fabrication of scaffolds with highly customised architecture (porosity, shape, 
mechanical properties etc.). In this project, AM technology was implemented 
together with new composite material comprising polycaprolactone (PCL) and 
bioactive glass (BG) for the production of bioactive composite scaffolds, with the 
ultimate aim of the production of an off-the-shelf composite bone scaffold product 
with superior bone regeneration capacity at affordable prices. Using melt extrusion, a 
form of AM technology, composite scaffolds made of PCL and BG particles were 
successfully fabricated with incorporation of up to 50 wt% of BGs in the PCL bulk. 
It was shown that composite scaffolds incorporated with 50 wt% of BG particles had 
greater in vitro bioactivity compared to that of PCL scaffolds containing 10 wt% of 
BG. Collectively the in vitro cell studies have shown that PCL/BG composite 
scaffolds could be osteoinductive. It was noted that the osteogenesis potential of 
composite scaffolds containing 50 wt% of BG particles were greater than that of 
composite scaffolds containing 10 wt% of BG particles. Further in vivo assessment 
on the osteoinductive potential of the scaffolds using a subcutaneous rat model 
showed that all scaffolds were well integrated and infiltrated with host tissue. This 
showed that these highly porous (> 75%) 3D scaffolds, with interconnected pores 
(~1500 μm) could act as a supporting structure for sustainable tissue growth for up to 
16 weeks. However, at the experimental endpoints, no mature/mineralised bone 
tissue was observed in any explants. This indicated that the PCL/BG composite 
scaffolds were not sufficiently osteoinductive after 16 weeks in vivo and that the BG 
incorporation should be increased to initiate this effect. 
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1.1 OVERVIEW 
Globally, musculoskeletal disorders are the second most common reason for 
consulting a general practitioner, accounting for 25% of total medical expenditure. In 
Australia, Arthritis and musculoskeletal conditions place a significant burden on the 
community, both economic and personal, costing ~$15 billion per annum [1]. For the 
past decade, the clinical outcome for treating and restoring full function of an injured 
limb has not been optimistic, for example, only 28% of patients with severe open 
fractures of the tibia were able to resume full function and hence return to 
employment [1]. Although bone has a remarkable ability to self-repair after an injury 
or fracture, these self-healing capabilities can be impeded beyond a certain critical 
size of defect and thus requires a platform to reunite and regenerate the fracture 
region. Currently, the clinical intervention for treating large bone defects include 
autografts (transplantation of patient’s own tissue/cells) or allografts (transplantation 
of another human tissue) [2, 3]. Despite exhibiting high healing rates, both autografts 
and allografts have associated disadvantages; approximately 20-30% of autograft 
patients experience donor site morbidity and more than 30% of allograft procedures 
are complicated by fracture, non-union and infection [2]. Therefore, effective 
treatments for large bone defects are urgently needed in the current clinical setting.  
Bone tissue engineering (TE) is an emerging interdisciplinary field which 
combines expertise from cell biology, material science, medicine and engineering 
and can help accelerate the process of developing an ideal scaffold which promotes 
bone regeneration, cell interactions, and new tissue in-growth [4]. Bone TE differs 
from standard drug therapies or permanent implant approaches such as the use of 
metallic devices, as the engineered scaffold may become integrated within the patient 
and gradually replaced by bone tissue over time, as it degrades thereby offering a 
permanent and specific alleviation of the diseased state or injury. However, not all 
engineered scaffolds are replaceable by host bone tissue, only resorbable scaffolds 
can be replaced by host bone tissue.  
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In bone TE, scaffolds have been used to provide a local environment for cells, 
serving as a temporary matrix to support/direct cellular growth/differentiation and to 
provide mechano-induction and ultimately support bone remodelling. Presently, 
scaffolds employed are polymer-based which can be osteoconductive (able to guide 
the reparative growth of the natural bone) but most of them lack osteoinductivity (the 
ability to induce differentiation of precursor cells into bone cells) and furthermore, 
are not high load bearing. Their tendency to creep and deform permanently under 
mechanical stresses require reinforcements, often using metallic plates in order to 
support the defected bone region during the early stages of bone healing. Hence, the 
field of bone TE is moving towards the development of composite scaffolds that 
have mechanically supportive structures that can resist creep failure whilst exhibiting 
osteoinductive capabilities. Other scaffold design considerations include the 
degradation properties, biocompatibility, intrinsic microarchitecture, porosity and 
suitable surface chemistry for guiding cellular behaviour and integration with host 
tissue. To further enhance the effectiveness of graft integration with the host defect; 
one can functionalise the scaffold surfaces with appropriate inorganic materials to 
allow better osseous tissue in growth, thus promoting full graft integration over long-
term implantation which is crucial in preventing implant loosening and further 
surgery. Alternatively, one can incorporate bioactive materials such as calcium 
phosphate (CaP)-based ceramics or bioactive glass (BG) into the polymer scaffolds, 
thereby creating a bioactive composite. These bioactive materials (CaP-based 
ceramic or BG) have the ability formed strong bone with bone when placed in the 
vicinity of host bone which is highly advantageous in bone TE [5].   
In this PhD project, I sought to create a new composite scaffold which 
combined polycaprolactone (PCL) with bioactive glass (BG). PCL is a synthetic 
polymer which has been widely used as a candidate for bone scaffold materials as it 
is FDA-approved and is mechanically robust with low melting temperature (~60°C), 
thus can be easily and cost effectively processed to any desired shape [6]. Although 
PCL scaffolds have been shown to be osteoconductive [7-10], they are not 
considered osteoinductive when used in isolation [11]. On the other hand, BG, which 
comprises a silicate backbone, was first developed in 1969 by Hench and co-
workers, and the original “recipe” for BG is commonly known as 45S5 Bioglass® 
[12]. These BGs are bioactive, that is they are able to form strong bonds with bone 
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when in close proximity through cycles of dissolution, poly-condensation and 
polymerisation of their ionic dissolution products [12-14]. Additionally, it has been 
widely reported that BG dissolution ions can stimulate osteogenesis [15] and have 
been shown to be osteoinductive in vivo [16, 17]. Clinically, 45S5 Bioglass® has 
been widely used for hard tissue regeneration for craniofacial, maxillofacial and 
periodontal applications due to its inherent bioactivity [12, 13]. Since then, many 
derivatives of 45S5 Bioglass® were developed and show different extents of 
bioactivity and osteogenic potential dependent on the glass composition. One such 
BG derivative that has gained a considerable amount of attention in the bone TE field 
is BG incorporated with the strontium (Sr) element. The development of Sr-
containing BG was inspired by the drug under the tradename of Protelos®, with the 
active ingredient of strontium-ranelate. Clinical use of this drug for postmenopausal 
osteoporotic woman has reported beneficial effects on bone metabolism by 
promoting bone formation and inhibiting bone resorption [18-20]. In conjunction, 
BG containing Sr have been shown to promote osteoblast proliferation and 
mineralisation in vitro [21-23], as well as promoting bone formation in vivo [24]. 
Although BGs possess favourable properties in promoting bone regeneration, 
unfortunately they are brittle. Therefore, it was anticipated in this PhD project that a 
combination of PCL and BGs, more specifically 45S5 Bioglass® and Sr-substituted 
bioactive glass (SrBG) could generate a composite scaffold material which combines 
the benefits of a polymeric matrix which could be easily manipulated into various 
shapes, would be mechanically robust and would have the benefits of BG inclusion 
which is highly osteoinductive and bioactive. This new composite material was 
hypothesised to potentially circumvent the need to use cells and growth factors; a 
current common practice for scaffolds in bone TE applications which incurs 
additional cost.  
Furthermore, the rapid advancement of additive manufacturing (AM) 
technologies over the last decade, especially in the field of tissue engineering [25], 
has provided a platform for the fabrication of 3D scaffolds with highly customised 
architecture (porosity, shape, mechanical properties etc.). However, the use of this 
technology for the fabrication of a composite material (PCL/BG composite in our 
case) is challenging. Most of the commercial 3D printing machines were originally 
designed for printing of non-composite materials. Due to the favourable properties of 
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3D scaffolds for bone regeneration [26], in this project, AM technologies were 
implemented to enable the production of bioactive composite scaffolds (PCL/BG 
composite), with the ultimate aim of providing a cell-free, growth factor-free 
composite bone scaffold product with superior bone regeneration capacity at 
affordable prices. 
 
1.2 PURPOSE OF RESEARCH 
The purpose of this research project was to develop and characterise a 
bioactive composite scaffold containing PCL and BG, more specifically 45S5 BG 
and SrBG, which may be suitable for treatment of bone defects. One way of 
achieving this goal was through the utilisation of 3D printing technology with the 
proposed bioactive composite (PCL and BGs). Once the scaffolds were fabricated 
and characterised, a series of in vitro and in vivo tests were required to verify the 
composite scaffold bioactivity and the ability to induce bone regeneration. Thus, the 
immediate first step was to test fabricated scaffolds’ toxicity, bioactivity and the 
ability of the scaffolds to induce osteoblast differentiation in vitro.  Following that, 
the in vivo effect of the fabricated scaffolds osteoinductivity (ability to induce 
differentiation of precursor cells into bone forming cells) was tested using a 
subcutaneous rat model. The findings of this research project have built a basic 
understanding of various factors which can affect the degradation behaviour, 
bioactivity and osteoinductivity of PCL/BG composite scaffold which serves to bring 
it nearer to potential clinical applications.  
 
1.3 SIGNIFICANCE OF RESEARCH 
The current clinical interventions for treating large bone defects are limited and 
far from ideal in most cases due to the high rate of post-surgery complications, such 
as donor site morbidity, non-union, and infections. From the clinical stand-point, 
bioactive composite scaffolds offer added advantages over current clinical treatments. 
For example, the use of bioactive composite scaffolds as bone substitutes can avoid 
donor site morbidity arising from autograft, where the patient must donate their own 
tissue to heal another defect bone site. Additionally, the bioactive composite 
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scaffolds can be easily sterilised and thus greatly reduce the risk of infections which 
might arise from allograft, where the patient receives tissue from another human 
donor. 
In clinical cases where growth factors such as bone morphogenetic protein-2 
(BMP-2) and BMP-7 are used to promote bone regeneration,  although effective [27], 
they involve huge cost due to the complex synthesis/isolation procedures [28]. The 
production of bioactive composite scaffolds is thus a more cost effective solution 
compared to the current therapies involving growth factors. In addition, in some 
clinical cases, the use of BMPs has caused undesirable heterotopic ossification which 
leads to irreversible impairment [28-30] due to the shortfall in delivery methods and 
uncontrolled suboptimal release of the growth factors [31]. On the other hand, to date, 
the clinical use of BGs [32, 33] or PCL (in isolation) [9, 34, 35] has not provoked 
unwanted side effects. Thus, at least in the mid-term, the risk of irreversible adverse 
reaction associated with the use of PCL/BG composite scaffolds can be considered 
much lower compared to that of BMPs. 
Additionally, in clinical cases involving a huge amount of bone removal due to 
cancer for example, autografting is not feasible as it is impossible to harvest enough 
bone to treat the bone defect; in such instances, AM technology can provide a highly 
viable alternative approach. The combination of AM technologies with the proposed 
bioactive composite material (PCL/BG) can enable the fabrication of osteoinductive, 
customised, anatomically-precise, patient-specific scaffolds using the patient’s own 
clinical scan data obtained through clinical computer tomography (CT) or magnetic 
resonance imaging (MRI). 
All in all, the production of bioactive composite scaffolds can potentially 
provide a cost effective alternative to the current clinical interventions for the 
treatment of critical-sized bone defects (a bone defect that will not heal over the 
natural lifetime without clinical intervention) with lower risk of infections and 
adverse reactions. This can in turn improve the quality of life for patients, and is the 
motivation behind this PhD project.  
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1.4 THESIS OUTLINE 
The overall aim of this PhD project was to develop a novel composite scaffold 
for bone regeneration using polycaprolactone (PCL) and bioactive glass (BG). To 
achieve the overall project aim, a research hypothesis stated in chapter 2 was 
developed for the assessment of composite scaffold osteoinductivity capability. The 
hypothesis was then tested through three individual but interrelated studies outlined 
in chapter 2, along with the individual study sub-aims.   
Before launching into the study outcomes, a comprehensive literature review of 
the research field will be presented in chapter 3. This chapter provides a concise but 
informative overview of human skeletal development and fracture healing. 
Following that, currently used AM technologies with emphasis on fused deposition 
modelling (FDM) and melt extrusion (ME) are described. The biomaterials 
commonly used for bone tissue engineering are also described, as well as the general 
mechanical properties and degradation behaviour of composite scaffolds. Finally, the 
ongoing research, both in vitro and in vivo using polymer-based/bioactive glass 
composite scaffolds for their osteoinductive and osteoconductive capabilities is 
described.  
In chapters 4, 5 and 6, the specific research findings are presented. Each of the 
chapters corresponds to independent but interrelated studies which were completed 
and published/submitted/in preparation for submission.  
Finally, in chapter 7, each chapter is collectively summarised and discussed 
(chapter 4, 5, and 6), followed by discussions surrounding the limitations of this PhD 
project, along with the recommended future work. Lastly, the overall conclusion 
drawn from the entire PhD project is presented. 
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2.1 HYPOTHESIS 
It was hypothesised that the combination of additive manufacturing (AM) 
technology with a new bioactive composite material concept, made of 
polycaprolactone (PCL) and bioactive glass (BG) could provide a custom-made, 
bioactive and osteoinductive scaffold. 
 
2.2 RESEARCH AIMS 
In this PhD project, three independent but interrelated studies were carried out 
to validate the bioactivity and osteoinductivity of the proposed PLC/BG composite 
scaffold. A brief overview of each study will be presented below, along with the 
respective aims. For the entirety of the project, all BGs (45S5 and SrBG) were kindly 
provided by Prof. Molly M. Stevens, Imperial College London, United Kingdom.  
 
2.2.1 (Study 1) Fabrication and in vitro characterisation of PCL, PCL/10-45S5 
and PCL/10-SrBG scaffolds for bone regeneration potential. 
In study 1, 45S5 and SrBG with particle sizes of < 38 µm were utilised. During 
this first study, due to the limitations posed by BG particle size and the hardware 
setup of the in-house melt extruder, only PCL-based composite containing 10 wt% of 
BG could be successfully fabricated into scaffolds which were then assessed for their 
in vitro bone stimulating properties. A comprehensive study was devised with the 
first aim (aim 1.1) being to fabricate the proposed bioactive composite scaffold 
(PCL/BG) using AM technology and ultimately (aim 1.4) assessing the osteogenic 
potential of the fabricated scaffolds in vitro. Aims 1.1-1.4 provide a brief description 
of the methodology undertaken to achieve this goal.  
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Aim 1.1: To optimise the fabrication and characterisation of PCL/BG 
composite scaffolds. 
Using the BGs (45S5 or SrBG, ≤ 38 µm particle size), 10 wt% of one of the 
two types of BG was first incorporated into the PCL bulk. The machine fabrication 
parameters (i.e. extrusion temperature, stage translational speed and nozzle size) for 
the fabrication of PCL and PCL/BG composites were optimised for the in-house melt 
extruder, a form of AM technology. The fabricated scaffolds’ properties such as 
porosity, topography, BG particle distribution and compressive Young’s modulus 
were characterised using micro-computer tomography (µ-CT), scanning electron 
microscopy (SEM) and biomechanical testing. 
In the following sub-aims (aim 1.2 to 1.4), three different scaffold groups were 
tested, as listed in table 2.1.  
 
Table 2.1 Summary of the scaffold groups utilised in study 1 with their respective 
abbreviation. 
 
Aim 1.2: Evaluation and comparison of PCL, PCL/10-45S5 and PCL/10-
SrBG scaffolds in vitro degradation behaviour using an established 
accelerated degradation model. 
An established model was utilised for the assessment of the scaffold in vitro 
degradation behaviour. The initial mass of the individual scaffolds were weighed and 
recorded, and then immersed in 5M NaOH for up to 7 days at 37ºC which 
represented an accelerated degradation situation. At pre-determined time-points, 
scaffolds were retrieved, washed, dried overnight and their final masses were 
measured and recorded. The percentage of mass loss for each scaffold was 
calculated.  The degraded scaffold surface morphology was also examined using a 
scanning electron microscopy (SEM). 
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Aim 1.3: Evaluation and comparison of the PCL, PCL/10-45S5 and PCL/10-
SrBG scaffolds in vitro bioactivity.  
To determine the in vitro bioactivity of scaffolds, which may be measured by 
the ability of scaffolds to form calcium phosphate-like precipitates on their own 
surfaces, scaffolds were immersed in serum-free culture media for up to 28 days at 
37ºC. At pre-determined time-points, scaffolds were retrieved, dried and examined 
using SEM for surface precipitates. Any precipitates formed were further analysed 
by Energy-dispersive X-ray spectroscopy (EDX) equipped on an SEM machine. 
Additionally, the immersion culture media was also collected, pH measured and 
analysed with Vista MPX Inductively Coupled Plasma - Optical Emission 
Spectrometer (ICP-OES) to quantify the concentration of Ca2+, PO4
3-, Si4+ and Sr2+ in 
the immersion media. 
 
Aim 1.4: Assessment of the in vitro osteogenesis potential of PCL, PCL/10-
45S5 and PCL/10-SrBG scaffolds. 
Sterilised scaffolds were seeded with MC3T3-e1 cells, and cultured in either 
non-osteogenic or osteogenic supplemented media (table 2.2). At pre-determined 
time-points, the cell/scaffold constructs were retrieved for the qualitative assessment 
of cell attachment and morphology using confocal laser scanning microscopy 
(CLSM), and SEM.  The scaffolds cytotoxicity was assessed using an MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cell proliferation and 
osteoblast differentiation were quantified using Quant-iT PicoGreen dsDNA assay 
and an alkaline phosphatase (ALP) activity assay, respectively. Additionally, the 
cell/scaffold constructs were stained with Alizarin red S for the assessment of matrix 
mineralisation. 
 
Table 2.2 In vitro cell culture experimental groups with the respective number of 
scaffolds used for each cell culture environment. 
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This study (study 1) has been completed and published.  
Poh, P.S.P., Hutmacher, D.W., Stevens M.M., Woodruff, M.A. (2013) Fabrication 
and in vitro characterisation of bioactive composite scaffolds, Biofabrication. 
5(4):045005. 
Details on this study are presented in depth in chapter 4.  
 
2.2.2 (Study 2) Biofabrication, scaffold characterisation and comparison of in 
vitro osteoinductive potential of PCL, PCL/CaP-coated, PCL/50-45S5 and 
PCL/50-SrBG scaffolds in static and dynamic culture environment. 
Our previous study (study 1) found that the bioactivity and osteogenic potential 
of the composite scaffolds (PCL/10-45S5 and PCL/10-SrBG) were not yet ideal. In 
order to achieve higher loading of BG particles within the composite system, the size 
of the BG particles was reduced from ≤ 38 µm to ≤ 20 µm, and the hardware design 
for the ME was slightly modified (detailed in Chapter 5, section 5.2.2). The 
combination of these modifications enabled the fabrication of PCL-based composite 
scaffolds containing up to 50 wt% of BG particles (45S5 or SrBG).  
In terms of polymer-based/BG composite scaffold bioactivity, it is generally 
accepted that composites containing higher amounts of BG would feasibly exhibit a 
greater degree of bioactivity, as indicated by the faster rate of CaP deposition in vitro 
[4, 36-42]. Therefore, in this study, PCL-based composite scaffolds containing 50 
wt% of BG particles (45S5 or SrBG) were fabricated, characterised and assessed in 
vitro for their bioactivity and osteogenesis potential.  
Routinely, calcium phosphate (CaP)-based biomaterial is used as a coating on 
metallic implants, as it supports bone growth along its surface when placed in the 
vicinity of host bone, improving the implants-to-bone integration, preventing 
implants loosening and potential resurgery [43-45]. Thus, coatings of polymer 
scaffolds with CaP have been widely explored [11, 46-50], and have been shown to 
promote osteoblast differentiation in vitro and/or bone formation in vivo [11, 51-54]. 
Additionally, the process involved in coating PCL scaffolds was relatively easier 
compared to the fabrication PCL/BG composite scaffold. Thus, in this study, PCL 
scaffolds were coated with CaP, and characterised and tested in vitro for osteogenesis 
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potential in comparison to PCL/BG composite scaffolds. Furthermore, generally, in 
vitro cell culture lacks dynamicity which mimics the in vivo environment leading to 
inefficient nutrient/waste transfer in a scaffold culture system. Thus, to further 
elucidate the effect of in vitro dynamic versus static culture environment on the 
osteogenesis potential of scaffolds listed in table 2.3, cell seeded scaffold constructs 
were also subjected to a dynamic culture environment. 
 
Table 2.3 Summary of the scaffold groups utilised in study 2 with the respective 
abbreviation. 
 
Listed below are the aims of this study (study 2) with brief overview of the 
methodology utilised to achieve each aim.  
 
Aim 2.1: Fabricate a PCL/BG composite scaffold containing 50 wt% loading 
of BG particles and characterising the fabricated scaffolds. 
Using the BGs (45S5 or SrBG, particle size ≤ 20 µm) as provided, 50 wt% of 
one of the two types of BG was successfully incorporated into the PCL bulk and 
fabricated into scaffolds using already optimised fabrication parameters for the in-
house ME. The fabricated scaffolds properties such as porosity, topography, BG 
particles distribution and compressive Young’s modulus were characterised using µ-
CT, SEM and biomechanical testing. 
 
Aim 2.2: Evaluation and comparison of the PCL, PCL/50-45S5, PCL/50-
SrBG and PCL/CaP-coated scaffolds in vitro degradation behaviour 
using an established accelerated degradation model. 
The method used for the evaluation of the degradation behaviour of the 
proposed scaffolds was similar to previously mentioned in section 2.2.1, aim 1.2.  
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Aim 2.3: Evaluation and comparison of the in vitro bioactivity of PCL/BG 
and PCL/CaP-coated scaffolds.  
The same method as in section 2.2.1, aim 1.3 was utilised to determine the 
scaffold in vitro bioactivity. To enable the evaluation of scaffold in vitro bioactivity 
for an extended period, the scaffolds were immersed in serum-free culture media for 
up to 10 weeks.  
 
Aim 2.4: Assessment of the in vitro osteogenesis potential of the fabricated 
composite scaffolds. 
In this study primary cells were used instead of a pre-osteoblast cell line (used 
in study 1). Sterilised scaffolds were seeded with ovine bone marrow stromal cells 
(BMSCs), and cultured in either non-osteogenic or osteogenic supplemented media. 
Ovine BMSCs were chosen over human BMSCs because the experimental design of 
the study required a high number of cells. If human BMSCs were used, potentially, 
cells from different donors may be needed, adding another variable factor into the 
experimental design. Therefore, ovine BMSCs originating from the same sheep were 
utilised throughout the experiment. At pre-determined time-points, the cell/scaffold 
constructs were retrieved for the qualitative assessment of cell attachment and 
morphology using confocal laser scanning microscopy (CLSM), and SEM. Cell 
proliferation was quantified using Quant-iT PicoGreen dsDNA assay, while 
osteoblast differentiation was evaluated through evaluation of osteoblasts specific 
gene expression determined using reverse transcription- quantitative polymerase 
chain reaction (RT-qPCR).  
 
Aim 2.5: Comparison of the effect of dynamic versus static culture condition 
for the in vitro osteoinductive potential of different scaffold materials.  
In a 3D culture system, the inefficient nutrient/waste transfer can be one of the 
limiting factors for in vitro osteogenesis. This was further explored in this study, 
where scaffolds were subjected to a dynamic culture environment using an 
established biaxial bioreactor after 7 days of pre-culture in either non-osteogenic or 
osteogenic media under a static environment. The cell morphology, proliferation and 
osteoblasts differentiation were assessed as described in aim 2.4 of this study.  
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Table 2.4 In vitro cell culture experimental groups corresponding to aim 2.4 and 2.5 
with the respective number of scaffold used for each cell culture environment.  
 
This study (study 2) has been completed and the manuscript is in preparation for 
submission. 
The detailed description of this study is presented in chapter 5. 
 
2.2.3 (Study 3)  Testing of osteoinductive capability of PCL/CaP-coated, 
PCL/50-45S5 and PCL/50-SrBG in vivo subcutaneous rat model.  
Study 2 showed that PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG 
scaffolds exhibited good in vitro bioactivity and/or upregulated the expression of 
osteoblast-related genes compared to PCL-only scaffolds. Thus, to evaluate the in 
vivo osteoinductive capability, PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG 
scaffolds were implanted into a subcutaneous rat model, which is an established 
approach for the evaluation of implants osteoinductive capability [11, 55, 56].  
In the past years, there is an accumulation of studies indicating that osteogenic 
differentiated cells along with the mineralised extracellular matrix (ECM) is the main 
driving force for promoting osteoinductivity or resorbable polymeric scaffolds [11, 
56]. Therefore, to evaluate if the use of cells can improve the scaffold 
osteoinductivity as compared to cell-free scaffolds, scaffolds were also seeded with 
ovine BMSCs and subjected to culture in osteogenic media prior to implantation.  
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Aim 3.1: Assessment of PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG 
scaffold osteoinductive capability in vivo using a small animal 
subcutaneous model.  
Scaffolds were implanted ectopically into nude rats to study their potential to 
induce bone formation when subjected to a non-favourable bone forming 
environment (Table 2.5). Through this subcutaneous model, any bone formed can be 
attributed to the scaffold’s inherent properties and/or to the cells seeded onto the 
scaffold, thereby giving an indication of biomaterial osteoinductivity. At 
experimental end-points, the scaffolds were explanted and processed accordingly for 
either paraffin or resin histology. For the paraffin-embedded samples, tissue sections 
were stained with haematoxylin and eosin for gross cell morphology. Using 
previously established and optimised immunohistochemistry procedures, the adjacent 
tissue sections were stained with specific tissue/ matrix markers (e.g. osteocalcin 
(OCN) and von-Willebrand Factor (vWF)) to enable further evaluation of the gross 
cell morphology observed in H&E stained tissue sections. Unlike paraffin histology 
where explants have to be decalcified for sectioning; resin histology enables the 
sectioning, staining and evaluation of calcified tissues. Thus, for the resin embedded 
samples, tissue sections were stained with Macneal’s tetrachrome-Von Kossa for the 
detection of any mineralised tissue. 
 
Table 2.5 Experimental groups for study 3 with the corresponding abbreviation and 
implant number.  
 
Study 3, an extended work from study 2 has been completed and a detailed 
description of this study is presented in chapter 6.  
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3.1 HUMAN SKELETAL SYSTEM 
An adult skeleton consists of approximately 206 bones, with slight variations in 
every individual. The human skeleton is divided into two portions, the axial skeleton 
and the appendicular skeleton. The bone that makes up the framework of the human 
skeleton system can be grouped into five different shapes, namely, long bone, short 
bone, flat bone, irregular bone and sesamoid bone. Generally, long and short bones 
are found in the appendicular skeleton, while flat and irregular bones occur in the 
axial skeleton. 
 
Table 3.1 Definition of bone shapes with respective examples. 
 
Bone consists of a heterogeneous combination of strong, stiff cortical bone 
with a functional low modulus trabecular bone. This unique architecture provides 
bone with high strength and high fracture toughness. Besides providing the skeleton 
with adequate load-bearing capacity, bone also protects the body’s internal organs 
from external forces and acts as homeostasis buffer through the storage of calcium 
and phosphate ions and regulation of key electrolytes in the blood [31]. 
Macroscopically, bone is a relatively stiff tissue. Microscopically, bone is a 
highly vascularised, complex and dynamic tissue [57], comprising cellular, organic 
and inorganic phases. The cellular phase consists of three different cell types, namely 
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osteoblasts, osteoclasts and osteocytes. These cells are essential for bone 
extracellular matrix (ECM) deposition and mineralisation as well as for modulating 
the complex mechanism of bone remodelling [58-60]. The ECM, where these cells 
reside, is comprised of organic and inorganic phases. The organic phase contains 
collagen and matrix proteins (i.e. glycoprotein, proteoglycans and sialoproteins). The 
inorganic phase is mainly made of hydroxyapatite (HA). These three phases are 
organised into highly structural and functional units known as osteons. These osteons 
are permeated with numerous voids and channels such as osteocyte lacunae, 
canaliculi and vasculature channels. Additionally, the complex hierarchical structure 
of human bone enables efficient distribution of mechanical load and activation of the 
bone remodelling processes via the strain-sensing mechanism of osteocytes [58, 59], 
thereby maintaining the optimal functionality of bone.  
 
3.2 BONE DEVELOPMENT AND REMODELLING 
During development, bones of the skull are derived from ectomesenchyme 
(neural crest cells) while other bones are derived from lateral plate mesenchyme 
[61].The development of human bone occurs via two distinct pathways, the 
endochondral ossification or intramembraneous ossification pathway. Most bones 
(e.g. long bone, short bone) develop through the endochondral ossification, with the 
exception of flat bones (e.g. parietal, occipital bone of the skull) which form through 
intramembraneous ossification.  
 
3.2.1 Endochondral ossification  
Endochondral ossification is the source of longitudinal bone growth via a 
cartilaginous model, formed through the condensation of mesenchymal cells. 
Mesenchymal cells differentiate into chondrocytes, resulting in the secretions of 
cartilage ECM components and development of periosteum, lining the outer surfaces 
of bone. Gradually, the primary ossification centre is established, leading to the 
deterioration of cartilage matrices, the in-growth of blood vessels and development 
of spongy bone and compact bone. The medullary cavity is formed as ossification 
continues, and the secondary ossification centres are established at the epiphyses, 
accompanied by blood vessel in growth. These centres of ossification gradually 
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replace the cartilage by laying down bone matrices, and eventually, hyaline cartilage 
remains only in the epiphyseal plates (between the primary and secondary 
ossification centre) and articular cartilage. The longitudinal growth of bone continues 
as long as the epiphyseal plates are still present. As skeletal maturity is reached, the 
epiphyseal plates become ossified, and compact bone (cortical bone) is formed on the 
diaphysis region [62].  
 
3.2.2 Intramembraneous ossification  
Intramembraneous ossification is the development of bone from connective 
tissue. It starts with a selected cluster of mesenchymal cells in the fibrous connective 
tissue membrane which differentiate into osteoblasts, forming an ossification centre. 
Non-mineralised bone matrix (known as osteoid) is secreted by osteoblasts within the 
fibrous membrane, forming calcified bone matrices, and trapped osteoblasts become 
osteocytes. The numerous calcified ossification centres fuse, accompanied by in-
growth of blood vessels, forming a network of trabeculae (trabecula of 
woven/spongy bone). Meanwhile, mesenchyme condenses on the external surfaces 
forming the periosteum. As these processes progress, trabeculae adjacent to the 
periosteum thicken, forming a plate of compact bone. The trabeculae persist 
internally (known as diploë), and their vascular tissue becomes red marrow. 
 
3.2.3 Bone remodelling  
Bone remodelling is a coupled, continuous and dynamic process which occurs 
throughout a human lifetime to repair and maintain the unique architecture of bone 
[57]. During bone remodelling (Figure 3.1), both healthy and unhealthy bones are 
actively resorbed by osteoclasts (bone resorption state) and are subsequently replaced 
by new, healthy bone formed by osteoblasts cells (bone formation state). This 
process of remodelling has been partly defined by Wolff’s law, which states that 
bone would respond and adapt in terms of mass and orientation to the magnitude and 
direction of imposed forces [63, 64]. However, Wolff’s law does not take into 
consideration the biochemical responses (detailed by Hadjidakis and Androulakis 
[65]) during the process of bone remodelling. 
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Figure 3.1 Bone remodelling cycle. 
 
3.3 FRACTURE HEALING 
Clinically, most fractures heal through a complex, but well-orchestrated process, 
known as secondary healing which involves the normal embryonic development 
process (endochondral and intramembranous ossification) coupled with the bone 
remodelling process [66]. To simplify the secondary healing processes, it is divided 
into 4 distinct stages. Whereby upon fracture, (1st stage) a hematoma forms at the site 
of injury accompanied by infiltration of inflammatory cells (i.e. macrophages and 
leukocytes) which secretes pro-inflammatory cytokines to initiate healing. The 
events of inflammation promotes (2nd stage) cell division and neovascularisation. In 
parallel, chondrocytes at the fracture site secretes new extracellular matrix (ECM), 
creating fibrocartilage that form the soft callus. With time, (3rd stage) the soft callus 
progress to form hard callus as the ECM mineralised through endochondral and/or 
intramembraneous ossification. And finally, the regenerating bone enters the 
remodelling stage (4th stage), where newly formed bone continue to remodel itself 
until a mechanically strong and highly organised bone structure is restored. However, 
in real life situation, these stages are a continuous process.  
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In cases where the patient experiences high risk of non-union or critical-sized 
large bone defects due to infections or trauma, healing and remodelling of the defects 
site by this process is compromised, and the only clinical intervention for treating 
these large bone defects is bone grafting. Bone grafting is a procedure where bone 
from elsewhere is extracted and implanted into the defect site, acting as a scaffolding 
to bridge the gap, thus promoting bone formation. In bone grafting, autografts 
(patient’s own tissue/cells) remain the gold standard, followed by allografts (another 
human tissue/cells) and in rare cases xenografts (other species animal tissue/cells) [2, 
3]. Despite exhibiting high healing rates, both autografts and allografts have 
associated disadvantages. Approximately 20-30% of autograft patients experience 
donor site morbidity and >30% of allograft procedures are complicated by fracture, 
non-union and infection [2]. Advantages and disadvantages of both autograft and 
allograft are listed in Table 3.2. 
 
Table 3.2 Advantages and disadvantages of autograft and allograft [3, 67] . 
 
Owing to the shortcomings associated with autografts and allografts, 
tremendous efforts have been made to find alternatives for bone grafting, leading to 
the evolvement of the tissue engineering (TE) field in the late 1980’s [68]. TE is an 
interdisciplinary field that applies the principles of engineering, life sciences and 
material sciences toward the development of biological substitutes which can restore, 
maintain, or improve tissue function or a whole organ [4]. However, public 
awareness on the relevance of TE to clinical therapies was only raised in 1997 
following the publication of a ground-breaking paper and widespread media attention 
regarding the growth of a human ear on athymic mice using a synthetic 
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biodegradable polymer seeded with chondrocytes [69]. Currently, tremendous efforts 
have been invested into the development of alternative treatments for various 
diseases, including cardiovascular, respiratory, musculoskeletal, eye, oral and renal 
diseases, via the TE route. Advancements in TE have proven useful in various 
clinical settings. For example, a patient who has suffered from floor-of-mouth cancer 
has successfully had the defected mandible replaced with an engineered mandible. 
Prior to transplantation, the patient served as his own-bioreactor as the engineered 
mandible was grown inside his lattissimus dorsi muscle (broadest muscle of the 
back) [70]. Although TE has proven to be useful in some clinical cases, the field still 
faces enormous challenges on many levels due to the complexity of the human body.  
 
3.4 BONE TISSUE ENGINEERING  
Bone TE is an interdisciplinary field that applies the principles of engineering, 
life sciences and material sciences toward the development of a resorbable 
substitutes which can be replaced by host bone tissue over time, thereby restoring the 
function of novel bone [4]. The current concept for bone TE involves the use of a 
polymeric scaffold in combination with biologically-derived factors (e.g. cells, 
growth factors). This is mainly because a polymeric scaffold (in isolation) only 
fulfills some of the mandatory requirements of a construct intended for bone 
regeneration. For example, resorbable polymeric scaffold could be (a) biocompatible, 
that is the materials must not demonstrate immunogenicity or cytotoxicity nor induce 
an unresolved inflammatory response, (b) bioresorbable, where the degradation rate 
is proportional to the re-growth rate of natural bone, (c) mechanically robust, 
corresponding to the intended application site, (d) highly porous (>80%) to allow cell 
penetration, tissue in-growth, vascularisation and nutrient delivery; thereby 
facilitating scaffold osteoconductivity (ability to direct in growth of host bone into 
the scaffold), (e) easily handled and processed to fit the specific defects in bone 
tissue, (f) easily sterilised to prevent infection  and (g) suitable for commercialisation 
[4, 26, 31, 71]. However, polymeric scaffolds (in isolation) are neither osteoinductive 
(ability to induce cells to differentiate into bone cells) nor bioactive (ability to form a 
strong and stable bond with host bone thereby improving osteointegration). 
Consequently, to improve the polymeric scaffold osteoinductivity and bioactivity, 
bioactive factors, either biologically-derived (e.g. growth factors and cells) or 
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synthetically-derived (bioactive materials, e.g. bioceramics and bioactive glass 
(BG)), are used in combination with the polymeric scaffold. The importance of 
scaffold osteoconductivity and osteoinductivity is illustrated in figure 3.2.   
 
Figure 3.2 (a) schematic illustration of a polymeric-based scaffold implanted into a 
critical-sized bone defect. In such large defects, complete bone regeneration can only 
be accomplished if the scaffolds exhibits both osteoconductivity and osteoinductivity 
capabilities. For example, (b) defects treated with autologous bone graft or scaffolds  
containing recombinant human-bone morphogenetic protein 7 (rh-BMP7), which are 
osteoinductive and osteoconductive, complete bridging of defect were observed after 
3 months as shown by X-ray imaging and microCT analysis. Conversely, in the 
scaffold only treatment group, whereby scaffold is osteoconductive but not 
osteoinductive, the defect did not bridge after 3 months but mature bone in-growth 
was shown at the periphery of the scaffold in contact with the host bone. Partially 
adapted from Reichert et al. [72].   
 
Using a slow degrading polymeric-scaffold as a carrier, bone morphogenetic 
proteins (BMPs) have been shown to improve bone regeneration in vivo [8, 72-74], 
and indicated a promising platform for the delivery of BMPs into the defect side. 
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However, this approach still involves a huge cost associated with the 
synthesis/isolation procedures of BMPs [28]. Additionally, it is still uncertain if this 
mode of BMP delivery method can cause adverse reactions such as those observed 
clinically, whereby BMPs were delivered to the defect site using a collagen sponge 
as a carrier [28-31]. On the other hand, to date, the clinical use of bioceramics or 
BGs [32, 33] has not provoked unwanted side effects. Thus, at least in the mid-term, 
the risk of irreversible adverse reactions associated with the use of bioceramics or 
BGs is much lower compared to that of BMPs. Therefore, in this thesis I opted to 
fabricate a fully synthetic scaffold comprising a resorbable polymeric matrix with 
bioactive materials as filler to achieve an osteoinductive and bioactive scaffold.  
In the following sections, the various methods of scaffold fabrication 
techniques will be outlined, with specific attention given to additive manufacturing 
(AM) technology, specifically, fused deposition modelling (FDM) and melt extrusion 
(ME) technique (section 3.5). Following that, the various types of synthetic polymers 
and bioactive materials currently used for the fabrication of scaffold intended for 
bone TE will be outlined (section 3.6).   
 
3.5 SCAFFOLD FABRICATION TECHNIQUES  
Fabrication of bone scaffolds can be achieved through conventional or additive 
manufacturing (AM) techniques. Conventional fabrication techniques include 
particulate leaching, phase separation, fibre meshing or bonding, melt moulding, gas 
foaming, membrane lamination, hydrocarbon templating, freeze drying, solution 
casting and emulsion freeze drying. These conventional techniques have a number of 
limitations. They usually lack the interconnected channel microstructure required for 
good tissue infiltration and vascular ingrowth and organic solvents are often required 
for processing (harmful organic solvents present a potential regulatory issue). These 
conventional methods are generally manual techniques providing inconsistent and 
inflexible processing procedures meaning the processes are not easily scalable to a 
highly reproducible manner [75]. Details on all conventional fabrication techniques 
will not be further discussed, only AM will be further elaborated on in the following 
section, and specifically, melt extrusion (ME) techniques will be discussed thereafter.  
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AM is a general term that covers a number of techniques that convert a digital 
blueprint of an item into a three-dimensional model. Solid Freeform Fabrication 
(SFF) and 3D-printing are both terms used to describe AM technologies. AM is the 
official industry standard term (ASTM F2792) for all applications of the technology, 
defined by Wohlers Associates as the process of joining materials to make objects 
from 3D model data, usually using a layer upon layer approach [76].  
Over the past two decades, AM technologies have been developed and 
commercialised with focus on the rapid manufacturing of prototypes for non-
biomedical applications. As the field of TE evolved, AM technologies have 
increasingly been adopted into it. These techniques (Table 3.3) offer precise control 
over the matrix architecture (size, shape, interconnectivity, branching, geometry and 
orientation), yielding biomimetic structures varying in design and even material 
composition. Through this, the ability to control mechanical properties, biological 
integration and degradation kinetics of the scaffolds has been advanced. AM 
techniques are easily automated and integrated with imaging techniques with the 
potential to generate patient and/or application-specific scaffolds [77]. A review by 
Melchels et al.[25], has extensively discussed AM for tissue and organ printing. 
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Table 3.3 Description of four common, commercially available AM techniques that 
are often employed in the preparation of tissue engineering scaffolds [25]. 
 
3.5.1 Principles of fused deposition modelling (FDM) and melt extrusion (ME) 
Typical AM processes use a number of methods to generate layer parameters 
that are translated into tool paths. The most common involve digitally slicing a 
computer aided design (CAD) models, digitally slicing computer tomography (CT) 
data (which can be obtained through patient’s medical scans) or direct generation of 
tool paths using mathematical algorithms. Using a CAD method provides the most 
hands-on approach as the final product can be visualised on a computer screen and 
easily manipulated. This also allows the generation of complex shapes with ease. 
Using CT data has the advantage of being the most physiologically accurate when 
generating patient specific implants. However, both these methods rely on pre-
defined generic algorithms to translate the data into layer parameters and ultimately 
tool paths. While powerful and enabling, these algorithms have the limitation that 
they lack precise control of the scaffold geometry and architecture. If this is an 
important requirement then direct mathematical generation of tool paths is the most 
flexible and tailorable approach. 
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Various types of code can be used to communicate tool paths. Most 
commercial systems rely on confidential approaches through which CAD models are 
sliced and transferred to instructional parameters. Most research laboratories rely on 
a script known as G-code. In all cases, the slices are formed on the x, y plane, with 
the z axis presenting a variable layer spacing or thickness. An AM machine follows 
tool path directions in the x, y axes to generate a deposition layer. Once the layer is 
complete, the z axis is incremented by one slice thickness and the process is repeated 
until the three dimensional model is generated. Deposited microfilaments are 
deposited as a raster (a grid of filaments) and sometimes a contour is used to better 
define the edge of the structure. Lay down patterns of filaments can be controlled and 
can be specified anywhere between 0° and 180° (with respect to x-axis). This angle 
of deposition is known as the Raster Angle (RA). 
Fused deposition modelling (FDM) is a particular type of AM process, which 
uses polymer filament (Figure 3.3). Many FDM systems contain two spools for the 
build and support materials respectively. The support material is used to maintain the 
scaffold structure and shape during the fabrication process. Once a polymer has been 
heated and deposited, it remains soft until it cools and the generation of complex 
overhanging shapes can lead to sagging and ultimate deformation of the final 
structure. This is where a support material is crucial. The support material is often 
water soluble facilitating easy removal. Driven by rollers, the polymer filaments are 
fed through the extrusion head and into the liquefier. The liquefier consists of heating 
elements which can be accurately controlled. The temperature is very important as it 
affects polymer flow characteristics; specific layer parameters are tailored to certain 
flow characteristics. As the filament passes through the liquefier, it is melted and 
extruded through a nozzle onto the collecting platform. 
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Figure 3.3 Schematic of a common setup for a fused deposition modelling (FDM) 
machine [78]. 
 
ME is another derivative of the AM process, which uses a melting chamber 
(Figure 3.4 a-b), thus allowing the use of different and exotic polymers. Medical 
grade polymers ordered in small custom batches can be fabricated into scaffolds 
using this method. The temperature of melting and extrusion chambers can be 
accurately controlled. Air pressure is applied to the inlet of the melting chamber to 
push molten polymer against the inlet of the extrusion chamber. This positive 
pressure gradient then allows a rotating screw within the extrusion chamber to collect 
molten polymer and exert a constant pressure along the length of the screw. Once the 
nozzle tip is reached the polymer is deposited onto the collecting platform. This 
rotating screw facilitates the mixing of molten polymer thereby producing a more 
homogeneous melt.  
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Figure 3.4 (a) photograph of ME machine and (b) Schematic of the extrusion 
chamber of ME machine. Adapted from Domingos et al.[79]. 
 
AM processes involve complex interactions between the hardware, software 
and material properties. When generating three dimensional models with FDM/ME, 
processing parameters must be carefully optimised to achieve the desired result. The 
processing parameters of FDM/ME with the respective effects are summarised in 
Table 3.4 [78, 80]. When fabricating a scaffold for bone TE purposes, changes to 
listed processing parameters in Table 3.4 can affect the scaffold structure by 
influencing the characteristics below: (Figure 3.5). 
 Road Width (RW); the diameter of the circular cross section of laid 
microfilament.  
 Fill Gap (FG); the edge-to-edge horizontal distance between adjacent 
filaments.  
 Fill Diameter (FD): the centre-to-centre horizontal distance between two 
consecutive filaments in the same layer.  
 Slice Thickness (ST): the vertical distance between the filament centre of 
adjacent layers.  
 Layer Gap (LG): the edge-to-edge vertical distance between layers of the 
same microfilament alignment.  
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Figure 3.5 (a) Cross-section of a typical FDM fabricated scaffold. (b) Three 
dimensional image of an FDM fabricated scaffold. Adapted from Zein et al.[78]. 
 
 
Table 3.4 Processing parameters of ME with their respective effects [78, 80]. 
 
3.6 SCAFFOLD MATERIALS 
As previously mentioned in section 3.4, scaffolds for bone TE are generally 
made of resorbable polymers. Although polymeric scaffolds can be osteoconductive, 
it generally lacks osteoinductivity and bioactivity. Thus, to fabricate a cell-free, 
growth factor-free scaffold which is osteoinductive and bioactive, bioceramics or 
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BGs are often incorporated into the polymer matrix as fillers. Table 3.5 aims to 
provide an overview of the materials most commonly used for fabrication of 
scaffolds intended for bone TE, and is by no means an exhaustive list.  
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Synthetic Polymer Crystallinity 
Predominant 
degradation 
mode/ route 
Degradation 
time 
Degradation 
products 
Polyglycolide [81] 
Semi-
crystalline 
Bulk, surface 
hydrolysis 
> 24 months Glycolic acid 
Poly(L-lactide) [81] 
Semi- 
crystalline 
Bulk, surface 
hydrolysis 
6 – 12 months Lactic acid 
Poly(D,L-lactide) [81] Amorphous 
Bulk, surface 
hydrolysis 
12 – 16 months Lactic acid 
Poly(L-lactide-co-D,L-
glycolide) [81] 
Amorphous 
Bulk, surface 
hydrolysis 
1 -  15 months 
(dependent on 
the blend) 
Lactic acid 
and glycolic 
acid 
Polycaprolactone [6] 
Semi-
crystalline 
Bulk, surface 
hydrolysis 
> 24 months Caproic acid 
Polyanhydrides [82] 
Semi-
crystalline 
Surface 
hydrolysis 
Days to years 
dependent on 
the blend 
Diacid 
monomers 
(dependent on 
the blend) 
Polyphosphazene [83] 
Semi-
crystalline 
Surface 
hydrolysis 
Weeks to 
months 
dependent on 
the side chain 
structure 
Phosphate, 
ammonia, and 
other products 
dependent on 
the side chain 
structure 
Poly(trimethylene 
carbonate) [84] 
Amorphous 
Surface 
enzymatic 
degradation by 
macrophages 
< 1 month 
Trimethylene 
carbonate and 
carbon 
dioxide[85] 
Polyhydroxyalkanoates 
[86] 
Semi-
crystalline 
Enzymatic 
degradation by 
microbial 
Weeks to years 
dependent on 
the 
environment 
Hydroxyacid 
Composite filler Example/ note (s) 
Degradation mode/ 
route 
Degradation / 
dissolution 
rate 
Calcium phosphate ceramics 
Hydroxyapatite (HA), 
α-/β- tricalcium 
phosphate (TCP) Dissolution of 
ceramics/bioactive 
glass by hydrolytic 
reaction releasing 
free ions into the 
surrounding [12, 13, 43] 
Weeks to 
months, but 
generally, the 
dissolution rate 
of amorphous 
HA/TCP > α-
TCP > β-TCP 
> crystalline 
TCP [43]. 
Silicate- based bioactive 
glass 
45S5 Bioglass® and its 
derivatives by addition 
of strontium, zinc, 
magnesium and etc. 
into the silicate-
network. 
Dependent on 
the 
composition of 
glass and 
degree of 
crystallinity [14]. 
Table 3.5 Commonly used polymer, calcium phosphate ceramics, and silicate-based 
bioactive glass for hard tissue engineering.  
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3.6.1 Polymers  
Natural and synthetic polymers have been investigated extensively for 
orthopaedic repair. However, most research has diverged from natural polymers to 
synthetic polymers. Natural polymers are mostly derived from an animal source, thus 
the material purity can differ from one batch to another and may cause zoonotic 
infections. In contrast, synthesis of synthetic polymers can be easily manipulated and 
the material impurities can be easily controlled. Consequently, the mechanical and 
physical properties of synthetic polymers can be correctly predicted and reproduced. 
Synthetic polymers which are widely used as scaffold materials include poly(lactide) 
(PLA), poly(glycolide) (PGA), polycaprolactone (PCL), polyanhydrides, 
polydioxanone and their copolymers and some are listed in Table 3.5. These 
synthetic polymers have variable melting temperature, glass transition temperature 
and degradation time [6]; dependent on the scaffold fabrication mode and intended 
application, one polymer may be favourable over another.  
For scaffolds intended for bone TE, it is preferable that the resorbable synthetic 
polymer possesses a relatively long degradation time (>12 months) to ensure that the 
scaffold retains its porous structural integrity, supporting the reparative in-growth of 
new bone from the adjacent host bone (osteoconductivity). Ideally, the scaffold 
should degrade at a rate compatible with bone tissue in-growth and maturation [6, 
87]. The concept of using a slow degrading porous scaffold with fully interconnected 
pores is illustrated in figure 3.6. For the production of such a scaffold, 
polycaprolactone (PCL), an aliphatic polyester, is a good candidate. PCL has a 
degradation time of >24 months and exhibits better rheological and viscoelastic 
properties compared to other aliphatic polyester [6]. Its low melting temperature (~ 
60°C) makes PCL easy to be fabricated into scaffold using a melt-based technique 
(e.g. ME) [6]. Additionally, PCL has been approved by the FDA for tissue 
engineering applications [88], thus will accelerate the transition of the yielded 
product into a clinical setting.  
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Figure 3.6 Schematic graph illustrating the interdependence of molecular weight loss 
and mass loss of a slow-degrading scaffold plotted against time. (a) Showing a 
scanning electron microscopy (SEM) image of scaffold fabricated via fused 
deposition modelling (FDM). (b-e) Showing a conceptual illustration of the bone 
formation process over time using a resorbable scaffold as a supporting matrix at the 
defect site. After implantation the scaffold is immediately filled with (c) haematoma 
followed by (d) vascularisation. (e) New bone is formed gradually within the 
scaffold. As the scaffold degrades over time, there is increased bone remodelling 
within the implant site until the scaffold pores are entirely filled with functional bone 
and vascularity (partially adapted from Muschler et al. [87]). The lower part of the 
figure shows the schematic visualisation long-term bioerosion processes of slow 
degrading synthetic polymer. Figure taken from Woodruff et al. [89]. 
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Although synthetic polymers have tailorable mechanical and degradation 
properties, it has been widely accepted that synthetic polymers, when used in 
isolation, have limited beneficial effects on bone formation, both in vitro [11, 90-95] 
and in vivo [11, 92, 96]. Thus, for bone TE purposes, the use of synthetic polymers in 
combination with bioactive materials such as CaP-ceramics and silicate-based BG 
are considered more favourable. It is widely believed that, with the optimal amount 
of bioactive materials incorporated within a polymer bulk, the composite is capable 
of creating an osteogenic environment to stimulate the differentiation of cells into 
bone-forming cells (osteoinductive), as well as promoting the development of a 
mineralised interface as a natural bonding junction between living tissues and non-
living scaffolds  (termed bioactive). Subsequently, encouraging regeneration of the 
defect sites with improved osseointegration between living bone and implant (direct 
structural and functional connection between living bone and implant [97]) .  
 
3.6.2 Bioactive materials 
Bioactive materials include calcium phosphate-based ceramics and bioactive 
glasses (BGs). This group of materials are known for their bioactivity, which is the 
ability to form a hydroxycarbonate layer at the material/fluid interface when exposed 
to biological fluid, thereby forming a strong bond to host bone [5, 98, 99]. Currently, 
the most common derivatives of bioactive materials include calcium phosphate 
(CaP)-based ceramics and bioactive glass (BG).   
 
Calcium phosphate (CaP) ceramics 
Inorganic calcium phosphate-based bioceramics include hydroxyapatite (HA), 
α- tricalcium phosphate (α-TCP), β-TCP, and biphasic calcium phosphate (BCP). 
The driving force for the research and development on these calcium phosphate-
based bioceramics is that they highly resemble the inorganic component of human 
bone. HA, when compared to TCP, has slower resorption rate and undergoes little 
conversion to a bone-like material after implantation [100]. Subsequently, BCP, a 
mixture of HA and α- or β-TCP was generated, of which their bioactivity and 
resorption kinetics are dependent on the HA: TCP ratio. An extensive review on the 
preparation, properties and application of BCP was published by LeGeros et.al. 
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[101]. All these bioceramics are non-toxic, biocompatible to the human body, and 
exhibit bioactive behaviour, that is they are able to interact with living tissue forming 
a strong bond to host bone. Consequently, they promote osteointegration (bonding of 
implants to host bone), as well as supporting osteoblasts adhesion and proliferation 
and are known to be osteoconductive (able to support new bone formation). In recent 
years, nano-sized HA (nHA) has gained considerable attention for bone TE 
applications due to their high resemblance to bone mineral composition, size and 
morphology [102, 103] . This may be attributed to the increased surface roughness 
and surface wettability which leads to enhanced protein adsorption and subsequently 
cell interaction with nHA surfaces in comparison to micro-HA surfaces  [104, 105]. 
Webster et al. [105, 106] have shown enhanced osteoblast adhesion [105], as well as 
enhanced osteoclast-like cell functions [106] on nHA sintered discs compare to 
micro-HA sintered discs. Similarly, Balasundaram et al. [107] has shown that the 
osteoblasts’ adhesion on nHA is comparable to that of arginylglycylaspartic acid 
(RGD)-functionalised micro-HA. However, the applications of CaP ceramics are 
limited due to their inherent brittleness and poor fatigue resistance. Thus, they are 
commonly used as fillers at non-load bearing sites and coatings for implants, but not 
in repairing large osseous defects. A recent review has extensively discussed the 
application of calcium phosphate-based bioceramics in biomedical applications 
[108].  
 
Bioactive glass (BG) 
The first generation of BG with a silicate composition was developed in 1969 
by Hench and co-workers, and is commonly known as 45S5 BG or Bioglass® (46.13 
SiO2 –2.60 P2O5 –24.35 Na2O– 26.91 CaO (mol%)). Over the years, various types of 
BGs with different chemical compositions have been developed. These BGs have 
additional elements incorporated into the silicate network such as magnesium, 
strontium, iron, boron, zinc, and copper [15, 71, 109].  
Generally, all BGs are bioactive, that is they are able to interact with living 
tissue forming a strong bond to bone and in some cases to soft tissue. The bioactivity 
of BG is driven by the continuous dissolution of the BG when in contact with 
physiological fluid, followed by condensation and polymerisation of the dissolution 
ions on the surface of BGs resulting in the formation of a crystalline carbonated-
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substitute HA-like layer on the surface of glass [5, 99, 110]. However, different glass 
composition can result in different extents of bioactivity due the change in BG 
dissolution rate. The BG dissolution rate is governed by the amount of glass network 
former or modifier within the silicate-glass network (table 3.6).  Consequently, this 
will affect the cell behaviour. One such BG derivative that has gained a considerable 
amount of attention in the bone TE field is the BG incorporated with strontium 
element. Clinically, oral administration of (Strontium) Sr-ranelate, under the trade 
name Protelos™, has been widely used in postmenopausal osteoporotic patients and 
shows good clinical outcomes [21, 111]. A long term study on treatment of 
postmenopausal osteoporosis with Sr-ranelate has shown that patient’s bone mineral 
density (BMD) was significantly increased, and data collected indicate some 
evidence of sustained anti-fracture efficacy [111]. In addition, numerous cellular 
studies have demonstrated that Sr-ranelate has a dual mode of actions in bone 
metabolism, in which it can promote bone formation by enhancing osteoblast 
replication, differentiation and mineralised matrix formation [112-114], while 
preventing bone resorption by inhibiting osteoclast activity [113, 115, 116], 
potentially through the disruption of the osteoclast actin-containing sealing zone 
[113]. Further studies show that the effect of Sr on osteoblast and osteoclast were, at 
least in part, mediated through the activation of calcium-sensing receptor [117-120]. 
Caverzasio et al. [112] indicated that Sr promotes osteoblastic lineage cells (MC3T3-
E1 and C3H10T1/2) replication by activating the CaSR, which in turn mediated the 
protein kinase C/protein kinase D (PKC/PKD) and or p38 signalling pathways. Study 
has demonstrated that Sr induced osteoblastic lineage cell (C3H10T1/2) 
differentiation by up-regulating the Runx2 transcriptional activity and 
phosphorylation, mediated by the Ras/mitogen-activated protein kinase (MAPK) 
signalling pathway [121]. On the other hand, Yang et al. [122] has shown that Sr 
induced osteobalstic differentiation of human umbilical cord MSCs through the 
activation of Wnt/β-catenin signalling pathway. As for the Sr effect on osteoclasts, 
Hurtel-Lemaire et al. [120] demonstrated that Sr promote rabbit osteoclasts apoptosis 
through the activation of CaSR, followed by stimulation of phospholipase C (PLC), 
which in turn activated the diacylglycerol (DAG)- PKCβII signalling pathway, 
leading to nuclear translocation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB).  
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On the basis of this, BG of various compositions containing strontium element 
(SrBG) were synthesised [21, 23, 24, 123-125]. It was shown that SrBG enhanced 
bioactivity compared to that of Bioglass®. In vitro studies using this SrBG indicated 
enhanced metabolic activity in osteoblasts while inhibiting osteoclasts activity [21] 
and could support normal cell attachment and proliferation. Further studies on these 
SrBGs indicated that addition of strontium or substitution of strontium in place of 
calcium in BGs, although minimal, could affect the glass physical properties [123]. 
However, cytotoxicity assessment showed that SrBGs were generally non-cytotoxic, 
could support osteoblasts proliferation and inhibit osteoclasts activities [21]. 
It is also well documented that selected dissolution ions of BG have a 
beneficial effect on bone cells and may have angiogenic potential. In vitro studies 
show increased secretion of vascular endothelial growth factors (VEGF) and in vivo 
studies suggest that BGs can stimulate neovascularisation [109, 126]. A list of 
selected ions with their corresponding effect on human bone metabolism and 
angiogenesis are listed in table 3.6. 
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Table 3.6 The effect of selected BG dissolution ions on human bone metabolism and 
angiogenesis.  Adapted from [15]. 
 
Ion Biological responses in vitro/ in vivo 
Glass network 
former/modifier 
[110] 
Silicate 
 essential for metabolic processes, formation and 
calcification of bone tissue [127, 128] 
 dietary intake of Si increases bone mineral density 
(BMD)[129] 
 aqueous Si induces HAp precipitation [130] 
 Si(OH)4 stimulates collagen I formation and 
osteoblastic differentiation  [131] 
Glass network 
former 
Calcium  
 favours osteoblast proliferation, differentiation and 
extracellular matrix (ECM) mineralization [132] 
 activates Ca-sensing receptors in osteoblast cells, 
increases expression of growth factors e.g. IGF-I or 
IGF-II [133, 134] 
Glass network 
modifier 
Phosphate 
 Stimulate expression of matrix Gla protein (MGP), a 
key regulator for bone formation[135] 
Glass network 
former 
Magnesium 
 stimulates new bone formation [136] 
 increases bone cell adhesion and stability (probably 
due to interactions with integrins)[137] 
Glass network 
former/modifier 
Boron 
 stimulates RNA synthesis in fibroblast cells [138] 
 dietary boron stimulates bone formation [139] 
Glass network 
former 
Strontium 
 shows beneficial effects on bone cells and bone 
formation in vitro and in vivo  [18, 19, 21, 140, 141] 
 promising agent for treating osteoporosis [19, 20] 
Glass network 
modifier 
Zinc 
 shows anti-inflammatory effect and stimulates bone 
formation in vitro by activation protein synthesis in 
osteoblasts [142, 143] 
 increases ATPase activity, regulates transcription of 
osteoblastic differentiation genes e.g. collagen I, ALP, 
osteopontin and osteocalcin [144] 
Glass network 
former/modifier 
Copper 
 induces differentiation of mesenchymal cells towards 
the osteogenic lineage [145] 
 stimulates proliferation of human  endothelial cells 
[146] 
 promotes synergetic stimulating effects on 
angiogenesis when associated with angiogenic growth 
factor FGF-2 [147] 
 significant amounts of cellular copper are found in 
human endothelial cells when undergoing angiogenes 
is [148] 
Glass network 
modifier 
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Similar to CaP ceramics, in the past few years, there is a paradigm shift of 
research into nano-sized BG (nBG) instead of the conventional micro-size BG [109, 
149, 150]. Furthermore, there is an increasing amount of research into the application 
of nBG as filler for composites intended for bone TE. This is because the use of nBG 
is expected to improve both the mechanical and biological properties of the 
composite compared to composite containing micro-size BG. Methods of nBG 
production can be found in Brunner et al.[149]. However, mixing of nBG instead of 
micro-size BG with polymer matrix presents great challenges due to higher 
occurrence of nBG agglomeration [149, 151]. Regardless of the size, all BGs have 
low mechanical strength and fracture toughness; thus, their applications are limited 
to non-load bearing defects or as coatings hence their combination with polymers to 
produce composites are very appealing. Extensive reviews on BGs and their 
applications have been recently published [15, 99, 110, 152]. 
 
3.7 SYNTHETIC BIOACTIVE COMPOSITES FOR BONE TE 
Bone is a complex, highly organised, natural occurring composite comprising 
cellular, organic and inorganic phases. Therefore, a hierarchical composite scaffold 
construct is inevitably more able to closely resemble the natural bone. Thus, to move 
toward the provision of an ideal bone substitute, material scientists must work in 
close collaborations with clinicians, cell biologist and engineers to devise an 
intelligent structural composite which may mimic the bone in terms of mechanical, 
biological and functional aspects. Materials listed in table 3.5 can be used in 
combinations to achieve a bioactive and osteoinductive composite. Additionally, by 
utilising AM technologies, an ideal bone scaffold may be fabricated which is 
mechanically robust and porous to allow tissue in-growth and vascularisation. 
Moreover, by the combination of different materials, one can alter the degradation 
rate of the composite to complement the bone regeneration rate. However, to date, 
researchers are yet to master the optimal process of fabricating an ideal bone scaffold 
which is osteoinductive, bioactive and mechanically robust with a controllable 
degradation rate.  
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3.7.1 Degradation behaviour of composite materials 
The degradation of synthetic polymers is through hydrolytic cleavage of ester 
bonds and enzymatic degradation facilitated by macrophages, with each polymer 
having a dominant degradation route. Erhan et al. have shown that poly(trimethylene 
carbonate) (TMC) and  copolymers of TMC with 10,  20 or 30 mol% of PCL were 
fully degraded in vivo in 28 days [153]. In another in vivo degradation study, Pego et 
al.[154] showed that TMC was completely degraded in < 1 month. However, TMC 
with 90 mol% of PCL only lost 6 wt% of its original mass after 1 year. These 
different degradation rates observed by Bat et al. [153] and Pego et al. [154] were 
due to the different degradation routes undertaken by TMC-PCL. TMC-PCL with a 
higher mol% of PCL following the degradation mode of PCL, where initial 
degradation is predominantly via hydrolytic cleavage of ester bonds [154]. Details of 
PCL degradation routes are described in Woodruff et al. [6]. Conversely, TMC-PCL 
with low mol% of PCL followed the degradation mode of TMC, where enzymatic 
degradation facilitated by macrophages predominates [153] as described by Zhu et 
al. [84]. Collectively, this demonstrates that the degradation rate of co-polyesters can 
be varied dependent on the blend. The addition of filler (i.e. CaP-ceramic and BG) 
into the vast variety of polyesters can further alter the composite degradation rate.    
Both the synthetic polymers and bioactive materials have considerably 
different rates/modes of degradation, as shown in table 3.5. To predict these synthetic 
composite degradation rates, one must not only consider degradation rate of the 
individual material, but also take into account the chemical/structural changes of the 
material during the compounding of composite, interfacial bonds between materials, 
volume ratio of matrix to filler and size and shape of filler. Moreover, for composites 
fabricated into scaffolds intended for bone TE applications, one must also take into 
account the scaffold fabrication methods and scaffolds’ architecture. All factors 
mentioned above will affect the composite material crystallinity and/or 
hydrophilicity/hydrophobicity, thereby, altering the composite degradation rate.  
Guarino et al.[155] showed that the combination of different materials in a 
composite system altered the material crystallinity, and subsequently, changed the 
composite degradation rate. It was observed that PCL crystallinity was highest in 
PCL/hyluronan, followed by PCL/hyluronan/bioactive ceramics particles and 
PCL/hyaluronan/PLA fibre composite. It was reflected in their degradation profile 
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that decreased PCL crystallinity resulted in a faster degradation rate, with the highest 
degradation rate observed for PCL/hyaluronan/PLA fibre composites. It was deduced 
that water can more easily diffuse into the loosely packed amorphous region compare 
to the crystalline domain. Therefore, PCL which possessed the lower degree of 
crystallinity were more susceptible to hydrolytic degradation, and thus, had a faster 
degradation rate.  
Chemical crosslinking of matrix components can also slow the degradation 
rate. As shown by Wang et al. [156], composites with inorganic fillers (i.e. nano-
sized bioactive glass (nBG)) and organic matrix (i.e. collagen-hyluronic acid-
phosphatidylserine), chemical crosslinking of the organic components greatly 
reduced the water swelling ratio, thereby deferring degradation.  
Generally, increased hydrophilicity of a composite system increases the 
composite degradation rate. It is well reported that incorporation of hydrophilic filler 
(i.e. BG or CaP ceramics) into a hydrophobic-polymer matrix, can accelerate the 
composite degradation rate [155, 157-163]. Furthermore, increased filler content or 
reduction in filler size (micro versus nano size) can increase the degradation rate 
[164] [40] [42] [93, 165]. The increased filler content and reduction in filler size 
within a polymer matrix increases the surface area available for hydrolytic 
degradation. Moreover, increased composite hydrophilicity increases water 
absorption into the interfacial space between matrix and filler via the composite 
bulk/surface imperfections (i.e. microcracks/microvoids) induced during composite 
scaffold processing. The continuous degradation of polymer matrix and filler 
particles enlarged the interfacial space, microcracks and microvoids within the 
composite bulk. This in turn increases water uptake/diffusion into the composite 
bulk, thereby accelerating degradation. 
Taken together, the degradation behaviour/trend of polymer-based composites 
is tuneable; however the interactions between different materials are very complex. 
To generate a composite with controllable degradation rate, one must fully 
understand the complex interaction between different materials, as well as the effect 
of various material processing methods, composite compounding and processing 
methods on the composite.   
The factors affecting the degradation of composite materials were discussed 
based on in vitro studies. In order to better estimate the degradation time of a 
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composite material, long term in vivo studies are essential. This is because the 
presence of cells, enzymes, physiological fluid etc. in vivo can contribute to the 
degradation of these composite materials. For example, Niiranen et al. [166] showed 
that the degradation of PLA and PLA/BG scaffolds was more pronounced in vivo 
compared to in vitro.  
 
3.7.2 Mechanical properties 
Mechanically, composites are considered anisotropic, where the mechanical 
properties vary with direction of loading. Generally, the inclusion of fillers into a 
polymer matrix can enhance the composite mechanical strength [161, 167, 168]. 
However, this is only true if filler loading does not exceed the upper threshold [93, 
165, 169, 170]. Misra et al. [165] showed that inclusion of < 20 wt% of spherical 
nBG into poly(3-hydroxybutyrate) (P(3HB)) matrix increased the composite 
Young’s modulus compared to pure P(3HB). Conversely, > 30 wt% spherical nBG 
loading decreased the composite Young’s modulus, but remained higher than pure 
P(3HB). Similar observations were reported by Vozzi et al. [169] and Mattioli-
Belmonte et al. [170], where inclusion of  > 11 wt% of carbon nanotubes (CNTs)  
into PLLA matrix [169] and > 20 wt% of CNT into PCL matrix [170], respectively, 
resulted in a rapid decrease in composite elastic modulus. 
The filler size can also affect the mechanical properties of the composite. As 
reported by Misra et al. [165] and Jo et al. [92], incorporation of nBG into a polymer 
matrix shown enhanced mechanical strength compared to a polymer matrix 
incorporated with micron-sized BG.  
The filler distribution and interfacial bonding between fillers and polymer 
matrix can also affect the composite mechanical strength. Liu et al. [94] who 
illustrated that surface modification of BG with diisocyanate (a short polymer chain) 
can improve the mechanical strength of Poly(L-lactide) (PLLA)/modified BG 
composite scaffolds as a comparison to unmodified PLLA/BG composite scaffold. It 
was observed that particle distribution was improved within the polymer matrix of 
modified BG/PLLA; thereby permitting efficient stress transfer between the matrix 
and filler, which would otherwise be compromised by the presence of particle 
agglomerations [94, 165]. Additionally, functionalisations of BG surfaces with 
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diisocyanate have enhanced the interfacial bonding between the BG with PLLA, 
which may be contributing to improved mechanical strength. Similarly, it has been 
shown that chemical crosslinking of the matrix component of nBG/Collagen-
hyaluronic acid-phosphatidylserine composite, greatly increased the composite 
elastic modulus compared to composites with non-crosslinked matrix [156].  
For a scaffold, it has been widely accepted that increased scaffold porosity 
leads to decreased mechanical strength [78, 167, 169-172]. The filament orientation 
also plays a role in determining the scaffold mechanical properties [173]. It was 
shown despite the same scaffold porosity (~61%), scaffolds with filament 
orientations of 0/72/144/36/108° have lower stiffness and yield strength compare to 
scaffolds with filament orientations of  0/60/120° [173]. Additionally, dependent on 
the scaffold fabrication techniques, scaffold mechanical strength varies [174, 175]. 
Jung et al. [174] illustrated that PLA/calcium metaphosphate (CMP) composite 
scaffolds possess higher tensile strength when prepared via their novel sintering 
process (0.72 MPa) compared to solvent casting methods (0.13 MPa). While Wu et 
al. [175] reported that 3D printed mesoporous BG (MBG) scaffolds have greater 
compressive strength (16.10 ± 1.53 MPa) compared to that of scaffolds prepared by 
polyurethane templating (0.08 MPa). 
Collectively, it is possible to tailor the composite scaffolds’ mechanical 
properties based on the requirement of intended application. However, to create a 
composite bone scaffold which is capable of promoting osteogenesis without 
additional cell and/or growth factor inclusion, one would also have to consider the 
inherent bioactivity of the composite scaffolds and how well it can promote 
osteogenesis.   
 
3.7.3 Bioactivity of polymer-based composite materials 
An obvious solution for the introduction of bioactive characteristic into 
polymeric material is the inclusion of bioactive materials such as CaP-based 
ceramics or BGs.  It has been well reported that with the right amount of bioactive 
material, polymer composites containing bioactive materials are able to display 
inherent bioactivity in vitro, as evidenced by the formation of CaP precipitates on the 
material surfaces when immersed in stimulated body fluid (SBF) or culture media 
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under physiological conditions [36-38, 40-42, 90, 91, 151, 176-180]. However, the 
extent of bioactivity (rate at CaP formation) of composites is dependent on the 
amount of bioactive material incorporated into the polymer bulk. Generally, 
composites containing higher amounts of bioactive material showed greater 
bioactivity and exhibited a faster rate of CaP precipitation [4, 36-42]. Additionally, it 
was also reported that inclusion of nano-sized bioactive material instead of micron-
sized bioactive material further accelerated the CaP formation rate [165]. The high 
content bioactive material with smaller bioactive material size, provide a larger 
surface area for the dissolution of bioactive materials when in contact with fluid at 
physiological conditions. This in turn accelerated the condensation and 
polymerisation of the dissolution ions on the surface of bioactive material, resulting 
in the faster rate of crystalline carbonated-substitute HA-like layer formation on the 
surface of composite.  
 
3.8 SYNTHETIC POLYMER-BASED BIOACTIVE GLASS COMPOSITE: 
IN VITRO AND IN VIVO EVALAUTION 
Both CaP-based ceramic and BG polymer-based composite scaffolds have 
shown tremendous potential in bone TE. However, for the purpose of this PhD 
project, hereon, the focus of review will be directed to the in vitro and in vivo 
evaluations of composites made of synthetic polymer and BG, in terms of their 
osteogenic behaviour.  
 
3.8.1 In vitro cell responses 
Cell attachment and proliferation, osteoblast differentiation and extra 
cellular matrix (ECM) mineralisation 
In most studies, in the absence of pre-treatment to decrease the hydrophobicity 
of  polymer surface, composites (synthetic polymer/BG composite) show better cell 
attachment with enhanced cytoskeletal extensions compared to pure polymer [90, 
174], as inclusion of highly hydrophilic BGs [12] into the synthetic polymer bulk 
increases the overall composite hydrophilicity, providing a more favourable surface 
for cell attachment. 
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Although different compositions of BG exert different effects on cells as listed 
in Table 3.6, regardless of BG composition, the incorporation of BG into the polymer 
bulk have been shown to accelerate the cell proliferation rate, especially at early 
time-points; as well as enhancing osteoblasts differentiation and matrix 
mineralisation when compared to polymer-only scaffolds [36-38, 41, 56, 90-92, 174, 
176, 181].  
Most studies show that increased BG loading can further enhance cell adhesion, 
cell proliferation, osteoblasts differentiation and matrix mineralisation [36, 90, 92]. 
For example, Kim et al. [90] incorporated 5 or 25 wt% of nBG (45S5 bioglass) into 
PLA and moulded the composite into a film by thermal compression. Cell 
proliferation and matrix mineralisation were greater in PLA/25BG > PLA/5BG> 
PLA [90]. Conversely, in some studies, no significant difference in terms of cell 
proliferation and matrix mineralisation were found between polymer-based 
composites loaded with different amounts of BG [38, 176]. Blaker et al. [38] 
incorporated 5 or 40 wt% of 45S5 BG into PDLLA bulk and porous scaffolds were 
fabricated using thermally-induced phase separation (TIPS). Cell proliferation and 
matrix mineralisation were greater on composites compared to neat PDLLA, 
however, no significant differences were observed between two composites. 
Similarly, Meretoja et al. [176] found no significant differences in osteoblast 
differentiation and mineralisation between poly(caprolactone-co-DL-lactide) (P(CL-
DLLA)) composites containing 5 or 10wt% of S53P4 granules (53% SiO2, 23% 
Na2O, 20% CaO, and 4% P2O5). In one of the studies it was shown that cell 
proliferation and osteoblast differentiation were lower in PDLLA/40wt%-45S5 
scaffolds group compared to PDLLA/5wt%-45S5 scaffold group [182]. Authors 
suggested that prolonged pre-treatment of the PDLLA/40wt%-45S5 scaffolds may 
prevent cytotoxic ion release, thereby improving the experimental outcomes. This is 
in line with the findings of Verrier et al. [183] who showed increased cellular 
adhesion to PDLLA/40wt%-45S5 scaffolds pre-treated in culture medium for 3 days 
prior to cell seeding compare to PDLLA or PDLLA/5wt%-45S5 scaffolds.  
All in all, it was found that composites containing BG had more beneficial 
effect on cells compared to pure polymer. However, the optimal amount of BG may 
vary between different studies and are not comparable as BG composition and size, 
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amount of BG incorporated into the polymer bulk, and scaffold fabrication 
techniques can all affect the outcomes. 
 
3.8.2  In vivo responses 
Angiogenesis 
The angiogenic effect of BG was shown to be more pronounced in BG-based 
scaffolds (e.g. BG loaded/coated sponges/meshes, porous BG scaffolds) (summarised 
in [126] and [152]) than in polymer-based composites incorporated with BG [184-
187]. In vivo studies which investigated the angiogenic potential of polymer/BG 
composites with varying BG content [184-187], only Day et al. [186] (incorporated 
0.625 wt% of 45S5 into PLGA matrix) and Gerhardt et al. [187] (incorporated 
20wt% of 45S5 into PDLLA matrix) reported greater tissue infiltration and higher 
blood vessel formation in polymer/BG scaffolds compared to polymer scaffolds 
alone. Interestingly, Day et al. [186] found that the blood vessel in-growth for 
compression-moulded BG composite foams was significantly higher than the 
corresponding unfilled polymer scaffolds. However, the same authors found no 
difference in the number of formed blood vessels for the same scaffolds prepared by 
thermally-induced phase separation (TIPS) technology. Collectively, the findings of 
these studies indicated that BG content, scaffold fabrication technique, morphology 
and geometry of the scaffolds can influence the complex mechanism of angiogenesis, 
subsequently affecting the angiogenic responses of the composite construct in vivo 
[126, 186, 188].  
 
Osseointegration: Interfacial bonding of polymer/BG implant to host bone 
Generally, it is accepted that BG can promote the formation of a strong bond 
with bone due to its inherent bioactivity [5, 13] and this property has been detailed in 
[12]. Likewise for polymer/BG composite, it was illustrated by Marcolongo et al. 
[189] that interfacial bond strength of polysulfone/BG composites (80: 20 wt%) with 
host bone tissue was significantly higher than polysulfone control groups (12.4 vs. 
5.2 MPa). However, no significant difference was found between composite and 
polysulfone groups in terms of bone contact at the implant surface. To date, to our 
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best knowledge, there is a lack of quantitative studies on interfacial bonding strength 
between polymer/BG composite with host bone.    
 
Osteoinductivity: ectopic mineralisation and bone formation 
Soft tissue animal models can be used to assess the osteoinductivity of any 
given biomaterial. Under the soft tissue environment, any mineralised tissue/mature 
bone formation observed can be directly attributed to the biomaterial’s inherent 
osteoinductive capability. However, in cases where a biomaterial is implanted in 
combination with additional factors, such as cells or growth factors, results should be 
carefully interpreted, as the mineralised tissue/ mature bone formation may be due to 
the influence of these additional factors.  
Several studies on soft tissue implantation of BG-only paste/scaffolds showed 
the ability of these scaffolds to form mineralised tissue and bone [16, 17]. 
Conversely, studies on subcutaneous implantation of polymer/BG composite 
film/scaffolds into small animal models showed limited mineral formation and, to 
our best knowledge, no mature bone formation was reported [56, 182, 190]. In one 
study, tissue in-growth was observed in the composite disk (P(CL-DLLA)/S52P4 BG 
composite – 50 or 70 wt% of BG) but not in neat polymer matrices. However, after 6 
months, no apparent bone formation was detected in any of the groups [190].   
Using porous scaffolds, similar outcomes were also reported by Gomide et al. 
[56] and Yang et al. [182] with PVA/BG (50 wt% BG, 70SiO2–30CaO (wt%)) and 
PDLLA/45S5 (5 or 40 wt% BG), respectively. Notably, 8 weeks post-implantation, 
Gomide et al.[56] showed that composite scaffolds seeded with differentiated MSCs 
showed some degree of osteoid tissue formation which was not observed  in cell-free 
scaffolds and scaffolds seeded with non-differentiated MSCs. Therefore, 
differentiated MSCs may be the major contributing factors to the observed osteoid 
formation. Authors also showed that in the cell seeded composite scaffold constructs, 
necrosis of cells was observed in the central region of the scaffolds. Unfortunately, 
no in depth discussion was presented by the authors with regards to the cell necrosis 
observed. In both studies [56, 182], the extent of vascularisation, which is a crucial 
factor in determining the rate of tissue remodelling, matrix mineralisation and bone 
formation within the scaffold [66, 191], was also not investigated.  
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Bone regeneration rate (bone defect animal model) 
In contrast to in vivo animal studies conducted using soft tissue models for the 
assessment of polymer/BG composite osteoinductivity, a greater consensus was 
generally observed in animal studies conducted using a bone defect model for the 
polymer/BG composite osteoconductivity. Generally, it was found that polymer/BG 
composites had an accelerated bone regeneration rate compared to the respective 
polymer-only film/scaffold [92, 192, 193].  Using a porous polyamide/BG (25wt% 
BG) scaffold obtained via solvent casting/porogen leaching technique, Su et al. [192] 
showed that polyamide/BG composite scaffolds had greater newly formed bone 
compared to polyamide-only scaffolds.  
In studies using non-porous polymer/BG composite [92, 193], Jo et al. [92] 
revealed that defects covered with PCL/BG composite membrane (20wt% of BG)  
have thicker and more bone growth compared to untreated defects and PCL 
membrane groups. Furthermore, histomorphometric analysis showed that the 
regenerated bone area of the composite group was significantly higher than the 
untreated defect and PCL membrane group. No significant difference between the 
untreated defect group and PCL membrane group was detected. Thus, the study 
indicated that incorporation of BG into PCL bulk could enhance the rate of bone 
regeneration [92]. In another study, where commercially available S53P4 BG (53 
SiO2, 23 Na2O, 20 CaO and 4 P2O5 (wt%)) was incorporated into fiber-reinforced 
composite (FRC) implants, it was shown that the biological behaviour of FRC and 
FRC/BG composite implant was comparable to that of a titanium implant after 4 and 
12 weeks of implantation. Furthermore, FRC/BG implants showed increased peri-
implant osteogenesis and bone maturation compared to FRC and titanium implant 
groups [193]. 
Collectively, to date, soft tissue implantation of cell-free polymer/BG 
composite scaffolds tested have not shown mineralised tissue/ mature bone formation. 
This indicates that the implanted PCL/BG composites are not sufficiently 
osteoinductive. However, when implanted in close vicinity to host bone (bone defect 
animal model), polymer/BG composites have demonstrated significant 
improvements in bone formation and regeneration at the defect site when compared 
to polymer-only constructs. This indicates that, polymer/BG composites possess 
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improved bone regeneration capability compared to polymer-only constructs. This 
may be because in a bone forming environment, the free ions released from the 
dissolution of BG has a synergistic effect with the surrounding host bone 
microenvironment, thus accelerating cell proliferation, differentiation, tissue 
remodelling, matrix mineralisation and bone regeneration.  
 
3.9 CONCLUSIONS 
Over the last two decades, many bone substitute materials have been evaluated 
with the intention of replacing autografts or allografts. The materials explored by 
scientists include bioactive ceramics or glasses, natural or synthetic polymers and 
their composites. Ideally, the engineered materials are osteoinductive, 
osteoconductive, capable of osteointegration, have controlled resorption rates and 
can be replaced by the body’s own newly regenerated bone over time [26, 31]. 
Current challenges in bone TE include the generation of materials which can fulfil 
both the mechanical and biological context of real bone tissue matrix and support the 
vascularisation of large tissue constructs. The incorporation of BG into 
biodegradable polymers with the use of AM technologies presents a promising step 
towards the development of improved biomaterials for bone regeneration and 
engineered scaffolds for TE applications. To date researchers are yet to come up with 
a bone scaffold with ideal osteoinductivity, osteoconductivity, bioactivity, robust 
mechanical strength and controllable degradation properties. Often, when high 
bioactivity is achieved, the mechanical strength is compromised. Moreover, in order 
to realise a clinically viable product from already established synthetic polymer/BG 
composites, more extensive and comprehensive in vitro and in vivo evaluations are 
required.  
In the following chapters 4, 5 and 6, the potential of such polymer-based 
scaffolds containing BG were fabricated utilising AM technologies, specifically, melt 
extrusion. Subsequently, the scaffolds were assessed in vitro (chapter 4 and 5), 
progressing to in vivo evaluation of osteoinductivity potential using a rat 
subcutaneous model (chapter 6).  
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Chapter 4: (Study 1) Fabrication and in 
vitro characterisation of PCL, 
PCL/10-45S5 and PCL/10-SrBG 
scaffolds for bone regeneration 
potential 
This study has been completed and published. 
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vitro characterisation of bioactive composite scaffolds, Biofabrication. 5(4):045005. 
 
4.1 INTRODUCTION 
Bone has the unique healing potential for self-repair after an injury. These self-
healing capabilities can be impeded beyond a critical size of defect and thus requires 
a platform to reunite and regenerate the fracture region. Scaffolds have been used to 
provide a local environment for cells, serving as a temporary matrix to support/direct 
cellular growth/differentiation and to provide mechano-induction and ultimately 
bone remodelling. Presently, scaffolds employed are polymer-based which lack 
osteoinductivity, bioactivity and are not high load bearing. Their tendency to creep 
and deform permanently under mechanical stresses require reinforcements using 
metallic plates in order to support the defect region during the early stages of bone 
healing. Hence, the field is moving towards the development of composite scaffolds 
that have mechanically supportive structures that can resist creep failure. Other 
scaffold design considerations include material type and their associated degradation 
properties, biocompatibility, intrinsic microarchitecture, porosity and suitable surface 
chemistry for guiding cellular behaviour and integration with host tissue. To further 
enhance the effectiveness of graft integration with the host defect; one can 
functionalise the scaffold surfaces with appropriate inorganic materials to allow 
better osseous tissue ingrowth, thus promoting full graft integration over long-term 
implantation which is crucial in preventing loosening and further surgery. 
Alternatively, one can incorporate bioactive materials such as calcium phosphate 
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(CaP)-based ceramics or bioactive glass (BG) into the polymer scaffolds, thereby 
creating a bioactive composite. This is because such bioactive materials (CaP-based 
ceramic or BG) have the ability to form strong bond with bone when placed in the 
vicinity of host bone [5].  These bioactive materials have been widely used in clinical 
settings to repair hard tissues in a variety of craniofacial, maxillofacial and 
periodontal applications due to their inherent bioactivity [12, 13]. However, they are 
brittle [14], thus limiting their application in load bearing/tension applications. 
In this study, polycaprolactone (PCL) was incorporated with one of 2 types of 
BG, to produce a composite and was used to fabricate composite scaffolds by the 
method of melt extrusion (ME). PCL is a suitable candidate for bone implants due to 
its good rheological and viscoelastic properties compared to other synthetic polymers 
[6]. Its low melting temperature (approximately 60°C) makes PCL easy to be 
fabricated into 3D constructs [6]. Additionally, PCL has been approved by the FDA 
for tissue engineering applications [88], thus will accelerate the transition of the 
yielded product into a clinical setting. However, PCL is inherently hydrophobic and 
lacks bioactivity. Therefore, to increase the bulk hydrophilicity and bioactivity of 
PCL, BG was incorporated to provide a composite scaffold. As reported by Li et al. 
[194], incorporation of BG into the polymer bulk increases the composite material 
hydrophilicity and bioactivity [194].  
In this study, two different types of BG were used; (1) 45S5 Bioglass® (45S5) 
containing 46.13 SiO2 –2.60 P2O5 –24.35 Na2O– 26.91 CaO (mol%) and (2) 
strontium-substituted bioactive glass (SrBG) containing 46.13 SiO2 –2.60 P2O5 –
24.35 Na2O– 26.91 (3SrO:1CaO) (mol%) [141]. BGs have been shown to promote 
bone formation in vitro and in vivo [21, 23, 24, 152, 195]. It has been reported that 
SrBG has enhanced potential in bone regeneration compared to 45S5 bioglass [21] as 
it is known that strontium is an important trace element in human bone. Sr2+ was also 
found to induce osteoblast activity by stimulating bone formation and reducing bone 
resorption [19, 196]. 
Additive manufacturing techniques enable the fabrication of biomaterials into 
scaffolds with 100% pore interconnectivity, controlled porosity and controlled 
geometrical structure [25, 197]. This technology has provided a promising platform 
for the development of so-called off the shelf as well as patient-specific scaffolds as 
the next generation of treatment options for bone regeneration as reported by various 
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research groups across the world [198-204]. In this study, the proposed bioactive 
composite material will be amalgamated with 3D printing technology, specifically 
ME for the production of bioactive composite scaffolds. The fabricated scaffolds 
were characterised for scaffold morphology, degradation behaviour and in vitro 
bioactivity. Subsequently, scaffolds were subjected to in vitro studies for the 
assessment of the scaffolds’ cytotoxicity, cell proliferation, osteoblast differentiation 
and extent of matrix mineralisation. 
 
4.2 METHODS AND MATERIALS 
4.2.1 Preparation of PCL/BG composite material  
45S5 or SrBG were incorporated into the PCL bulk by fast precipitation into 
excess ethanol [205]. Briefly, 20 g of PCL pellets (CAPA 6500, Perstorp, United 
Kingdom) were dissolved in 200 ml of chloroform (MERCK Millipore, Australia) at 
room temperature to obtain a 10% (w/v) PCL solution with relatively low viscosity 
for easy mixing of BG particles. Then, 10 wt % of BG relative to the PCL mass was 
added into the PCL solution and stirred until a homogenous mixture was achieved. 
The PCL/BG solution mixture was then precipitated into 5-fold excess of 100% 
ethanol (MERCK Millipore, Australia). The solid PCL/BG composite was then 
isolated and air dried.  
 
4.2.2 Scaffold fabrication  
All scaffolds were fabricated using ME based AM technology [79] (refer to 
figure 3.4 of melt extruder in Chapter 3). Briefly, PCL, PCL/10-45S5 or PCL/10-
SrBG composite was loaded into the material reservoir and the material was melted 
by setting the heating inductor coils to the desired temperature. PCL scaffolds were 
fabricated at 100°C while PCL/10-45S5 and PCL/10-SrBG were fabricated at 110°C. 
As air pressure was applied, molten material moved towards the rotating screw 
chamber and was extruded through the nozzle tip aided by the rotational movement 
of the screw. All scaffolds were designed and fabricated with a lay-down pattern of 
0-90°, filament gap of 2 mm and layer thickness of 0.4 mm. All scaffolds were 
fabricated using a 21G nozzle. Scaffolds of 50 × 50 × 2.4 mm were fabricated, and 
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then cut to 4 × 4 × 2.4 mm. The scaffolds measuring 4 × 4 × 2.4 mm were used for 
all in vitro studies. 
 
4.2.3 Surface morphology, porosity, and BG distribution  
The surface morphology of the fabricated scaffolds was examined using SEM 
(Quanta SEM-FIB) at 10 kV after gold sputter-coating. Scaffolds’ porosity and the 
distribution of BG particles within the scaffolds were examined using μCT 40 
scanner (Scanco Medical, Brüttisellen, Switzerland) at a voxel size of 6 µm. Samples 
(n = 8) were evaluated at a filter width of 1.0 pixels,  filter support of 2.0 pixels and 
lower threshold of 2% for PCL elements, 9% for 45S5 and SrBG elements.  
 
4.2.4 Compressive Young’s modulus  
Mechanical compression tests were conducted using an Instron 5848 
microtester fitted with a 500N load cell (Instron, Australia).  Scaffolds (n = 6) were 
subjected to 10% compression at a rate of 1 mm min-1 and the compressive Young’s 
modulus of the scaffolds was determined using the initial linear portion of the  stress 
versus strain data. 
 
4.2.5 Accelerated in vitro degradation  
Degradation of scaffolds (n = 8) was studied using an accelerated hydrolysis 
reaction as described by Lam et al. [161]. Each scaffold was immersed in 1ml of 5M 
sodium hydroxide (NaOH) (Sigma-Aldrich) and maintained at 37°C. Scaffolds were 
removed at daily time-points for up to 7 days. At designated time-points, scaffolds 
were rinsed with dH2O, and dried under vacuum for 48 hours before further 
evaluation. The percentage of mass loss from each individual scaffold was 
determined using the following equation: 
 × 100% 
The mass of scaffolds was measured using an electronic balance with 0.1 mg 
resolution. At respective time-points, scaffold morphology and surface topography 
were subjected to scanning electron microscopy (SEM) imaging.  
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4.2.6 Scaffolds ion release profile  
Scaffolds were immersed in α-MEM (Life Technologies) at 37°C for a period 
of 4 weeks.  Each scaffold (dimensions 4 × 4 × 2.4 mm) was immersed in 6 ml of α-
MEM. At 1, 2 and 3 days, 1, 2, 3, and 4 weeks, the immersion media was collected 
and the scaffolds were retrieved. The concentration of Ca2+, PO4
3-, Si4+ and Sr2+ in the 
immersion media was quantified using Vista MPX Inductively Coupled Plasma - 
Optical Emission Spectrometer (ICP-OES, Varian, USA) and pH was measured 
using a pH meter. The retrieved scaffolds were dried under vacuum for 24 hours, and 
viewed under SEM. Scaffold surface precipitates were analysed by Energy-
dispersive X-ray spectroscopy (EDX) equipped on the SEM machine. 
 
4.2.7 Cell culture 
Scaffolds were surface treated with 5M NaOH at 37°C for 0.5 hours to increase 
the scaffold surface hydrophilicity to promote initial cell attachment [206], as well as 
to increase the exposure of BG particles embedded within the PCL bulk at the 
scaffold surface. Prolonged scaffold surface treatment with 5M NaOH was avoided 
to prevent excessive dislodging of BG particles from the scaffold surfaces.  Prior to 
cell seeding, scaffolds were sterilised by immersion in 70% ethanol for 1 hour and 
ultraviolet (UV)-sterilisation for 20 minutes on each surface [207-210] to ensure 
complete sterilisation of the scaffold, thereby minimising the risk of infection.  
All in vitro cell studies were conducted using murine-derived preosteoblast cell 
line (MC3T3-e1), passage 8. Each scaffold was seeded with 12,000 cells. The 
experimental period was up to 28 days. All scaffolds were cultured in basal growth 
media (α-MEM media supplemented with 10% (v/v) foetal bovine serum (FBS) and 
1% (v/v) penicillin/streptomycin) or osteo-supplemented growth media (basal growth 
media supplemented with 10 mM glycerol 2-glycerophosphate, 50 µg/mL L-ascorbic 
acid-2-phosphate and 100 nM dexamethasone (Sigma)), under static conditions. 
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Table 4.1 In vitro cell study groups with the corresponding number of scaffolds used 
for each group. Cell/scaffold constructs were cultured in either non-osteogenic (non-
osteo) or osteogenic supplemented (osteo) media. 
 
Cells were maintained in T75 or T175 tissue culture flasks with basal growth 
media. During cell seeding, each scaffold was initially seeded with 60 µl of cell 
suspension (12,000 cells) in 48-well plates. The pre-seeded scaffolds were incubated 
at 37°C for 90 minutes before being topped up with 700 µl of basal growth media. 
After 24 hours, half of the cultures were changed to osteo-supplemented growth 
media. From here on, the cell seeded scaffolds will be referred to as cell/scaffold 
constructs (table 4.1). 
 
4.2.8 Cell morphology  
At time-points (3, 14, 28 days), cell/scaffold constructs were retrieved and 
processed accordingly for the assessment of cell morphology using SEM and CLSM.  
Cell/scaffold constructs processing for SEM: Briefly, cell/scaffold constructs were 
fixed with 3% (w/v) glutaraldehyde then washed thoroughly with 0.1M cacodylate 
buffer. The samples were treated with 1% (w/v) osmium tetroxide before being 
dehydrated sequentially with ethanol solutions. In order to preserve cell/scaffold 
constructs’ surface detail, they were air dried by evaporation of hexamethyldisilazane 
(HMDS) before being sputter coated with gold for 75 seconds at 30kV using Biorad 
SC500 and imaged using SEM.  
Cell scaffold constructs staining for CLSM: The cell attachment onto scaffold 
surfaces was visualised using actin staining and nuclei staining. Briefly, 
cell/scaffolds constructs were fixed in 4% (w/v) paraformaldehyde (PFA), 
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permeabilised with 0.2% (v/v) Triton X-100/PBS, and stained with 0.8 U/ml 
rhodamine-conjugated phalloidin (Invitrogen) and 5 µg/ml 4’,6-diamino-2-
phenylindole (DAPI, Invitrogen) in 0.5% (w/v) BSA/PBS. Then, cell/scaffold 
constructs were washed with dH2O to remove excess stain. Viewing and analysis 
were performed using the Leica TCS SP5 Confocal Microscope. 
 
4.2.9 Scaffolds’ cytotoxicity  
Scaffold cytotoxicity was determined using a MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay. MTT, a yellow tetrazole, is reduced to 
purple formazan in living cells, thus allowing the assessment of cell viability [211]. 
In brief, on day 1, 3, 7 and 14 days; cell/scaffold constructs (n = 6) were transferred 
to a new 48-well plate. Immediately, 500 µl of fresh media and 20 µl of MTT 
solution (5mg/ ml in PBS) (Sigma) were added to each well and cell/scaffold 
constructs were incubated at 37°C for 4 hours, after which the media was aspirated 
and the MTT-formazan product was solubilised with 200 µl of dimethyl sulfoxide 
(DMSO) (MERCK Millipore) and transferred to a 96-well plate. Absorbance was 
read at 540 nm with a microplate reader.   
 
4.2.10  Cell proliferation  
The DNA content of samples was quantified using Quant-iT PicoGreen 
dsDNA assay kit (Invitrogen) according to the manufacturer’s protocol. Briefly, the 
cell/scaffold constructs (n = 4) were washed with PBS and incubated in 0.2% (v/v) 
Triton-X in 1x Tris-EDTA solution at -20°C for 10 minutes. Cell lysates were 
collected and centrifuged at 10,000 rpm for 10 minutes at 4°C. The cell lysates were 
diluted with 1x Tris-EDTA buffer in a 1:1 ratio. Then, 100µl of the diluted cell lysate 
was pipette into opaque 96-well plates followed by 100µl of the Quant-iT PicoGreen 
aqueous working solution and incubated for 5 minutes at room temperature on a 
rocker plate. Fluorescence was measured with a Polar Star Optima plate reader 
(BMG Labtech, Offenburg, Germany) at an excitation wavelength of 485 nm and an 
emission wavelength of 520 nm.  
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4.2.11 Cell differentiation  
Alkaline phosphatase (ALP) activity assay: At time-points (7, 14, 21 and 28 days), 
ALP enzyme activity, an early osteoblast differentiation marker, was quantified 
using a colorimetric assay. The cell/scaffold constructs (n = 4) were washed with 
PBS and incubated in 0.2% (v/v) Triton-X in 1x Tris-EDTA (TE) solution at -20°C 
for 10 minutes. Cell lysates were collected and centrifuged at 10,000 rpm for 10 
minutes at 4°C, after which 100µl of the cell lysate supernatant were incubated with 
200µl of p-nitrophenylphosphate (1 mg/ml) in 0.2 M Tris buffer (Sigma-Aldrich) in 
96-well plates. After 30 minutes, the absorbance was measured using a Polar Star 
Optima plate reader at 405 nm. ALP activity was normalised against the sample 
DNA content, determined in PicoGreen assay (cell proliferation).  
 
4.2.12 Matrix mineralisation   
Alizarin red staining and semi-quantification: At time-points (7, 14, 21 and 28 
days), the extent of matrix mineralisation on the cell/scaffold constructs (n = 3) were 
semi-quantified using Alizarin red staining, which binds to the Ca2+ of calcium 
deposition. Briefly, the cell/scaffold constructs were washed twice with PBS and 
fixed using ice-cold methanol for 10 minutes at room temperature. The cell/scaffold 
constructs were washed with distilled water (dH2O) and incubated with 1% (w/v) 
Alizarin red S (Sigma-Aldrich) in dH2O, pH 4.1, for 10 minutes on a rocker plate. 
After which, unincorporated dye was washed away using several rinses of dH2O and 
scaffolds were air-dried. For semi-quantification of the staining, 10% (v/v) acetic 
acid was added to each well and incubated at room temperature for 30 minutes. The 
cell/scaffolds constructs were mechanically agitated and the resultant lysate was 
transferred to a 1.5 ml microcentrifuge tube and vortexed for 30 seconds. Following 
this, 300 µl of mineral oil was added to each eppendorf tube and samples were 
heated at 85°C for 10 minutes, then, placed on ice for 10 minutes. After 
centrifugation at 20,000 x g for 15 minutes, 500 µl of the supernatant was transferred 
to a new 1.5 ml eppendorf tube and 200 µl of 10% (v/v) ammonium hydroxide was 
added to neutralise the acid. Next, 150 µl of each sample was transferred to 96-well 
plates in triplicates and absorbance was read at 405 nm using a Polar Star Optima 
plate reader. It should be noted that the Alizarin red S dye was shown to stain the 
composite scaffolds in areas of BG inclusion giving false positive readings. Thus, to 
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negate this effect, at all time-points, acellular scaffolds immersed in culture medium 
were used as empty controls to enable the subtractions of background reading.   
 
4.2.13 Data Analysis 
All data were represented as mean ± SD and were subjected to one-way 
analyses of variance (one-way ANOVA) and Tukey’s post-hoc test (SPSS Version 
11.02). Significance levels were set at p < 0.05. In all statictical analysis, normality 
and equal variance was assumed. 
 
4.3 RESULTS 
4.3.1 Characterisation of scaffolds 
All fabricated scaffolds were shown to have similar scaffold morphologies 
(figure 4.1(a-l)). From figure 4.1(c, g and k), it was shown that microfilaments of 
PCL/10-45S5 and PCL/10-SrBG scaffolds were rougher when compared to PCL 
scaffolds. From the 3D µCT reconstructed images, both PCL/10-45S5 (figure 4.1(h)) 
and PCL/10-SrBG (figure 4.1(l)) scaffolds showed a homogenous distribution of 
glass particles across the PCL bulk. The axial pores of the scaffolds were larger than 
the transverse pores of the scaffolds. This was confirmed by µCT measurements 
(figure 4.2(a)), where the smaller pore sizes reflect the transverse pores of the 
constructed scaffolds as seen in figure 4.1(b, f, and j). The larger pore sizes reflect 
the axial pores of the scaffolds as seen in figure 4.1(a, e, and i). From figure 4.2(a), it 
is noticeable that PCL/10-45S5 and PCL/10-SrBG scaffolds generally have higher 
percentage of lower range pore sizes as compared to PCL scaffolds.  
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Figure 4.1 SEM and micro-CT imaging of PCL, PCL/10-45S5, and PCL/10-SrBG 
scaffolds. (a – d) PCL scaffolds. (e - h) PCL/10-45S5 scaffolds. (i – l) PCL/10-SrBG 
scaffolds. (a, e, i) SEM images of scaffolds from top view. (b, f, j) SEM images of 
scaffolds from transverse view. (c, g, k) SEM images of scaffolds showing good 
fusion of polymer microfilaments between layers (red arrow). (d, h, j) Scaffold 3D 
reconstruction images of micro-CT. 45S5 (h) and SrBG (l) particles (red) are 
homogenously distributed across the PCL bulk. 
 
4.3.2 Compression modulus of scaffolds 
The compressive Young’s modulus of PCL scaffolds was found to be 42.19 
±1.51 MPa (figure 4.2(b)). The addition of BG increased the scaffold compressive 
 59 
Chapter 4: (Study 1) Fabrication and in vitro characterisation of composite scaffold for bone TE. 59 
Young’s modulus, with values of 48.35 ±2.57 MPa for PCL/10-45S5 scaffolds and 
59.18 ±0.97 MPa for PCL/10-SrBG scaffolds (figure 4.2(b)). The compressive 
Young’s modulus of PCL/10-SrBG scaffolds was found to be significantly higher 
compared to PCL/10-45S5 scaffolds.   
 
Figure 4.2(a) Porosity and pore size distribution of PCL, PCL/10-45S5 and PCL/10-
SrBG scaffolds.  (b) Axial compressive modulus of PCL, PCL/10-45S5 and PCL/10-
SrBG scaffolds (n =6). Mean ± S.D. * indicate significantly higher (p < 0.05) 
compressive modulus compared to PCL scaffolds. † indicates significantly higher (p 
< 0.05) compressive modulus compared to PCL/10-45S5 scaffolds. 
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4.3.3 Accelerated in vitro degradation of scaffolds  
The main mode of initial degradation of high-molecular weight polyesters is 
via random hydrolytic scission [212]. The cellular degradation (also known as 
biodegradation) only takes place during the later stage, involving only low molecular 
weight (Mn < 5000) polyester that could feasibly be recognized and ingested by 
phagocytes [212]. Thus, to recapitulate the initial degradation of PCL in vitro, we 
opted to utilise 5M NaOH to enhance the hydrolysis of PCL; this would also mimic 
the physiological condition but at an accelerated rate [161].   
The accelerated degradation studies were conducted for up to 7 days in 5M 
NaOH. After 1 day of immersion in 5M NaOH, PCL/10-SrBG scaffolds lost 48.6 
±3.8% of their original mass, compared to 12.1 ±2% and 1.6 ±1% for PCL/10-45S5 
and PCL scaffolds, respectively (figure 4.4). After 2 days of immersion, PCL/10-
SrBG scaffolds were no longer retrievable for further analysis (figure 4.3(c)).  Over 7 
days of immersion in 5M NaOH, PCL scaffolds only lost 24.7 ± 1.6% of their 
original mass (figure 4.4). PCL scaffold surfaces were roughened due to the 
hydrolytic degradation of PCL on the surface, but the overall structure of scaffolds 
remained intact (figure 4.3(a)). PCL/10-45S5 scaffolds lost their mass steadily over 
time when immersed in 5M NaOH (figure 4.4), and the scaffold microfilaments 
reduced in size over time (figure 4.3(b)). It was also observed that as the PCL 
degraded, the 45S5 particles dislodged from the PCL microfilament, leaving 
numerous pits on the scaffold surfaces (figure 4.3(b)). After 7 days of immersion in 
5M NaOH, PCL/10-45S5 scaffolds were not retrievable for further analysis (figure 
4.3(b)) as all scaffolds had disintegrated into pieces. The degradation rate of PCL/10-
SrBG was significantly faster compared to PCL and PCL/10-45S5 scaffolds.   
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Figure 4.3 Pictures and SEM images of (a) PCL, (b) PCL/10-45S5 and (c) PCL/10-SrBG scaffolds after 1, 3, 5, and 7 days degradation in 5M 
NaOH. For PCL/10-45S5 (day 7) and PCL/10-SrBG (day 2 onwards), as shown in the below picture, scaffolds were disintegrated into pieces and 
not retrievable for further analysis. * Pits on PCL microfilaments due to dislodge of BG particles. 
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Figure 4.4 Graph showing the percentage of mass loss of PCL, PCL/10-45S5 and 
PCL/10-SrBG scaffolds over time. Mean ± SD. 
 
4.3.4  Bioactivity of scaffolds 
The study of in vitro scaffold bioactivity using culture media or stimulated 
body fluid (SBF) has always been much debated [15, 213-215]. We have studied the 
in vitro bioactivity using culture media (α-MEM) as commercially available α-MEM 
is a more controlled source compared to laboratory prepared SBF. Additionally, all 
our cell culture studies were performed using α-MEM media, thus, the bioactivity 
studies outcomes will be more reflective of our cell culture studies outcomes. 
We assessed the changes of ionic concentration of Ca2+, PO4
3-, Si4+ and Sr2+ of 
the immersion media of PCL, PCL/10-45S5 or PCL/10-SrBG scaffolds, as shown in 
figure 4.5 (a-d). The Ca2+ concentration (figure 4.5(a)) across all groups remained 
fairly constant up to 3 days of incubation.  As incubation time was lengthened, the 
Ca2+concentration in the culture media of the PCL group decreased from day 3 to day 
7, followed by a fairly constant level for up to 28 days of incubation. In contrast, the 
Ca2+ concentration in the media of PCL/10-45S5 and PCL/10-SrBG groups gradually 
decreased until the end of experiments.  The PO4
3- concentration (figure 4.5(b)) 
followed the profile of Ca2+. Through SEM, no precipitates were observed on PCL 
scaffold surfaces after 28 days immersion, while patches of precipitates were 
observed on PCL/10-SrBG scaffold surfaces at day 28 (figure 4.5(e)).  From day 0 to 
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3, both dissolution media of PCL/10-45S5 groups and the PCL/10-SrBG groups 
indicated an initial rapid increase of Si4+ concentration. From day 3 to day 21, the 
Si4+ level of PCL/10-SrBG groups remained relatively constant and further increased 
from day 21 to 28. The Si4+ level of PCL/10-45S5 groups remained relatively 
constant from day 3 through day 28 (figure 4.5(c)).  
The pH of the culture media immersed with PCL remained fairly constant 
throughout the 28 days as shown in figure 4.5(f). After 24 hours immersion of either 
PCL/10-45S5 or PCL/10-SrBG, the pH of culture media increased from the basal 
level (pH 7.21±0.01) to pH 7.35±0.01 and pH 7.32±0.01, respectively. Thereafter, 
the pH remained fairly constant as shown in figure 4.5(f).  
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Figure 4.5 (a-d) Ca2+, PO4
3-, Si4+ and Sr2+ concentration from scaffolds dissolution 
test. Mean ± S.D. (e) SEM images of PCL/10-SrBG scaffolds after 28 days of 
immersion in culture media. (f) pH value of media immersed with PCL, PCL/10-
45S5 or PCL/10-SrBG. Mean ± S.D. 
 
4.3.5 Cell attachment and morphology  
As shown in the SEM and confocal images in figure 4.6(a, g, and m) and (d, j 
and p) respectively, after 3 days of culture, cells were well attached onto all scaffold 
microfilaments. By day 14 (figure 4.6(b, e, h, k, n, and q)), a dense and continuous 
layer of cell sheet (cell and cell matrices) were formed along the scaffold’s 
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microfilaments. On day 28 (figure 4.6(c, f, i, l, o, and r)), it was observed that cell 
sheets had begun to bridge across scaffold’s microfilaments.  
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Figure 4.6 SEM (a-c, g-i, and m-o)  and confocal (d-f, j-l, and p-r)  images of PCL 
(a-f), PCL/10-45S5 (g-l) and PCL/10-SrBG (m-r) cell scaffold constructs cultures for 
3 (a, d, g, j, m, and p), 14 (b, e, h, k, n, and q) and 28 (c, f, i, l, o, and r) days under 
osteo-induced condition.  * indicates cell sheet bridging across microfilaments (d-f, j-
l, and p-r).    
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4.3.6 Cytotoxicity 
After scaffolds had been cultured for 7 and 14 days, MTT activity (figure 4.7) 
was seen to be increased significantly; indicating that all scaffolds (PCL, PCL/10-
45S5, and PCL/10-SrBG) were non-cytotoxic and were able to support cell 
attachment and growth. Furthermore, it was noted on day 3, 7 and 14, that the MTT 
activity (figure 4.7) of PCL/10-45S5 and PCL/10-SrBG cultured under control or 
osteogenic-induced conditions had significantly higher MTT activity compared to 
PCL. However, no significant difference was detected between PCL/10-45S5 and 
PCL/10-SrBG constructs.  
 
Figure 4.7 Graph showing MTT absorbance at 540 nm of PCL, PCL/10-45S5 and 
PCL/10-SrBG scaffolds far day 1, 3, 7, and 14. Mean ± SD; significance at p<0.05. † 
indicated significantly higher MTT activity compare to PCL scaffolds of the 
respective culture conditions. * indicate significantly higher (p < 0.05) MTT activity 
compared to day 3 of the respective materials and culture conditions. 
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4.3.7 Cell differentiation  
ALP expression was assessed to determine the osteogenic potential of 
composite scaffolds (PCL/10-45S5 and PCL/10-SrBG). To further assess the 
osteoinductivity of the composite scaffolds in vitro, the constructs were cultured in 
osteogenic supplemented (osteo) or non-osteogenic supplemented (control) media. 
For constructs cultured under control media, the ALP activity (figure 4.8) was 
minimal, indicating that no cells differentiated into osteoblasts.  For cell scaffold 
constructs cultured in osteo media, ALP activity (figure 4.8) was significantly higher 
compared to their respective control group at all time-points, except PCL in 7 days 
culture. ALP activity was significantly increased on day 28 compared to all other 
time points, indicating differentiation of pre-osteoblasts into mature osteoblasts. For 
inter-group comparison, it is worth noting that PCL/10-45S5 (day 7, 14, 21 and 28) 
and PCL/10-SrBG (day 7 and 21) cultured under osteo condition has significantly 
higher ALP activity compared to PCL scaffolds cultured under the same condition.  
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Figure 4.8 Graph showing ALP expression of PCL, PCL/10-45S5 and PCL/10-SrBG 
scaffolds at day 7, 14, 21, and 28. Mean ± SD; significance p < 0.05. * indicated 
significantly higher ALP activity compare to cell-scaffold construct of the same 
material cultures under control (non-osteogenic) condition of respective days. ‡ : 
indicate significantly higher ALP activity compare to PCL cell-scaffold constructs 
cultured under osteogenic-induced conditions of respective days. † indicated 
significantly higher ALP activity compare to day 21 of the respective materials and 
culture conditions. 
 
4.3.8 Matrix mineralisation 
At Day 7 and 14, PCL/10-SrBG (control and osteo group) showed a 
significantly higher degree of mineralisation compared to all other groups (figure 
4.9); indicating that PCL/10-SrBG can stimulate earlier matrix mineralisation. With 
prolonged culture (21 and 28 days), the degree of mineralisation was no different 
between all groups cultured in control media (figure 4.9). No difference was found in 
PCL groups cultured under control or osteo conditions. However, it was noted that 
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under osteo conditions, PCL/10-45S5 and PCL/10-SrBG showed significantly higher 
mineralisation compared to PCL cultured under the same condition. 
 
Figure 4.9 (a) Qualitative visualisation of alizarin red staining on scaffold. (b) Semi-
quantitative of alizarin red staining intensity on scaffolds. Mean ± SD; significance p 
< 0.05. * indicated significantly higher Alizarin red S stain intensity compare to PCL 
cell-scaffold construct of the respective culture conditions and days. 
 71 
Chapter 4: (Study 1) Fabrication and in vitro characterisation of composite scaffold for bone TE. 71 
4.4 DISCUSSION 
4.4.1 Characterisation of scaffolds 
All fabricated scaffolds showed similar morphology (figure 4.1) and porosity 
despite the different extrusion temperature used. PCL was extruded at 100°C while 
the composite materials (PCL/10-45S% and PCL/10-SrBG) were extruded at 110°C. 
By qualitative observations of the ME process, the viscosity of PCL/45S5 and 
PCL/SrBG was higher compared to PCL. Therefore, the temperature was raised to 
110°C to allow continuous extrusion. During scaffold fabrication, it was also 
observed that a phenomenon known as microfilament sagging (Figure 4.1(j)) 
occurred in PCL/10-45S5 and PCL/10-SrBG scaffolds, contributing to the higher 
percentage of smaller pore sizes compare to PCL scaffolds. This may have resulted 
from the delayed cooling and solidification of the microfilaments due to the slightly 
higher temperature required for the fabrication of composite scaffolds, hence 
solidification of the microfilament would be slightly longer. Also, after a long period 
of extrusion time, a small fraction of BG particles may accumulate on the extrusion 
nozzle tip, and when it is extruded; this may result in heavier microfilaments, 
contributing to the sagging of microfilaments.  
 
4.4.2 Compression modulus of scaffolds 
The compressive Young’s moduli of fabricated PCL scaffolds (42.19 ±1.51 
MPa) lie within the range as previously reported [78, 216] and can be comparable to 
some spongy bone compressive Young’s moduli [217]. The addition of BG increased 
the scaffold compressive Young’s modulus, which was expected as it has been 
previously reported by Shor et al. [216] that inclusion of hydroxyapatite particles (25 
wt%, 10-25 µm) into the PCL bulk increases the scaffold compressive Young’s 
modulus regardless of the scaffold porosity. Korpela et al. [218] and Jiang et al. 
[219] also illustrated that inclusion of 10 wt% BG particles (<50 µm) and 10 to 40 
wt% of hydroxyapatite particles (2.1 ±0.4 µm) respectively, into PCL scaffolds 
increased the scaffolds’ compressive Young’s modulus. Collectively, PCL/BG 
scaffolds revealed better stiffness than PCL scaffolds which might be better suited 
for hard tissue engineering. The cause behind the higher compressive Young’s 
modulus found for PCL/10-SrBG scaffolds compared to PCL/10-45S5 scaffolds is 
unclear. However we speculate that this might be attributable to the difference in the 
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silicate-glass network of 45S5 and SrBG. It is reported that substituting calcium with 
strontium leads to expansion of the SrBG silicate-glass network [123, 141, 220] and 
suppresses the crystallization of the orthophosphate phase in SrBG which is present 
in 45S5 [123, 141]. In line with this, it is reported that the crystalline structure and 
size within a composite system can affect the interfacial adhesion between the matrix 
(PCL in our case) and the filler (45S5 or SrBG in our case); which in turn affects the 
mechanical performance of the composite (PCL/45S5 or PCL/SrBG) [221, 222]. 
This finding is in agreement with the conclusion reached by Gerhardt et al. [152] 
who described that the composition of the glass phase affects the mechanical 
properties of scaffolds although the actual mechanism of interfacial interaction 
between 45S5 and SrBG with PCL is not well understood.  
 
4.4.3 Accelerated in vitro degradation of scaffold  
Overall, we demonstrated the accelerated degradation of PCL/10-45S5 and 
PCL/10-SrBG composite scaffolds compared to PCL scaffolds. Melt extruded PCL 
scaffolds have relatively smooth surfaces (figure 4.1(c)). The inclusion of BGs into 
PCL bulk for melt extrusion yielded composite scaffolds (PCL/10-45S5 and PCL/10-
SrBG) with micro-pores on the scaffold microfilament surfaces (figure 4.1(g, k)). 
These micro-pores served to increase the surface area for hydrolytic degradation and 
thus increased the degradation rate of the composite scaffolds. Additionally, BG 
particles are highly hydrophilic [12], which increases media diffusion into the 
microfilament bulk and increases residual media in the micro-voids at the PCL and 
BG particles’ interface [161]. The coupling of these micro-voids and dislodging of 
BG particles increases the interfacial surface area for media intrusion and attack, 
which in turn increases the scaffolds degradation for the composites; PCL/10-45S5 
and PCL/10-SrBG compared to scaffolds comprising PCL alone. 
We also demonstrated that the degradation rate of PCL/10-SrBG scaffolds was 
faster than PCL/10-45S5 scaffolds. The SrBG used in this study were formulated by 
the substitution of the calcium for strontium within the silicate glass network, 
expanding the glass network of SrBG as previously mentioned. The expansion of the 
silicate glass network leads to the weakening of the glass network, resulting in higher 
dissolution rates of the SrBG. Similar observations for Sr-containing glass were 
reported by Fredholm et al. [124]. In the context of composite scaffolds comprising a 
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polymer matrix combined with bioactive glass particles, the higher dissolution rate of 
SrBG particles leads to increased interfacial surface area for media intrusion and 
attack within a short period of time; thus, resulting in faster degradation rates for 
PCL/10-SrBG scaffolds compared to PCL/10-45S5 scaffolds. Taken collectively, the 
rates of degradation of these scaffolds were: PCL/10-SrBG > PCL/10-45S5 > PCL 
scaffolds.  
 
4.4.4 Bioactivity of scaffolds 
Si4+ and Sr2+ have been shown to play a role in stimulating cells during bone 
formation [223]. The increase in Si4+ concentration  was contributed to by the 
breakup of the outer silica layers (Si-O-Si bond) of the BG network [14]. We 
hypothesise that the steady level of Si4+  detected in the media during incubation was 
due to the depletion of the BG exposed on the PCL microfilament surfaces. Over 
time, as PCL was degraded and media was able to diffuse through the PCL 
microfilaments via the pits on microfilament surfaces (surfaces previously occupied 
by BG which has dissolved/dislodged to the surrounding media), more BG may 
come into contact with the immersion media, thus  increasing the level of Si4+. The 
concentration of Sr2+ for PCL/10-SrBG increased over the incubation time following 
the similar trend of Si2+ dissolution ion profile. Taken together, the data suggests that 
BG incorporated into PCL bulk can act as a long term reservoir of BG and will 
enable a constant diffusion of ions which are implicated in bone formation into the 
local microenvironment.  
Despite the release of Ca2+ from 45S5 and SrBG, the depletion of Ca2+ coupled 
with decreased level of PO4
3- from culture media leads to the formation of a CaP 
layer on the scaffolds surfaces which have been reported to play a major  role in 
biomaterial-host tissue bonding in vivo [189]. However, in this study, only patches of 
precipitates were observed on the composite scaffold surfaces, this maybe due to the 
insufficient amount (wt %) of BG imcoporated into the PCL bulk to promotes CaP 
precipitation.  
The increase in pH observed in PCL/10-45S5 and PCL/10-SrBG immersion 
media is likely caused by the dissolution of glass modifier (Na+ and K+). A similar 
phenomenon but higher pH value has been observed by Fu et al. [204] and Russias et 
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al. [202] when immersing 6P53B glass scaffolds or 6P53B glass (70 
wt%)/polylactide scaffolds into SBF. The higher pH value observed by Russias et al. 
[202] may contribute to the  denser apatite crystal layer formed on the surface of 
6P53B glass/polylactide scaffolds compared to the thin layer of apatite crystal 
colonies observed on  the PCL/SrBG scaffold (figure 4.5(e)). Higher pH values 
indicate a higher level of free BG dissolution ions (Na+, K+, Sr2+ etc.). This increases 
the rate of ion exchange of Na+ from the glass with H+ and H3O
+ from surrounding 
solution, followed by a polycondensation reaction of surface silanols to create high-
surface area for heterogeneous nucleation and crystallisation of a biologically 
reactive hydroxy-carbonate apatite (HCA) layer [13]. 
 
4.4.5 Cell responses to scaffolds 
All scaffold groups (regardless of material) within the experimental timeframe 
could support initial cell attachment, cell proliferation and secretion of extracellular 
matrices, leading to the commencement of cell bridging and cell sheet formation 
across scaffold’s microfilaments. The metabolic activity of PCL/10-45S5 and 
PCL/10-SrBG group were higher than PCL group, suggesting that  dissolved ions 
released from the BG (45S5 or SrBG) further enhanced the metabolic activity of 
MC3T3 cells. However, no significant difference was detected between PCL/10-
45S5 and PCL/10-SrBG constructs. This was not in agreement with Gentleman et al. 
[21] who demonstrated significantly enhanced MTT activity of SrBG groups 
compared to 45S5 group. However it must be noted that this study, Gentleman et al. 
[21] used pure BG discs with greater availability of BG to elute into the media and 
exert an effect on the cells. This leads to the conclusion that in the present study, 
using composite scaffolds, the amount of SrBG incorporated into the PCL bulk was 
too low, or the exposed particles, at any one time were too few to allow Sr2+ ions to 
exert as strong an effect on the cells as when using SrBG in isolation. However there 
was clearly a significant positive effect of both BG groups compared to PCL-alone in 
terms of cell metabolic activity. 
The significantly higher degree of mineralisation found in PCL/10-SrBG group 
compared to other groups can be attributed to the accelerated dissolution rate of 
SrBG, and consequently the faster degradation rate of PCL/SrBG scaffolds which in 
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turn exposed more SrBG particles to the surrounding media for dissolution, leading 
to earlier matrix mineralisation. Under osteo conditions, PCL/10-45S5 and PCL/10-
SrBG showed significantly higher osteoblast differentiation compared to PCL 
cultured under the same condition. This finding indicates that the dissolution ions of 
BG had a significant contributory effect in promoting the differentiation of 
osteoblasts, although this effect was only evident in the presence of osteogenic media. 
Furthermore, it was noted that under osteo conditions, PCL/10-45S5 and PCL/10-
SrBG showed significantly higher mineralisation compared to PCL cultured under 
the same condition, indicating a synergistic effect between the BG dissolution ions 
and the osteogenic supplements in the culture media to promote matrix 
mineralisation.  
 
4.5 SUMMARY OF STUDY 1 
Fabrication of PCL scaffolds incorporated with BG was shown to be feasible. 
Results indicated that the inclusion of BG does promote increased cell differentiation 
and matrix mineralisation when cultured in osteogenic-induced condition. However, 
an ultimate aim of a biomaterial suitable for bone regeneration is that it is able to 
induce bone formation in the absence of osteogenic-inductive factors (such as growth 
supplements or growth factors such as BMPs). In order to achieve such a goal, it is 
anticipated that inclusion of higher wt% of BG into the PCL bulk and the subsequent 
fabrication of these composite scaffolds will leads to improved bioactivity and hence 
better outcomes in terms of stimulating differentiation of osteoblasts. In these 
studies, 45S5 and SrBG of < 38um particles size is one of the limiting factor with 
regards to scaffold fabrication. This particle size range sometimes caused blockage 
of the machine’s extrusion nozzle during fabrication, if greater than 10 wt% of BG 
was incorporated into the PCL bulk. In order to enable the fabrication of scaffolds 
containing higher wt% of BG particles, smaller BG particles should be considered. 
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Chapter 5: (Study 2) Biofabrication, 
scaffold characterisation and 
comparison of in vitro 
osteoinductive potential of PCL, 
PCL/CaP-coated, PCL/50-45S5 
and PCL/50-SrBG scaffolds in 
static and dynamic culture 
environment.  
The findings from chapter 5 and 6 will be combined and the writing of the 
manuscript is currently in progress. 
Poh P.S.P., Hutmacher D.W., Holzapfel B.M., Stevens M.M., and Woodruff M.A. 
Comparison of in vitro and in vivo bone formation potential of PCL, PCL/CaP-
coated, PCL/50-45S5 and PCL/50-SrBG scaffolds.  
 
5.1 INTRODUCTION 
The self-healing capabilities of bone can be impeded beyond a critical size 
defect and requires clinical intervention to reunite and regenerate the defect region. 
One promising approach to provide the supporting platform is the use of scaffolds 
fabricated via the rapidly evolving 3D printing technology [26]. These scaffolds can 
act as a temporary matrix to support/direct cellular growth/differentiation and to 
provide mechano-induction and ultimately bone remodelling. Presently, there is a 
wide variety of materials and 3D printing technologies available for the fabrication 
of scaffolds [25]. Dependent on the intended applications, the choice of materials and 
printing techniques may vary. In bone tissue engineering, the currently used polymer 
scaffolds undergoing clinical trials [9, 34, 35] lack bioactivity. Thus, the 
incorporation of other components such as cells/growth factors is required to 
stimulate/promote bone regeneration, adding to the operational cost. To improve the 
bioactivity and the effectiveness of the polymer scaffold’s integration with the host 
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bone, one can functionalise the scaffold surfaces with appropriate inorganic materials 
(which are mostly CaP-based). Routinely, CaP-based biomaterials are used as a 
coating on metallic implants, as it supports bone growth along its surface when 
placed in the vicinity of host bone, improving the implants-to-bone integration, 
preventing implants loosening and potential resurgery [43-45]. Thus, coatings of 
polymer scaffolds with CaP have been widely explored [11, 46-50], and have been 
shown to promote osteoblast differentiation in vitro and/or bone formation in vivo 
[11, 51-54]. Alternatively, one can incorporate bioactive materials, such as CaP-
based ceramics or bioactive glass (BG) into the polymer matrix. These bioactive 
materials are widely used clinically for the repair of hard tissue in a variety of 
craniofacial, maxillofacial and periodontal applications due to their inherent 
bioactivity [12, 13, 43, 98]. The combination of an inert polymer with bioactive 
materials can give rise to a bioactive composite polymer [4, 37, 39, 71, 224]. 
In this study, the ability of PCL-based bioactive composite scaffolds to 
promote cell growth, proliferation and osteoblasts differentiation was investigated in 
vitro. Bioactive composite scaffolds were fabricated as described previously [225]. 
In our previous study, it was found that the bioactivity of BG (45S5 Bioglass® 
(45S5) or strontium-substituted bioactive glass (SrBG)) was hindered when loaded in 
low wt% into PCL scaffolds, resulting in minimal beneficial effect on osteoblast 
differentiation compared to PCL scaffolds [225]. Hence, in this study, we increased 
the BG amount, whereby 50 wt% of BG (45S5 or SrBG) was incorporated into the 
PCL scaffold with the anticipation that higher loading of BG will further enhance the 
composite scaffold bioactivity and improve the osteoblasts differentiation. 
Furthermore, the added effect of SrBG compared to 45S5 was also investigated. It 
has been reported that SrBG has enhanced potential in bone regeneration compared 
to 45S5 [21] as strontium is an important trace element in human bone and also 
found to induce osteoblast activity by stimulating bone formation and reducing bone 
resorption [19, 196]. 
To further elucidate the cell responses to polymer scaffolds coated with CaP as 
compared to the proposed bioactive composite scaffolds, PCL scaffolds were coated 
with a layer of CaP. Additionally, it was reported that under static culture conditions, 
the cell proliferation and viability have been limited due to the inefficient exchange 
of nutrients/waste [226]. Therefore, a biaxially rotating bioreactor was used in this 
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study to improve the cell density and homogeneity throughout the scaffold [227-229] 
as it creates a controllable and mechanically-active environment to aid in the 
effective proliferation and growth of cells [230-232].  In précis, cell/scaffolds 
constructs were subjected to dynamic culture using a rotating bioreactor [226], and 
cell responses were evaluated in comparison to cell/scaffold construct cultured under 
static conditions.  
 
5.2 METHODS AND MATERIALS 
5.2.1 Preparation of PCL/BG composite material  
In this study, BG (45S5 and SrBG) with particle size ≤ 20 µm were utilised. 
45S5 Bioglass® (45S5)  with the composition of 46.13 SiO2 - 2.60 P2O5 - 24.35 Na2O 
- 26.91 CaO (mol%) and strontium-substituted bioactive glass (SrBG) with the 
composition of 46.13 SiO2 - 2.60 P2O5 - 24.35 Na2O - 26.91 (1 CaO: 3 SrO) (mol%) 
[141] were incorporated into the PCL bulk by fast precipitation into excess ethanol 
[205]. Briefly, 10% (w/v) PCL solution was prepared by dissolving 10 g of PCL 
pellet (CAPA 6500, Perstorp, United Kingdom) in 100 ml of chloroform (MERCK 
Millipore, Australia) at room temperature. Then, 50 wt% of BG relative to the PCL 
mass was added into the PCL solution and stirred until a homogenous mixture was 
achieved. The PCL/BG solution mixture was then precipitated into 5-fold excess of 
100% ethanol (MERCK Millipore, Australia). The solid PCL/BG composite was 
then isolated and air dried.  
 
5.2.2 Scaffold fabrication  
All scaffolds were fabricated using melt extrusion based additive 
manufacturing (AM) technology [79]. Briefly, PCL, PCL/50-45S5 or PCL/50-SrBG 
composite was loaded into the material reservoir (melting chamber) and the material 
was molten by setting the heating inductor coils to 90°C for PCL, PCL/50-45S5 and 
PCL/50-SrBG composite. As pressure was applied, molten material moved towards 
the extrusion chamber and extruded through the nozzle tip driven by the rotational 
movement of the screw. All scaffolds were designed and fabricated with a lay-down 
pattern of 0-90°, filament gap of 2 mm and layer thickness of 0.4 mm. Scaffolds of 
50 × 50 × 6 mm or 50 × 50 × 2.4 mm were fabricated, then cut to 4 × 4 × 6 mm or 4 
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× 4 × 2.4 mm  respectively. Scaffolds characterisation was undertaken using 4 × 4 × 
6 mm scaffolds, while all in vitro studies were done using 4 × 4 × 2.4 mm scaffolds. 
All scaffolds were fabricated using a 21G nozzle.  
Refinement of melt extruder components (improvement on the machine since study 
1): In this study, the melting chamber of the melt extruder was modified to a smaller 
size with an additional Teflon plunger (figure 5.1 b-d) compared to the original 
column (figure 5.1 a).  This enabled the direct attachment of the stainless steel 
melting chamber to the extrusion chamber (figure 5.1e), eliminating an additional L-
shaped attachment which connected the melting chamber to the extrusion chamber 
(figure 5.1a). The Teflon plunger enables equal distribution of force applied on the 
molten material; subsequently, the molten material can be efficiently pushed towards 
the rotating screw chamber with minimal wastage. These improvements enable 
fabrication of scaffolds at lower temperature. (This change in design was undertaken 
by Dr. Fabio Z. Valpato.) 
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Figure 5.1 (a) The setup of the original version of extrusion unit on the melt extruder. 
(b-e) Modified version of the melting chamber made up of (b) a Teflon plunger and 
(c) a stainless steel column. Once material was loaded into the stainless steel column, 
a Teflon plunger was fitted in, as shown in (d). Then the column was connected to 
the extrusion chamber (e). Acknowledgement to Dr. Fabio Z. Volpato for the design 
of the improved version of melting chamber. 
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5.2.3 Calcium phosphate (CaP) coating on PCL scaffolds 
PCL scaffolds were coated with CaP as described by Vaquette et al. [11] 
adapted from Yang et al. [46]. Briefly, the process involved three successive steps. 
(1) Surface activation: the scaffolds were immersed in 70% ethanol and placed 
under vacuum for 10 mins to remove entrapped air bubbles that could impact on the 
coating homogeneity. Following that, samples were placed in pre-warmed 37°C, 5M 
sodium hydroxide (NaOH) under vacuum for 10 mins, and transferred to 37°C water 
bath for 1 hour. The scaffolds were rinsed with MilliQ water to remove residual 
NaOH until the pH of the rinsing water was ~ pH 7. (2) CaP deposition: The pre-
prepared 10x simulated body fluid (SBF), initially described by Kokubo et al. [233] 
was adjusted to pH 6 with sodium bicarbonate (NaHCO3) under gentle stirring. In a 
50 ml falcon tube containing 10 scaffolds, 40 ml of SBF solution filtered through a 
22 μm filter was added. To ensure optimal infiltration of solution throughout the 
scaffolds, the samples were placed under vacuum for 10 mins before being 
transferred to a 37°C water bath for 30 mins.  After which, the 10x SBF solution was 
refreshed and placed in a 37°C water bath for another 30 mins. The samples were 
then rinsed twice with MilliQ water.  (3) Post-treatment: To homogenise the coated 
CaP phase, the scaffolds were immersed in 0.5M NaOH at 37°C for 30 mins. The 
scaffolds were rinsed with MilliQ water until the rinsing solution reached ~pH 7. 
 
5.2.4 Surface morphology, porosity, and BG distribution  
The surface morphology of the fabricated scaffolds was examined using 
scanning electron microscopy (SEM) (Quanta SEM/FIB) at 10 kV after gold sputter-
coating. Scaffold porosity and the distribution of BG particles within the scaffolds 
were examined using Micro-CT 40 scanner (Scanco Medical, Brüttisellen, 
Switzerland) at a 3D voxel size of 6 µm3. Samples (n = 8) were evaluated at a filter 
width of 1.0 pixels,  filter support of 2.0 pixels and lower threshold of 2% for PCL 
elements, 9% for 45S5 and SrBG elements.  
 
5.2.5 Compressive Young’s modulus  
Mechanical compression tests were conducted using an Instron 5848 
microtester fitted with a 500N load cell (Instron, Australia).  Scaffolds (n = 6) were 
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subjected to 10% compression at a rate of 1 mm min-1 and the compressive Young’s 
modulus of the scaffolds was determined using the initial linear portion of the stress 
versus strain curve. 
 
5.2.6 Accelerated in vitro degradation 
As described in our previous work [225], to recapitulate the initial degradation 
of PCL in vitro, we opted to utilize 5M NaOH to enhance the hydrolysis of PCL; this 
would also mimic the physiological condition but at an accelerated rate as described 
by Lam et al. [161]. We undertook this owing to the time constraints as PCL takes 
many months to degrade under normal conditions hence we utilised this accelerated 
degradation system to enable more data to be acquired. Scaffolds were immersed in 
5M sodium hydroxide (Sigma-Aldrich) and maintained at 37°C. Scaffolds were 
removed after 6 hours and then after 1, 3, 4, 5, 6, and 7 days, rinsed with dH2O, and 
dried under vacuum for 48 hours before further evaluation. The percentage of mass 
loss from each individual scaffold was determined using the following equation: 
 × 100 % 
The mass of scaffolds was measured using an electronic balance with 0.1 mg 
resolution. Scaffold morphology and surface topography were subjected SEM 
imaging as described previously. 
 
5.2.7 Scaffolds ion release profile 
Scaffolds (n = 3) were immersed in α-MEM (Life Technologies) at 37°C for a 
period of 10 weeks. Each scaffold (dimensions 4 × 4 × 2.4 mm) was immersed in 6 
ml of α-MEM. At 3 and 6  hours; 1, 2, and 3 days; and 1, 2, 3, 4, 5, 6, 8, and 10 
weeks, the concentration of Ca2+, PO4
3-, Si4+ and Sr2+ in the α-MEM was quantified 
using Vista MPX Inductively Coupled Plasma - Optical Emission Spectrometer 
(ICP-OES) (Varian, USA) and pH was measured using a pH meter. The scaffolds 
were retrieved and air-dried for 48 hours under vacuum. The surface morphology of 
scaffolds was examined using SEM at 10 kV after gold sputter-coating and the 
precipitation on scaffold surfaces were examined by Energy-dispersive X-ray 
spectroscopy (EDX) equipped on the SEM. 
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5.2.8 In vitro cell studies  
PCL, PCL/50-45S5 and PCL/50-SrBG scaffolds were surface treated with 5M 
NaOH at 37°C for 30 minutes to increase the scaffold surface hydrophilicity to 
promote initial cell attachment [168], as well as to increase the exposure of BG 
particles embedded within the PCL bulk at the composite scaffold surface. Prolonged 
scaffold surface treatment with 5M NaOH was avoided to prevent excessive 
dislodging of BG particles from the scaffold surfaces. All scaffolds were sterilised by 
immersion in 70% ethanol for 15 minutes and UV-sterilisation for 20 minutes on 
each surface.  
 
5.2.9 Cell culture 
All scaffolds were immersed in α-MEM media with 1% (v/v) 
penicillin/streptomycin for 1 week prior to cell seeding. Ovine bone marrow stromal 
cells (BMSCs) passage 3 were used for all cell culture experiments. Cells were 
maintained in T175 tissue culture flasks with growth media comprising α-MEM 
media supplemented with 10% (v/v) foetal bovine serum (FBS) and 1% (v/v) 
penicillin/streptomycin. During cell seeding, each scaffold (4 × 4 × 2.4 mm) was 
initially seeded with 60 µl of cell suspension (100,000 cells/ scaffold) in 48-well 
plates. The pre-seeded scaffolds were incubated at 37°C for 90 minutes before being 
topped up with 700 µl of α-MEM growth media. After 24 hours, half of the cultures 
were changed to osteogenic induction media, consisting of growth media 
supplemented with 10 mM glycerol 2-glycerophosphate, 50 µg/mL L-ascorbic acid-
2-phosphate and 100 nM dexamethasone (Sigma) (table 5.1). From here on, the cell 
seeded scaffolds will be referred to as cell/scaffold constructs. After 1 week in static 
culture, half of the cell/scaffold constructs were subjected to dynamic culture using a 
TisXell biaxial bioreactor (figure 5.2) [226]. 
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Table 5.1 Summary of cell culture groups with numbers of scaffold used for each 
group. Cell/scaffold constructs were cultured in either non-osteogenic (non-osteo) or 
osteogenic supplemented (osteo) media.  
 
 
Figure 5.2 Biaxial bioreactor design: The bioreactor system consisted of a spherical 
culture vessel (volume of 500 ml) connected to the medium reservoir through tubings 
through which a perfusion flow is generated (flow direction indicated by red arrows). 
The spherical vessel sits on an articulator which allows rotation in two perpendicular 
axes (X and Z) [226]. 
 
5.2.10 Cell morphology 
At day 1, 14, or 21, cell/scaffold constructs were retrieved and processed 
accordingly for the assessment of cell attachment and morphology using confocal 
laser scanning microscopy (CLSM) and/or SEM. 
SEM: Briefly, cell/scaffold constructs were fixed with 3% (w/v) glutaraldehyde then 
washed thoroughly with 0.1M cacodylate buffer. The samples were treated with 1% 
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(w/v) osmium tetroxide before being dehydrated sequentially with ethanol solutions. 
In order to preserve cell/scaffold constructs’ surface detail, they were air dried by 
evaporation of hexamethyldisilazane (HMDS) before being sputter coated with gold 
using Biorad SC500 and imaged using SEM.  
CLSM: The cell attachment onto scaffold surfaces was visualised using actin 
staining and nuclei staining. Briefly, cell/scaffolds constructs were fixed in 4% (w/v) 
paraformaldehyde (PFA), permeabilised with 0.2% (v/v) Triton X-100/PBS, and 
stained with 0.8 U/ml rhodamine-conjugated phalloidin (Invitrogen) and 5 µg/ml 
4’,6-diamino-2-phenylindole (DAPI, Invitrogen) in 0.5% (w/v) BSA/PBS. Then, 
cell/scaffold constructs were washed with dH2O to remove excess stain. Viewing 
and analysis were performed using the Leica TCS SP5 Confocal Microscope. 
 
5.2.11 Cell proliferation 
At day 7, 14, and 21 (n = 3), cell number was quantified using Quant-iT 
PicoGreen dsDNA assay kit (Invitrogen) according to the manufacturer’s protocol. 
Briefly, the cell lysates retrieved were diluted with 1x TE buffer in a 1:1 ratio. Then, 
100 µl of the diluted cell lysate was pipette into opaque 96-well plates followed by 
100 µl of the Quant-iT PicoGreen aqueous working solution and incubated for 5 
minutes at room temperature on a rocker plate. Fluorescence was measured with a 
Polar Star Optima plate reader (BMG Labtech, Offenburg, Germany) at an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm. 
 
5.2.12 Real time- quantitative polymerase chain reaction (RT-qPCR).  
The osteogenic gene expressions of BMSCs on scaffolds were quantified using 
RT-qPCR. At day 14 and 21, three cell/scaffold constructs were combined together 
and placed in a new 48-well plate. After being washed once in PBS, the cells were 
lysed in 600 μl of lysis buffer (Invitrogen) supplemented with 1% (v/v) β-
mercaptoethanol (Sigma-Aldrich) and total RNA was isolated using PureLink RNA 
micro kit (Invitrogen) according to manufacturer protocols. All samples were treated 
with DNase (Invitrogen) to eliminate genomic DNA present in the samples. Total 
RNA was eluted in 15 μl of RNase-free water, and its concentration and purity 
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(A260/A280 ratio) were determined using a Nanodrop Microvolume UV-Vis 
spectrophotometer (ThermoFisher Scientific, Australia). 
The isolated total RNA was reverse transcribed into 1000 ng of complementary 
DNA (cDNA) using DyNAmo* cDNA Synthesis Kit (Thermo Scientific, Australia) 
as per manufacturer instructions. RT-qPCR was performed by an Applied 
Biosystems viaa7 (Applied Biosystems, Australia) using SYBR Green (Applied 
Biosystems) as detection reagent. The thermal profile of the reactions consisted of an 
initial 5 min of incubation at 50ºC to activate heat-labile uracil DNA glycosylase, 
followed by 2 min denaturation at 95ºC and 40 cycles consisting of a denaturation 
step at 95°C for 15 s, and an annealing/extension step at 60°C for 1 min. The 
expressions of osteopontin (OPN), osteocalcin (OCN) and GAPDH were quantified 
and analysed in triplicate. For each cDNA sample, the Ct value of each target 
sequence was subtracted from the Ct value of the reference housekeeping gene 
(GAPDH), to derive Delta-Ct. 
Gene Sequences 
GAPDH  Forward 5’ AGA TCA TCA GCA ATG CCT CCT GG 
Reverse 5’ ATG GCA TGG ACT GTG GTC ATG AG 
Osteopontin (OPN) Forward 5’ TGA CCA TTC CAA CGA GTC TCA CCA 
TTC 
Reverse 5’ TGG CAT CTG CAC TCT CAA CGT TAG 
ATC 
Osteocalcin (OCN) Forward 5’ CAC AGC CTT CGT GTC CAA GC 
Reverse 5’ GCT CAG ACA CCT CCC TCC TG 
Table 5.2 Sequences of forward and reverse primer for GAPDH, osteopontin (OPN) 
and osteocalcin (OCN). Primers were designed by Dr. Thor Fris. 
 
5.2.13 Data Analysis 
All data were represented as mean ± SD and were subjected to one-way 
analyses of variance (one-way ANOVA) and Tukey’s post-hoc test (SPSS Version 
11.02). Significance levels were set at p < 0.05. 
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5.3  RESULTS 
5.3.1 Fabrication and scaffold characterisation  
All fabricated scaffolds had similar porosities (~75%), pore size and filament 
thickness distribution as shown in figure 5.3 a, c, and d respectively. Additionally, 
the BG particles (45S5 and SrBG) seemed to be homogeneously distributed across 
the scaffolds as illustrated in figure 5.3 e and f. However, the compressive Young’s 
moduli of PCL/50-45S5 (36.4 ± 1.4 MPa) and PCL/50-SrBG (35.6 ± 2.5 MPa) were 
significantly lower than PCL (42.2 ± 3.6 MPa) and PCL/CaP (41.9 ± 3.3 MPa) 
scaffolds (figure 5.3b). 
SEM of scaffold surfaces (figure 5.4 a, e & g) showed that composite scaffold 
(PCL/50-45S5 and PCL/50-SrBG) surfaces were rougher compared to PCL scaffold 
surfaces, with visible BG particles on its surface.  In contrast, for PCL scaffolds 
coated with CaP, a thin layer of precipitates (2.67 ± 0.33 µm) was observed on its 
surface (figure 5.4 c & d). The cross-section of the composite scaffold strut (figure 
5.4 f & h) revealed that BGs particles (45S5 or SrBG) were embedded within the 
polymer matrices in very close proximity to each other. 
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Figure 5.3 Scaffold physical characteristics. (a) scaffold porosity and scaffold 
compressive Young’s modulus, (b) graphical representative of scaffold filament 
thickness from micro-CT 3D reconstruction, (c) scaffold filament thickness 
distribution, (d) scaffold pore size distribution, and (e-f) show BG particle 
distribution (red) across PCL/50-45S5 and PCL/50-SrBG scaffold. * indicates 
significantly higher compressive Young’s moduli compared to that of PCL/50-45S5 
and PCL/50-SrBG scaffold. 
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Figure 5.4 SEM image of PCL (a & b), PCL/CaP-coated (c & d), PCL/50-45S5 (e & 
f) and PCL/50-SrBG (g & h) scaffold surface (a, c, e, g) and cross-section (b, d, f, h). 
Visible BG was marked with *.  
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5.3.2 Accelerated degradation of scaffolds 
Over 7 days of immersion in 5M NaOH, PCL and PCL/CaP scaffolds lost 24.6 
± 1.6% and 24.2 ± 2.4% of their original mass respectively (figure 5.5). Through 
SEM observation of scaffold strut surfaces, it was revealed that over time, both PCL 
and PCL/CaP scaffold surfaces were roughened and increasing number of pits were 
observed on the scaffold surfaces (figure 5.6). Additionally, after 6 hours of 
immersion in 5M NaOH, it was observed that the CaP coating on PCL/CaP scaffolds 
detached from the scaffold surfaces and were completely absent on the scaffold 
surfaces after 3 days (figure 5.6).  
On the other hand, with only 6 hours of immersion in 5M NaOH, PCL/50-45S5 
lost 15.5 ± 1.9% of its original mass and PCL/50-SrBG lost 39.84 ± 3.56% of its 
original mass (figure 5.5). After 24 hours immersion, both PCL/50-45S5 and 
PCL/50-SrBG scaffolds had disintegrated into pieces and were not retrievable for 
further analysis. Although the strut of PCL/50-45S5 and PCL/50-SrBG scaffolds 
appeared intact after 6 hours of immersion in 5M NaOH (figure 5.6 q & s), closer 
inspection of the scaffold surfaces revealed that numerous large pits were present on 
the scaffold surfaces due to dislodging of the BG particles from the PCL 
microfilaments (figure 5.6 r & t). Furthermore, with only 6 hours of immersion in 
5M NaOH, PCL/50-45S5 and PCL/50-SrBG scaffold surfaces were much rougher 
compared to PCL and PCL/CaP scaffolds immersed in 5M NaOH for the same 
period of time.   
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Figure 5.5 Percentage  mass loss of PCL, PCL/CaP, PCL/50-45S5 and PCL/50-SrBG 
scaffolds over time when immersed in 5M NaOH, at 37°C. n= 8, Mean ± SD. 
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Figure 5.6 (a – p) Representative SEM images of PCL and PCL/CaP scaffolds after 6 
hours, 1, 3 and 7 days immersion in 5M NaOH. (q-t) Representative SEM images of 
PCL/50-45S5 and PCL/50-SrBG scaffold after 6 hours immersion in 5M NaOH, 
After 24 hours, all PCL/50-45S5 and PCL/50-SrBG scaffolds were disintegrated into 
pieces and not retrievable for further analysis. Red arrows () show pits presence on 
PCL or PCL/CaP scaffold surfaces. Yellow * represents pits on PCL strut due to 
dislodgement of BG particles. Red * indicates BG particles. n = 8.  
 
5.3.3 Scaffold in vitro bioactivity 
The changes of [Ca2+], [PO4
3-], [Si4+] and [Sr2+] in the culture media which had 
been immersed with either PCL, PCL/CaP, PCL/50-45S5 and PCL/50-SrBG 
scaffolds were assessed, as shown in figure 5.7. For PCL, the [Ca2+] remained 
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relatively constant throughout the experimental period. On the other hand, [PO4
3-] 
slightly decreased in the first 3 days, then increased and remained relatively constant 
from week 1 to week 4, followed by a decrease from week 4 to week 6. Thereafter, 
the [PO4
3-] remained relatively constant up to the end of the experimental period.  
The [Ca2+] and [PO4
3-] for PCL/CaP and PCL/50-45S5 decreased over 
immersion time upto 8 weeks, thereafter, the [Ca2+] and  [PO4
3-] remained fairly 
constant until the end of experiment. It was also noted that from week 3 onwards, the 
[Ca2+] and [PO4
3-] for PCL/50-45S5 group were lower than that of PCL/CaP group. 
In contrast, the [Ca2+] and [PO4
3-] in the media containing PCL/50-SrBG decreased 
over time for up to 3 weeks. Then, the [Ca2+] gradually increased, reaching a 
maximum of ~60 ppm at 8 weeks, and remained fairly constant up to 10 weeks. On 
the other hand, the [PO4
3-] increased after week 3, reaching a maximum at week 5 
(~22 ppm), then gradually decreased, reaching the same [PO4
3-] as PCL/CaP group at 
week 10.  
The [Si4+] of PCL/50-45S5 and PCL/50-SrBG showed an initial rapid increase 
in the first 48 hours of immersion. Thereafter, the [Si4+] of PCL/50-45S5 continued 
to increase up to week 10. Conversely, after 48 hours of immersion, the [Si4+] of 
PCL/50-SrBG decreased slightly, then increased from week 1 through week 10. It 
was noted that throughout the 10 weeks immersion period, the [Si4+] of PCL/50-
SrBG group was higher than PCL/50-45S5 group. The presence of Si4+ was not 
detected in the PCL and PCL/CaP group. Generally, the  [Sr2+] of PCL/50-SrBG 
group increased through to week 8, reaching a maximum of ~90 ppm at week 8. The 
[Sr2+] decreased slightly from week 8 to week 10. The presence of Sr2+ was not 
detected in all other groups.   
The pH of the immersion media was measured over time. The pH of the media 
immersed with PCL was slightly below the media’s base pH level, otherwise 
remained fairly constant throughout the 10 weeks. The pH level of media immersed 
with PCL/CaP fluctuated between pH 7.20 to 7.45 throughout the experimental 
period. The slightly lower pH level observed for the immersion media of PCL/CaP 
compare to PCL (figure 5.7e) corresponded with the gradual depletion of Ca2+ 
(alkaline) and PO4
3-   from the immersion media (figure 5.7c & d).   
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After 24 hours immersion of either PCL/50-45S5 or PCL/50-SrBG, the pH of 
culture media increased from the basal level (pH 7.46 ± 0.02) to pH 7.75 ± 0.01 and 
pH 7.82 ± 0.02, respectively (figure 5.7e). The pH of PCL/50-SrBG immersion 
media remained at ~pH 7.8 up to week 3. Therafter, the pH decreased and fluctuated 
between ~pH 7.35 to 7.65. A similar pattern was observed for immersion media of 
the PCL/50-45S5 group, from week 1 to week 4, the pH remained at ~pH 7.75-7.85, 
then decreased to pH 7.63 ± 0.01 on week 5, thereafter fluctuated ~pH 7.35 to 7.65.  
 
Figure 5.7 (a-d) Si4+, Sr2+, Ca2+ and PO4
3-, concentration from scaffolds dissolution 
test. n= 4. Mean ± S.D. (e) pH value of media immersed with PCL, PCL/CaP-coated, 
PCL/50-45S5 or PCL/50-SrBG. n=4. Mean ± S.D. 
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Figures 5.8 and 5.10 show the SEM images of scaffold surfaces after a period 
of immersion in culture media. It was observed that the CaP coating on PCL 
scaffolds persisted after 10 weeks of immersion in culture media, with a thickness of 
1.75 ± 0.34 µm. EDX confirmed that the coating was predominantly Ca and P (figure 
5.9 a-d) and semi-quantitative analysis of the EDX profile shows an increase of Ca/P 
wt% ratio from week 3 to week 6.  
After 1 day of immersion, no precipitates were formed on PCL/50-45S5 and 
PCL/50-SrBG scaffold surfaces (figure 5.8 g & m). After 1 week of immersion, 
precipitates were found on both PCL/50-45S5 and PCL/50-SrBG scaffold surfaces 
(figure 5.8 h & n), and EDX analysis showed that the precipitates were 
predominantly Ca and P with trace element of Si and/or Sr (figure 5.9 f & j). With 
increased immersion time, the precipitates formed a dense layer, covering the entire 
scaffold surfaces (figure 5.8 g-r). However, it was noted that the precipitates formed 
on the surface of PCL/50-45S5 scaffold were thicker compare to PCL/50-SrBG 
scaffold, with a mean of 1.81 ± 0.06 µm and 1.44 ± 0.13 µm, respectively.  
Semi-quantitative analysis of the surface precipitates on PCL/50-45S5 and 
PCL/50-SrBG at week 3 showed that the Ca/P wt% ratio was very similar. As 
immersion time prolonged (week 6 and 10), the Ca/P wt% ratio of PCL/50-45S5 
precipitates increased and were similar to that of CaP coating on PCL/CaP scaffolds 
(figure 5.9 g & h), with non-significantly different Ca/P wt% ratio. Conversely, the 
precipitates formed on PCL/50-SrBG scaffold surfaces had decreased Ca/P wt% ratio 
over time, with significantly lower Ca/P wt% ratio compared to that of PCL/CaP 
(week 6 and 10) and PCL/50-45S5 (week 10). Notably, the element of Sr was 
detected (figure 5.9 k & l), and the ratio of Sr/Ca increased over immersion time.   
Throughout the 10 weeks, no precipitates were found on PCL scaffolds (figure 
5.10 a-c). However, the immersion of PCL scaffolds in media changed the PCL 
surface morphology, with visible cracks on the PCL surfaces on week 10.  
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Figure 5.8 (a-r) Representative SEM images of (a-f) PCL/CaP-coated, (g-l) PCL/50-
45S5 and (m-r) PCL/50-SrBG scaffold surface precipitates when immersed in α-
MEM for 1 day, 1, 2, 3, 6 and 10 weeks. n = 4. 
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Figure 5.9 EDX profile of (a-d) PCL/CaP-coated, (e-h) PCL/50-45S5 and (i-l) 
PCL/50-SrBG scaffold surface precipitates after 1 day, 3, 6 and 10 weeks immersion 
in α-MEM with respective Ca/P and Sr/Ca weight ratio.  
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Figure 5.10 (a-c) SEM images of scaffold surfaces and (d-f) EDX profile of PCL 
scaffold immersed in α-MEM for 1, 3 and 10 weeks.  
 
5.3.4 Cell morphology – attachment and growth 
After 1 day, cells appeared to be flat and attached well on all scaffold surfaces 
except the PCL group. As shown in figure 5.11 (a & e), cells on PCL scaffolds were 
more elongated compared to other groups. It was also observed in PCL/CaP, 
PCL/50-45S5 and PCL/50-SrBG that the cells had more attachment points on the 
scaffold surface compared to PCL scaffold.  
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Figure 5.11 (a-d) SEM and (e-h) CLSM images showing cell morphology on scaffold 
surfaces after 1 day in culture.  
 
 
All scaffolds groups were cultured under static conditions for 7 days before 
being subjected to dynamic culture conditions for a further 7 or 14 days. This pre-
culture under static conditions was done to enhance cell attachment to scaffold 
surfaces, preventing cell detachment from scaffold surfaces when cultured under 
dynamic conditions.  
Qualitative observations show that generally, after 14 days in culture (14S: 
cultured under static condition for 14 days and 7S7D: cultured under static condition 
for 7 days, followed by cultured under dynamic condition for 7 days), the cell growth 
on PCL/CaP, PCL/50-45S5 and PCL/50-SrBG scaffolds was greater compared to 
PCL scaffolds (figure 5.12). The bridging of cell sheets across scaffold struts were 
observed in most PCL/CaP, PCL/50-45S5 and PCL/50-SrBG scaffolds after 14 days 
of culture under static or static/dynamic conditions (figure 5.12).  
In prolonged culture up to 21 days (21S: cultured under static condition for 21 
days and 7S14D: cultured under static condition for 7 days, followed by cultured 
under dynamic condition for 14 days.), across all groups, it was noted that cell 
growth was further enhanced when cell/scaffold constructs were subjected to 14 days 
of dynamic culture, with more cell sheet bridging observed in the 7S14D groups 
compared to the respective 21S groups (figure 5.13). Furthermore, cell bridging was 
more extensive in the PCL/50-45S5 and PCL/50-SrBG compared to PCL and 
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PCL/CaP cell/scaffold constructs, with cell sheet covering the entire scaffold pores 
as observed on some of the PCL/50-45S5 and PCL/50-SrBG groups (figure 5.13).  
 
Figure 5.12 SEM images 14 after days culture on PCL, PCL/CaP, PCL/50-45S5 and 
PCL/50-SrBG scaffolds in non-osteogenic (control) or osteogenic (osteo) media. 
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14S: culture under static condition for 14 days. 7S7D: cultured under static condition 
for 7 days, and subsequently subjected to dynamic culture for 7 days.  
 
Figure 5.13 SEM images 21 days culture on PCL, PCL/CaP, PCL/50-45S5 and 
PCL/50-SrBG scaffolds in non-osteogenic (control) or osteogenic (osteo) media. 
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21S: culture under static condition for 21 days. 7S14D: cultured under static 
condition for 7 days, and subsequently subjected to dynamic culture for 14 days. 
5.3.5 Cell proliferation 
The cell number can be extrapolated from the dsDNA content [234, 235]. In 
static culture (figure 5.14), across all groups, the cell number decreased or remained 
relatively the same between day 7 (7S) and 14 (14S). However, at 21 day (21S) the 
cell numbers on PCL/50-45S5 and PCL/50-SrBBG scaffolds were significantly 
higher than that at 14 days (14S), while the cell numbers on PCL and PCL/CaP 
scaffolds remained relatively constant. On both 14S and 21S, there was no apparent 
difference in the cell number on the same material constructs cultured in non-
osteogenic and osteogenic media. On day 21 (21S), the cell number on PCL/50-45S5 
and PCL/50-SrBG was significantly higher than PCL and PCL/CaP groups, in both 
non-osteogenic and osteogenic culture media.  
In the 7S7D group (14 days culture), there was an overall increase in cell 
number for cell/scaffold constructs cultured in osteogenic media compared to that of 
cultures in non-osteogenic media. However, only PCL/50-45S5 cultured in 
osteogenic media showed a statistically significant increase in cell number compared 
to PCL/50-45S5 cultured in non-osteogenic media. In 7S14D group (21 days 
culture), the cell number on PCL and PCL/CaP scaffolds was significantly higher 
when cultured in osteogenic media compared to the same material scaffolds cultured 
in non-osteogenic media, but no difference was detected in the PCL/50-45S5 and 
PCL/50-SrBG groups cultured in two different conditioned media. Additionally, the 
cell number on PCL/50-45S5 and PCL/50-SrBG was significantly higher compared 
to PCL, in both non-osteogenic and osteogenic culture media. On the other hand, the 
cell number for PCL/CaP groups was only found significantly higher than PCL 
groups when cultured under dynamic and in osteogenic conditions. It is noteworthy 
that in the 7S14D groups, the cell numbers on PCL/50-SrBG scaffolds were 
significantly higher compared to all other groups, in both non-osteogenic and 
osteogenic culture media. 
It was shown in figure 5.14, when subjected to the dynamic culture condition 
for 7 days (7S7D), there is an overall increase in the cell number when compared to 
that of cells cultured under static condition for the same period of time (14S). 
However, only PCL/CaP, PCL/50-45S5 and PCL/50-SrBG showed significant 
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increases in cell number. Between the 7S14D and 21S groups, all cell/scaffold 
constructs showed statistically significant increase in cell number with culture time, 
except PCL cell/scaffold constructs cultured in non-osteogenic media. Additionally, 
in the 21S and 7S14D groups respectively, no statistically significant differences 
were found in the cell number for PCL/50-45S5 scaffolds cultured in non-osteogenic 
or osteogenic culture media. Similar trends were observed for PCL/50-SrBG 
cell/scaffold constructs. 
 
 
Figure 5.14  dsDNA content of PCL, PCL/CaP. PCL/50-45S5 and PCL/50-SrBG cell 
scaffold constructs after 7, 14 and 21 days of culture under static or static/dynamic 
environment in non-osteogenic (Ctrl) or osteogenic (Os) culture media. Mean ± S.D., 
p< 0.05, n=3. *: significantly higher than PCL group with the same culture period, 
culture media and environment. †: significantly higher than 14S group of the 
respective material and culture environment. ¶: significantly higher than 21S group 
of the respective materials, culture media and environment. ‡: significantly higher 
than PCL/CaP with the same culture period, culture media and environment. •: 
significantly higher than the scaffolds cultured in non-osteogenic media of the 
respective material, culture period and environment. ₴: significantly higher than 
PCL/50-45S5 of the same culture period, culture media and environment. Note: xS 
indicates culture under static environment for “x” number of days. xSyD indicate 
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culture under static environment for “x” number of days, and subsequently subjected 
to dynamic environment for “y” number of days.  
 
5.3.6 Osteoblasts gene expression 
OPN gene expression (figure 5.15a) 
For all PCL cell/scaffold constructs, the OPN gene expression was 
significantly higher in the osteogenic media compared to non-oseteogenic media at 
all time-points. However, no apparent difference was found for its OPN gene 
expression in the static culture and dynamic culture condition. On the other hand, 
PCL/CaP, PCL/50-45S5 and PCL/50-SrBG showed an overall upregulation of OPN 
gene expression when subjected to dynamic culture (14S vs.7S7D and 21S vs. 
7S14D), except in the PCL/50-SrBG group cultured in osteogenic media. 
Additionally, PCL/CaP, PCL/50-45S5 and PCL/50-SrBG, regardless of culture 
media and culture condition, showed significantly higher OPN gene expression 
compared to PCL scaffold groups, of the same culture period.  
It was noted that in the 14S, 7S7D and 21S groups, the OPN expression was 
generally higher for PCL/CaP and/or PCL/50-45S5 group when compared to 
PCL/50-SrBG group of the same culture media. However, after 14 days of dynamic 
culture (7S14D), the OPN expression of PCL/50-SrBG group was comparable to that 
of PCL/CaP and PCL/50-45S5 group. 
 
OCN gene expression (figure 5.15b) 
The OCN gene expression remained relatively low for all scaffolds in the 14S, 
non-osteogenic group. With increasing culture time, the expression of OCN gene was 
upregulated (14S vs. 21S and 7S7D vs. 7S14D). Across all scaffolds, it was found 
that the OCN expression was significantly higher in osteogenic groups, whether in 
static or dynamic culture condition. However, it was noted that for PCL and 
PCL/CaP scaffolds cultured in non-osteogenic media, the OCN gene expression 
remain relatively low compared to that of PCL/50-45S5 and PCL/50-SrBG scaffolds 
culture in non-osteogenic media. While in the osteogenic culture, although the OCN 
gene expression for PCL and PCL/CaP groups were upregulated compared to that of 
non-osteogenic culture, the expression level remained lower than that of PCL/50-
45S5 and PCL/50-SrBG groups cultured in osteogenic media.  
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After 7 days of dynamic culture (7S7D), it was observed that the OCN 
expression for PCL/50-SrBG cell/scaffolds construct was significantly higher 
compared to that of static culture (14S), for both non-osteogenic and osteogenic 
culture. Similar trend were observed for PCL/50-SrBG cell/scaffold constructs when 
comparing at 21S and 7S14D. With prolonged dynamic culture (7S14D), The OCN 
expression for PCL and PCL/CaP cell/scaffold constructs cultured in osteogenic 
media was significantly higher compared to the respective cell/scaffold constructs 
cultured under static conditions. It is noteworthy that the expression of OCN was 
higher in the PCL/50-45S5 group compared to that of the PCL/50-SrBG group, 
except for the 7S7D culture. 
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Figure 5.15 Relative gene expressions of osteopontin (OPN) and osteonectin (OCN) 
normalised to GAPDH (house-keeping gene) on cell/scaffold constructs after 14 and 
21 days of culture under static or static/dynamic environment in non-osteogenic 
(Ctrl) or osteogenic (Os) media. Error bar represent the relative standard error. p< 
0.05, n=3. •: Significantly higher than PCL group of the same culture period, culture 
media and environment. *: Significantly higher than PCL/SrBG culture of the same 
culture period, culture media and environment. †: Significantly higher than scaffolds 
cultured in non-osteogenic media of the same culture period and environment. ‡: 
Significantly higher than static environment of the same culture period and media 
Note: xS indicate culture under static condition for “x” number of days. xSyD 
indicate culture under static condition for “x” number of days, and subsequently 
subjected to dynamic culture condition for “y” number of days. 
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5.4  DISCUSSION 
5.4.1 Scaffold fabrication and characterisation 
Macroscopically, all fabricated scaffolds (PCL, PCL/50-45S5 and PCL/50-
SrBG) look very similar. Microfilament sagging in PCL/BG composite scaffolds 
observed in previous work [225] was not observed in this current study. This may be 
due to the lower temperature used during the scaffold fabrication process. In most 
melt extrusion settings, high temperature (115°C – 160 °C) was usually utilised for 
the fabrication of PCL-based scaffolds [80, 236-238]. However, it was observed that 
with high content of BG incorporated into the PCL matrix (50 wt% in our case), 
extrusion at a higher temperature (110°C) caused unacceptable level of 
microfilament sagging, and consequently compromises the scaffold porosity. A slight 
modification on the in-house 3D printer, has enabled the fabrication of PCL-based 
composites at lower temperature (90°C), which may have resulted in faster cooling 
and solidification of the extruded microfilament, hence prevented microfilament 
sagging. 
The compressive Young’s modulus of PCL scaffolds (42.2 ± 3.6 MPa) was in 
line with literature which shows that the compressive Young’s modulus for PCL 
scaffolds with porosity between 70–85% lies within the range of 30 to 50 MPa [78, 
216, 225].  The coating of PCL scaffolds with CaP did not significantly affect the 
scaffolds’ porosity [54] and compressive Young’s modulus compared to PCL-only 
scaffolds. Previous findings have shown that incorporation of 10 wt% of 45S5 or 
SrBG increased the composite scaffolds’ compressive Young’s modulus compared to 
PCL scaffolds [225]. However, incorporation of 50 wt% of 45S5 or SrBG 
significantly decreased the composite scaffolds’ compressive Young’s modulus 
compared to PCL or PCL/CaP scaffolds. The microCT 3D reconstruction image 
seems to show that BG particles were distributed across the entire scaffold (figure 
5.3 e & f). On the other hand, microscopic view of the cross-section of the scaffold 
microfilaments revealed that BGs were in very close proximity to each other (figure 
5.4 f & h), and may be the contributing factor to the decreased compressive Young’s 
modulus of PCL/50-45S5 and PCL/50-SrBG scaffolds [239].  Another reason behind 
the deteriorated compressive Young’s modulus may be that the interfacial bond 
within the composite system is entirely dependent on the mechanical interlocking 
between the BG particles and the PCL matrix [239]. This gives rise to a weaker 
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interfacial bonding strength compared to chemical bonding [240-243], thus applied 
load may not be effectively transferred across from the matrix (PCL) to the 
reinforcement (BG particles). Additionally, PCL matrix incorporated with 50 wt% of 
BG particles is regarded as a highly filled polymer system [239, 244]. The presence 
of minor imperfection within the composite system can lead to failure of the system 
under mechanical stresses. In order to achieve ideal blending of the composite, 
specially designed processing equipment and controlled processing parameters is 
often required.  
 
5.4.2 Accelerated degradation of scaffolds 
Consistent with our previous study [225], PCL microfilament surfaces of PCL 
and PCL/CaP scaffold were roughened due to the hydrolytic degradation of PCL [6, 
212], but the overall structure of scaffolds remained intact even after 7 days of 
immersion in 5M NaOH. The degradation of PCL microfilament may have 
weakened the interfacial bonding between the CaP and the PCL surfaces, leading to 
the detachment of the CaP layer from the PCL scaffold surfaces.  
Generally, the degradation rate of PCL/BG composites (PCL/50-45S5 and 
PCL/50-SrBG) were greater compared to PCL and PCL/CaP scaffolds. This finding 
was in line with previous studies [159, 161, 225], where incorporation of BG or TCP 
particles into PCL matrix accelerated the composite scaffolds degradation rate. These 
accelerated degradation rates of PCL/BG composites is due to the formation of 
micro-pores on the composite scaffold surfaces during fabrication process and the 
inclusion of hydrophilic BG particles into the hydrophobic polymer matrix as 
described in our previous work [225].   
After just 6 hours of immersion in 5M NaOH, it was found that the rate of 
degradation of PCL/50-SrBG was 2.5 times greater than PCL/50-45S5. Similar 
outcomes were observed in our previous study [225]. The substitution of calcium for 
strontium can lead to the expansion of the silicate glass network [123, 124, 245], 
resulting in weakening of the glass network, resulting in higher dissolution rates of 
the SrBG. From a BG-containing composite scaffold perspective, the higher 
dissolution rate of SrBG particles leads to increased interfacial surface area for media 
intrusion and attack within a short period of time; thus, resulting in faster degradation 
rates for PCL/50-SrBG scaffolds compared to PCL/50-45S5 scaffolds.  
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In our previous work [225], the composite scaffolds containing 10 wt% of BG 
particles were retrievable after 24 hours of immersion in 5M NaOH. However, in this 
study, after 24 hours of immersion in 5M NaOH, all composite scaffolds were 
disintegrated and were no longer retrievable. These indicated that as the BG content 
increased, the degradation rate of the composite scaffold accelerated. Similar 
findings were reported by El-Kady et al. [42]. The increased amount of hydrophilic 
BG particles within the polymer matrix resulted in increased interfacial surface for 
media diffusion into the PCL bulk and increased surface area for degradation of 
PCL. As the PCL degraded, the continuous matrix system was disrupted to a point 
that it could not hold up the entire structure of the scaffolds. Thus, scaffolds became 
disintegrated and non-retrievable.  
 
5.4.3 Scaffold in vitro bioactivity  
The process of surface mineral nucleation and growth is a biomimetic process, 
involving a cycle of dissolution-reprecipitation mechanism [246]. The morphological 
and Ca/P ratio changes observed in the CaP coating on PCL scaffolds indicated that 
the CaP coating was undergoing transformation during the period of immersion in α-
MEM corresponding to the pH and ion concentration changes in the immersion 
media.  
The pronounced pH rise (figure 5.7e) observed in the immersion media of 
composite scaffolds (PCL/50-45S5 and PCL/50-SrBG) is a typical effect observed in 
immersion media containing BGs [123, 202, 247] due to the dissolution of BGs [13, 
124], releasing free ions into the immersion media as shown by the increased Si4+ 
and/or Sr2+ in the immersion media of composite scaffolds (figure 5.7a & b). This 
initial increase in pH has been reported to aid apatite formation by LeGeros [98]. The 
reduction of pH over time (figure 5.7e) is likely caused by the gradual apatite 
formation [13, 124] as seen in figure 5.8 g-r. The higher pH observed (first 3 days of 
immersion) for PCL/50-SrBG compare to PCL/50-45S5 may indicate higher 
dissolution rates of SrBG. This higher dissolution rate of SrBG can be explained by 
the weaker network bond and expanded glass network due to the substitution of 
calcium with strontium [123, 141, 245].  
Typically, dissolution of BG releases its ions into the immersion media 
prompting the exchange of Na+ from the glass with H+ and H3O
+ from the 
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surrounding solution, followed by a polycondensation reaction of surface silanols to 
create large surface area for heterogeneous nucleation and crystallization of a 
biologically reactive apatite layer [13, 14]. The concentration profile of Si4+, Sr2+, 
Ca2+ and PO4
3- of various scaffold’s immersion media (figure 5.7 a-d) and the EDX 
analysis of scaffold surface precipitates (figure 5.9 e-l) showed that the form of 
precipitates on PCL/50-45S5 and PCL/50-SrBG were different in composition, with 
Sr2+ incorporated into the network of apatite formed on PCL/50-SrBG surfaces. As 
the dissolution of BGs (45S5 or SrBG) continues, the immersion media are 
supersaturated with BG dissolution ions (Si4+, Ca2+ and PO4
3-), with Sr2+ as an 
additional element in the immersion media of PCL/50-SrBG scaffolds. With both the 
Ca2+ and Sr2+ being highly similar bivalent cations, Sr2+ can occupy the Ca2+ sites 
[246, 248, 249], thereby a mixed Ca-Sr-apatite was precipitated on the surface of 
PCL/50-SrBG scaffolds. It was also noted that, over time, as the Sr2+ concentration 
in the immersion media increased, the amount of Sr2+ incorporated into the apatite 
network increased. These findings were in line with Bigi et al. [248] and O’Donnell 
et al. [249] which reported that the preference for Sr2+ to enter the Ca2+ site in the 
mixed apatite is concentration dependent.   
As compared to our previous study [225], an increased amount of BG within 
the polymer matrix improved the scaffold’s in vitro bioactivity. In PCL composite 
scaffolds containing 10 wt% of BGs, only patches of precipitates were found on the 
scaffold surfaces after 28 days of immersion in α-MEM [225]. In this study, after a 
week of immersion in α-MEM, both PCL/50-45S5 and PCL/50-SrBG showed 
calcium-based precipitates on the scaffold surfaces which grew in thickness with 
immersion time. The increased wt% of BG within the PCL bulk [250] and the 
reduced BG particle size (higher BGs surface area/volume ratio) [250, 251] 
improved the composites bioactivity. The breakup of the outer silica layers of the BG 
network contributed to the increased level of Si4+ in the immersion media of PCL/50-
45S5 and PCL/50-SrBG, as well as releasing free Sr2+ into the immersion media of 
PCL/50-SrBG. In contrast to our previous work [225], inclusion of 50 wt% of BGs 
into the PCL matrix ensure continuous dissolution of  the BGs up to 10 weeks and 
can act as a long-term reservoir of BG and enable a constant diffusion of ions which 
are implicated in bone formation into the local microenvironment.  
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PCL scaffolds were not bioactive. The surface morphology changes observed 
on the PCL microfilament surfaces (figure 5.10 a-c) was most likely due to the 
degradation of PCL through non-enzymatic hydrolysis [6, 212]. 
Taken together, it is shown that PCL scaffolds containing 50 wt % of BG 
particles was bioactive in vitro (able to form precipitates when immersed in media). 
Moreover, all surface precipitates on scaffolds (PCL/CaP, PCL/50-45S5 and 
PCL/50-SrBG) undergo structural and compositional changes in response to the 
surrounding liquid conditions. However, to better characterise the scaffold surface 
precipitates, further chemical, morphological and structural analysis will be required. 
 
5.4.4 In vitro studies 
Pre-conditioning of scaffolds in culture media  
As shown in figure 5.7e, PCL/50-45S5 and PCL/50-SrBG caused a drastic pH 
increase in the immersion media in the first 24 hours. Thus, all scaffolds were pre-
conditioned with serum-free culture media for a week prior to cell seeding, 
preventing a potential cytotoxic effect on cells due to the drastic change in pH of 
culture media [38, 252].The pre-conditioning of the PCL/50-45S5 and PCL/50-SrBG 
scaffolds did not halt the dissolution of BG embedded within the PCL matrix, as 
shown by the continuous silica release from the composite (Figure 5.7a). 
Additionally, as shown in figure 5.8 (h & n), the pre-conditioning of PCL/50-45S5 
and PCL/50-SrBG scaffolds resulted in the formation of CaP-like precipitates on 
their surfaces. Similarly, Pryce and Hench [253] reported that pre-conditioning of 
BG has shown to decrease the rate of calcium and sodium dissolution, but did not 
affect the silica release from the 45S5 BG. While for PCL/CaP scaffolds, 
preconditioning does not significantly change the CaP coating morphology. The 
preconditioning of the PCL scaffolds in media for a week roughened the PCL 
scaffold surfaces (figure 5.10a), which can be beneficial for cell attachment. The 
duration of pre-conditioning of polymer-based bioactive scaffolds can potentially 
affect the cell survival, attachment, proliferation and ultimately osteogenesis [182, 
183]. For example, Verrier et al. [183] have pre-treated PDLLA/Bioglass® scaffolds 
in culture medium for 3 days and observed increased MG-63 cellular adhesion to 
scaffolds with 40 wt% of Bioglass® compared to scaffolds loaded with 5 wt% of 
Bioglass®. Conversely, Yang et al. [182] subjected PDLLA/Bioglass® scaffolds for 
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24 hours pre-treatment in culture medium, and found that scaffolds loaded with 5 
wt% of Bioglass® had significantly higher alkaline phosphatase (ALP) activity 
compared to scaffolds loaded with 40 wt% of Bioglass®. Authors suggest that 
prolonged pre-treatment on the scaffolds might be required as the alkalinisation of 
the culture medium upon dissolution of BG may be sufficient to be cytotoxic to 
osteoblasts, and hence decrease the alkaline phosphatase activity. 
 
5.4.5 Cell attachment, growth, proliferation and differentiation 
It has been reported that the surface micro-/nano-topography [254-258] and 
macro-/micro-porosities [259, 260] can influence cell morphology during 
attachment, as well as cell proliferation and differentiation. Cells on PCL scaffolds 
appeared more elongated, while the cells on PCL/CaP, PCL/50-45S5 and PCL/50-
SrBG scaffolds showed a more cuboidal shape with increased extension of filopodia 
and attachment points on scaffold surfaces as indicated on figure 5.11. The 
enhancements of filopodia extension, resulted in more extensive cellular bridges 
formation across the scaffolds’ microfilament (figure 5.12 and 5.13) on PCL/CaP, 
PCL/50-45S5 and PCL/50-SrBG scaffolds compared to that of PCL scaffolds.  
After 21 days in static culture (21S), the cells on PCL/50-45S5 and PCL/50-
SrBG scaffolds continued to proliferate and showed superior ability to extend and 
form cellular bridges across the microfilaments as compared to PCL and PCL/CaP 
scaffolds.  This may be because the dissolution of BGs (45S5 or SrBG) constantly 
released free ions, such as Ca2+, Si4+ and/or Sr2+ into the surrounding environment 
[12], accelerating proliferation of cells [12, 196, 261], leading to formation of cell 
sheet bridges across the scaffold pores. As illustrated in figure 5.16 (using PCL/BG 
composite scaffold as an example), cells on the scaffold are regulated by the scaffold 
surface chemistry and/or the BG dissolution ions present within the surrounding 
culture media. Therefore, it is not surprising to get improved cell growth and 
proliferation on PCL/50-45S5 and PCL/50-SrBG scaffolds as compared to PCL-only 
scaffolds. For cells seeded on PCL scaffolds, no additional chemical cue was present 
to regulate cell growth and proliferation. We speculate that, although, CaP-coating 
on the PCL scaffolds undergoes transformation through ion exchange with the 
surrounding culture media, the rate of the CaP precipitate’s transformation was 
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slower and less dynamic than that of dissolution of BGs, thereby the effect on cell 
growth and proliferation was not prominent in the 21 days static culture.  
 
 
 
 
 
 
 
 
 
 115 
Chapter 5: (Study 2) Comparison of composite scaffold osteogenesis potential in vitro.                                  115 
 
Figure 5.16 (a-b) illustrates the dissolution of (a) 45S5 bioactive glass (BG) or (b) 
strontium-substituted BG (SrBG) particles embedded within a polycaprolactone 
(PCL) matrix upon exposure to biological fluid. At the early stage, dissolution of BG 
particles only occurred to BG particles exposed on the composite surface. Over time, 
as PCL degraded away, BG particles embedded within the PCL matrix were 
exposed, thus dissolution of BG continued.  Dependent on the quantity/type of BG 
incorporated into the composite system, the amount/type of dissolution ions released 
into the surrounding environment varied, which could in turn affect the cell 
behaviour.  (c-e) An illustration of the progress of cell growth on a composite 
scaffold containing BG particles. (c) During the early phase of cell culture, cells 
attached to the scaffold microfilament surfaces and were regulated by the scaffold 
surface chemistry, as well as BG dissolution ions (i.e. Ca2+, Si4+, Sr2+, PO4
3- etc.) 
present in the media. Over time, (d) the cells proliferate and secrete extracellular 
matrix (ECM) forming a confluent layer of cells along the scaffold microfilaments. 
As this progresses, (e) cell sheet (cells + extracellular matrix (ECM)) start bridging 
across the scaffold pores. The cells present at the cell sheet were regulated by the BG 
dissolution ions but not the scaffold surface chemistry.  
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The commonly used assays to determine extracellular matrix (ECM) 
mineralisation, such as von Kossa (stains for calcium phosphate and calcium 
carbonates) and Alizarin red S (stains for calcium), were not utilised as the PCL/CaP, 
PCL/50-45S5 and PCL/50-SrBG scaffolds contain large amounts of calcium and 
phosphate ions, and can give rise to false positive results. Therefore, gene expression 
was used to quantify the extent of cell differentiation between the different materials. 
OPN was expressed in the early stage of differentiation of osteoblast progenitors in 
the bone marrow and is a direct indicator of pre-osteoblast proliferation in vitro [262, 
263]. On the other hand, OCN is secreted by mature osteoblasts, thereby is 
commonly used to represent terminal osteoblast differentiation [263, 264].  
Under static culture conditions, it was shown that the OPN gene expression 
was significantly higher in PCL/CaP, PCL/50-45S5 and PCL/50-SrBG groups 
compared to that of PCL groups, cultured in non-osteogenic and osteogenic culture 
media. This indicated that the CaP-coating and incorporating BGs within PCL 
scaffolds can stimulate pre-osteoblast proliferation. In the 14 and 21 days culture 
(14S and 21S), across all groups, OCN expression was higher when cultured in 
osteogenic media. This indicated that osteo-supplemented media can promote early 
and enhanced osteoblast differentiation. However, in prolonged culture (21S), even 
in non-osteogenic media, although not comparable to the same material cultured in 
osteogenic media, OCN expression for PCL/50-45S5 and PCL/50-SrBG groups was 
upregulated. This indicated that the dissolution products of the BGs can promote 
osteoblast differentiation [15, 265-267].   Currently, the reason behind the observed 
elevated OCN expression for PCL/50-45S5 (in 14S-Os, 21S-Ctrl and 21S-Os, figure 
5.15b) compared to PCL/50-SrBG is not known, but can be narrowed down to the 
difference in the ion dissolution products of 45S5 and SrBG. It has been reported that 
culture medium microenvironment changes due to the presence of BGs, for example, 
pH [268] and BG dissolution ions [15, 134, 268], can subsequently affect cell 
behaviour. To help identify the roles of different BGs in osteoblast proliferation and 
differentiation; future studies should include the respective pH changes, as well as 
ion concentrations within the cell culture medium.  
Using a conventional tissue culture plate and static environment for a scaffold 
culture presents limitations on the nutrients/waste transfer. It has been widely 
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reported that dynamic culture environments can positively induce cell proliferation 
and osteogenic differentiation due to mechano-transduction forces exerted on the 
scaffold [226, 231, 235, 269-271]. When subjected to dynamic culture environments, 
cell growth and proliferation were generally elevated, especially in pro-longed 
culture periods (21S vs. 7S14D). Additionally, for PCL and PCL/CaP scaffolds, 
where the proliferation was seen to be halted in the static culture (14S through to 
21S), in dynamic environment, the cells continue to proliferate (7S7D through to 
7S14D). Under static and dynamic culture environments, the OPN and OCN gene 
expression profiles were similar (14S vs. 7S7D and 21S vs. 7s14D). However, the 
OPN and OCN gene expressions in the dynamic culture condition were generally 
higher when compared to those of the static culture environment.  The increased 
efficiency in nutrients/wastes transport and the mechano-transduction forces exerted 
on the scaffold in the dynamic culture condition may have contributed to the 
increased in vitro osteoblast differentiation observed.  
It was also noted that while the OPN expression was upregulated for the 
PCL/CaP scaffolds, when cultured in non-osteogenic media, OCN was not highly 
expressed in the same group. Conversely, when cultured in osteogenic media, the 
OCN expression was upregulated. Thus, it is speculated that although the CaP 
coating can help direct cells towards a pre-osteoblast phenotype, the deficiency in 
osteogenic supplements failed to further direct the pre-osteoblast differentiation into 
mature osteoblasts in vitro. Most studies using CaP or CaP-like coated polymer 
scaffolds showed an upregulation of OCN; however, in these studies, the 
cell/scaffold constructs were cultured in osteogenic media which is a considerable 
boost to the osteogenicity of the system [51, 54, 272]. In another study, with CaP-
coated PCL scaffolds, the authors utilised the alkaline phosphatase (ALP) activity 
assay to assess the ability of cells to differentiate into osteoblasts (ALP is an early 
marker for osteoblast differentiation, upstream of OPN) and µ-CT to help determine 
the extent of mineralisation [11]. It was shown that when cultured in non-osteogenic 
media, the ALP activity was enhanced, but the mineralisation on the scaffolds was 
negligible; however, when cultured in osteogenic media, both the ALP and the extent 
of mineralisation were drastically increased [11]. Although the methods used were 
different, the findings of this study coincide with our findings.  
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5.5 SUMMARY OF STUDY 2 
Fabrication of composite scaffolds containing a high loading of BGs was 
shown to be feasible. The inclusion of higher wt% of BGs into the polymer bulk can 
improve the composite scaffolds bioactivity but compromised the scaffolds’ 
compressive Young’s modulus. The CaP coating on PCL scaffolds provides an 
alternative to improve the scaffold surface bioactivity without compromising the 
scaffold’s compressive Young’s modulus, but does not provide a long term reservoir 
of free ions which could be beneficial for bone regeneration. The increased BG 
content within the PCL scaffolds accelerated the rate of PCL/BG scaffold 
degradation in vitro, while CaP-coating had negligible effects on the rate of in vitro 
scaffold degradation as compared to PCL scaffolds. All the scaffolds were able to 
support cell adhesion, growth and proliferation. All scaffolds showed the capabilities 
to upregulate osteoblast-related gene expression (OPN and OCN) when cultured in 
osteogenic media. Conversely, when cultured in non-osteogenic media, PCL/CaP 
scaffolds upregulated OPN expression, whilst PCL/50-45S5 and PCL/50-SrBG 
scaffolds upregulated both OPN and OCN expression. When subjected to a dynamic 
culture environment, the rate of cell growth, proliferation and osteoblast-related gene 
expression was enhanced across all scaffold groups.      
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Chapter 6: (Study 3) Testing of 
osteoinductive capability of 
PCL/CaP-coated, PCL/50-45S5 
and PCL/50-SrBG scaffolds in 
vivo using a subcutaneous rat 
model.  
6.1 INTRODUCTION 
Chapter 6 is a continuation of the work covered in Chapter 5 whereby the 
scaffolds which were developed and tested in vitro (in Chapter 5) were then 
implanted in vivo in a small animal model.  
In Chapter 5, it was indicated that polycaprolactone (PCL) scaffolds coated 
with calcium phosphate (PCL/CaP), and PCL scaffolds containing 50 wt% of 45S5 
Bioglass® (PCL/50-45S5) or strontium-substituted bioactive glass (PCL/50-SrBG) 
upregulated the expression of osteoblast-related genes, indicating a better bone 
formation potential compared to PCL-only scaffolds. Therefore, in this next study, 
these scaffolds (PCL/CaP, PCL/50-45S5 and PCL/50-SrBG) were subcutaneously 
implanted into the back of nude rats with or without pre-cultured sheep bone marrow 
stromal cells (BMSCs) in osteogenic supplemented media under dynamic culture 
conditions. At experimental end-points, scaffolds were explanted and underwent 
paraffin or resin histological analysis for the assessment of host tissue infiltration and 
blood vessel in-growth into the scaffolds’ pores, as well as mineralised tissue 
formation.    
 
6.2 METHODS AND MATERIALS 
6.2.1 Scaffold implantation groups 
PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG scaffolds fabricated via 
melt extrusion, measuring 6 × 6 × 6 mm with ~75% porosity were used in this study. 
The scaffolds were characterised as previously described in Chapter 5. Each scaffold 
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group was further divided into 2 experimental groups which either included cells or 
were cell-free as listed in Table  6.1.  
 
Table 6.1 Lists of experimental groups for subcutaneous implantation. 
 
6.2.2 Cell culture 
All scaffolds were sterilised by immersion in 70% ethanol (MERCK) for 15 
minutes, and were air dried to allow complete evaporation of the 70% ethanol and 
underwent UV-sterilisation for 20 minutes on each surface. All scaffolds were pre-
conditioned in serum-free culture media consisting of α-MEM media (Invitrogen) 
and 1% (v/v) penicillin/streptomycin (Invitrogen) for 1 week prior to cell seeding. 
Ovine bone marrow stromal cells (BMSCs), passage 3, were used for all cell 
cultures. Cells were maintained T175 tissue culture flasks with growth media 
consisting of α-MEM media, 1% (v/v) penicillin/streptomycin and 10% (v/v) foetal 
bovine serum (FBS) (Invitrogen) prior to cell seeding.  
 
Cell seeding and culturing on scaffolds: 
Scaffolds (6 × 6 × 6 mm) were initially seeded with 500 µl of cell suspension 
(1 million cells/ scaffold) in 6-well plates. The pre-seeded scaffolds were incubated 
at 37°C for 90 minutes before being topped up with 3 ml of growth media. After 24 
hours, the cultures were changed to osteogenic induction media, consisting of growth 
media supplemented with 10 mM glycerol 2-glycerophosphate, 50 µg/mL L-ascorbic 
acid-2-phosphate and 100 nM dexamethasone (Sigma). From here on, the cell seeded 
scaffolds will be referred to as cell/scaffold constructs. After 1 week in static culture, 
the cell/scaffold constructs were subjected to dynamic culture using TisXell biaxial 
bioreactor [226] for 2 weeks in an enclosed vessel containing 500 ml of culture 
media. 
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6.2.3 In vivo studies 
Scaffold preparation prior to implantation: 
Scaffold only group:  
Scaffolds were sterilised by immersion in 70% ethanol for 15 minutes and UV-
sterilisation for 20 minutes on each surface. Subsequently, scaffolds were pre-treated 
in culture media (α-MEM + penicillin/streptomycin) for 1 week prior to 
implantation. The scaffolds were maintained in a humidified incubator at 37ºC and 
5% CO2, until implanted. 
 
Cell seeded scaffold group: 
On the day of implantation, cell/scaffold constructs were retrieved from the 
biaxial bioreactor and placed in a tissue culture plate after 3 weeks in vitro culture. 
The cell/scaffold constructs were maintained in a humidified incubator at 37ºC and 
5% CO2, until implantation.  
 
Subcutaneous implantation: 
Animal work was approved by the Animal Ethics Committee of Queensland 
University of Technology (ethics approval number: 11-147) (Appendix B).  In vivo 
studies were undertaken using an athymic nude rat subcutaneous model. Eight-week 
old male RNU rats (Animal Resources centre, Australia) were purchased and 
anaesthetized with a mixture of Ketamine (100 mg/kg) and xylazine (10 mg/kg). In a 
sterile manner, six small incisions were made longitudinally along the central line of 
the shaved dorsal area, approximately 2 cm apart, and subcutaneous pockets were 
created with a pair of surgical scissors. Each individual pocket held one scaffold of 
each of the scaffold groups listed in Table 6.1. Scaffolds were randomly assigned to 
the subcutaneous pocket created. The surgical incisions were closed with surgical 
sutures. The animals were sacrificed after eight and sixteen weeks and the explants 
(n = 6 for each group) were retrieved and fixed in 4 % paraformaldehyde in PBS at 
pH 7.4 overnight, then stored in 70% ethanol until further analysis. 
 
6.2.4 Histology and immunohistochemistry 
Paraffin embedding and sectioning: 
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Explants were decalcified in 10% EDTA at pH 7.4 for 3 months at 4°C with 
changes of solution twice a week. Following decalcification, samples were 
dehydrated in a graded series of ethanol and infiltrated with paraffin using a tissue 
processor (Thermo Scientific, Excelsior ES) in an overnight protocol (3 changes of 
70% ethanol, 1 hour each; 2 changes of 90% ethanol, 1 hour each; 3 changes of 
100% ethanol, 45 minutes each; 3 changes of xylene, 45 minutes each; and 3 changes 
of paraffin, 45 minutes each). Then, samples were embedded into blocks of paraffin 
(Thermo Scientific Shandon, Histocentre 3) and stored at room temperature until 
sectioning.  Paraffin embedded samples were sectioned using a microtome (Leica 
RM2265) to obtain 5 µm thick sections which were collected onto Polysine® 
microscope slides (Thermo Scientific) and dried overnight at 50ºC.  
 
Histochemistry and immunohistochemistry: 
For all histology and immunohistochemistry analyses, tissue sections near the 
central area of the implants were used. For histological analysis, tissue sections were 
stained with haematoxylin and eosin (H&E) using an autostainer (Leica, ST5010 
Autostainer XL). Briefly, the tissue sections were deparaffinised (2 changes of 
xylene, 6 minutes each) and rehydrated in a graded ethanol series (100%, 90%, and 
70% ethanol, 3 minutes each; dH2O for 3 minutes). Following that, tissue sections 
were stained with Mayer’s Haematoxylin for 10 minutes, washed with tap water for 
10 minutes, and stained with Eosin for 10 seconds. Then, tissue sections were 
dehydrated through ascending ethanol series (70%, 90% and 100% ethanol, 3 
minutes each, and 2 changes of xylene, 6 minutes each) and cover-slipped using 
Eukitt® mounting media (Sigma-Aldrich).  
For immunohistochemistry, samples were deparaffinised and rehydrated, 
endogenous peroxidase activity within the sections was quenched by incubating with 
3% H2O2 for 20 minutes then blocked with 2% BSA for 60 min at room temperature 
to minimise non-specific antibody binding. After 3 washes with Tris-HCL (pH 7.4, 2 
minutes each), antigen retrieval was performed using Proteinase K solution (DAKO) 
for 10 minutes. Then, samples were incubated in mouse-anti-human osteocalcin 
(Abcam, ab13418, stock: 2mg/ml, dilution 1:500), and rabbit anti-human von 
Willebrand factor (Milipore, AB7356, stock: 1mg/ml, dilution 1:300) primary 
antibody in 2% BSA/PBS overnight at 4°C in a humidified chamber. To rule out 
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non-specific reactions of rabbit or mouse IgG on the examined sections, non-
immunised mouse or rabbit IgG was used as an isotype control. Samples were 
washed 3 times in Tris-HCL and incubated with peroxidase-labelled dextran polymer 
conjugated goat anti-mouse and anti-rabbit immunoglobulins (DAKO Envision + 
Dual Link System Peroxidase, Botany Australia) at room temperature for 45 minutes 
in a humidified chamber. The antibody complexes were visualised by the addition of 
a buffered diaminobenzidine (DAB)-based system (DAKO). After colour 
development, samples were washed with Tris-HCL and counterstained with Mayer’s 
haematoxylin (HD Scientific Pty. Ltd., Australia) for 3 minutes and blued in tap 
water for 10 minutes. Subsequently, tissue sections were dehydrated in a graded 
ethanol series (50%, 70%, 95% ethanol, 2 minutes each; 2 changes of xylene, 5 
minutes each) and mounted with Eukitt® mounting media (Sigma-Aldrich). 
All stained sections for histochemistry and immunohistochemistry were 
imaged using a histology slide scanner (Leica, SCN400) at x20 magnification.      
 
Resin embedding, sectioning and staining 
For the assessment of tissue calcification, half of the explants were embedded 
in Technovit® 9100 resin system to enable detection of mineralised tissue formation 
within the explants. Prior to embedding, explants were dehydrated through a series of 
ethanol, at 4°C: 70 % ethanol for one week, 80% ethanol for one week, 90% ethanol 
for one week, and 2 changes of 100% ethanol for 3 days each. After which, the 
dehydrated explants were immersed in two changes of xylene for 4 hours each at 
room temperature, and transferred into Technovit® 9100 pre-infiltration solution for 
one week, at 4°C. Then, the explants were transferred into Technovit® 9100 
infiltration solution and stored at 4°C for a week. Subsequently, the explants were 
transferred into Technovit® 9100 embedding solution, and subjected to vacuum 
infiltration for 5 minutes to ensure the elimination of entrapped bubbles within the 
explants. Finally, the explants in the embedding solution were stored at -20°C until 
completely polymerised. All Technovit® 9100 solutions were prepared as 
recommended by the manufacturer (Heraeus Kulzer, Germany).      
After completion of the embedding process, the resin blocks were trimmed 
using the EXAKT 310 diamond bandsaw. Then, the embedded samples were cut into 
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6 µm sections using a sledge microtome (Reichert-Jung, Polycut S), flattened with 
100% ethanol and collected onto a gelatine-coated microscope glass slide. Sections 
were overlaid with a plastic film, clamped together and dried for 12 hours at 62ºC. 
Throughout the sectioning period, tissue blocks were kept moist with 30% ethanol.  
MacNeal’s tetrachrome with von Kossa staining were performed on thin resin 
sledged sections obtained near the central area of the sample for visualisation of 
mineralised bone. Briefly, the sections were deplastified with three changes of 
acetone for 20 minutes each, at room temperature. Then, slides were hydrated with 
descending concentration of ethanol (100 %, 90% and 70% for 5 minutes each), and 
rinsed with distilled water for 5 minutes. Following that, slides were stained with 
silver nitrate solution (Fisher) (20 g in 400 mL distilled water) for 5 minutes. After 
being washed with three changes of distilled water for one minute each, the stain was 
developed in sodium carbonate-formaldehyde solution (Fisher) (22.5 g sodium 
carbonate, 112.5 mL formaldehyde, and 337.5 mL distilled water) for 2 minutes. 
Then, slides were washed in two changes of distilled water for one minute each, and 
submerged in Farmer’s diminisher solution (Fisher) (2 g potassium ferricyanide, 40 g 
sodium thiosulfate, and 420 mL distilled water) for 30 seconds, with gentle agitation. 
Subsequently, slides were placed under running tap water for 20 minutes, and stained 
with Macneal’s tetrachrome (12 g in 600 mL distilled water) for 5 min, rinsed in 
distilled water for 30 s, and dehydrated in ascending concentrations of ethanol (70% 
and 100% ethanol for 30 seconds each), and two changes of xylenes (Fisher) for 3 
min each. Slides were finally mounted using Eukitt mounting media and scanned 
using a histology slide scanner (Leica, SCN400). 
 
6.2.5 Histomorphometry 
Histomorphometrical analyses for the extent of vascularisation within explants 
were undertaken using the Osteomeasure histomorphometry analysis system 
(Osteometrics Inc., Decatur, GA, USA). The tissue sections which were stained with 
H & E were examined and only blood vessels within the pores of scaffold with 
visible red erythrocytes within the vessel lumen were counted. The measurement was 
performed blinded on 3 tissue sections from each scaffold at each time-point. Data 
presented are the number of blood vessel per mm2 of tissue area.  
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6.2.6 Data Analysis 
Quantitative data presented as mean ± S.D. and were subjected to two-way 
analyses of variance (two-way ANOVA) and Tukey’s post-hoc test (SPSS Version 
11.02). Significance levels were set at p<0.05. 
 
6.3 RESULTS 
6.3.1 Cell morphology  
The cell morphology on scaffolds after 7 days of static culture, and a further 14 
days of dynamic culture were visualised using light microscopy. Cells were able to 
form cell sheets and bridge across the scaffolds microfilaments, regardless of 
material (figure 6.1 a-f). On the transverse pores (figure 6.1 a, c, and e), cell sheet 
bridging were more extensive in the PCL/50-45S5 and PCL/50-SrBG scaffolds 
compared to that of PCL/CaP scaffolds.  
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Figure 6.1 Light microscopy images of (a, b) PCL/CaP, (c, d) PCL/50-45S5 and (e, f) 
PCL/50-SrBG cell/scaffold constructs prior to implantation. * represents cell sheet 
(cells + extracellular matrix (ECM)) bridging across the scaffold pores. Scale bar = 
500 µm. 
 
6.3.2 Ectopic bone assay 
Subcutaneous implantation, post-surgery and explantation: 
Scaffolds (PCL/CaP, PCL/50-45S5 and PCL/50-SrBG) with or without cells (figure 
6.2a) were implanted into the back of male RNU rats (figure 6.2b). After 2 days, 
rashes were observed on one of the rat skin but resolved within the 1st week of post-
surgery. All animals survived until the pre-determined end-point of the experiments 
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(8 and 16 weeks). During explantation, it was observed that the scaffolds integrated 
well with host tissue within the subcutaneous pocket and ample host vasculature in-
growth into the scaffold was observed (figure 6.2 c & d).   
 
Figure 6.2 Representative photos of scaffolds before and after implantation. (a) 
Scaffold prior to implantation. (b) Implantation of scaffold into subcutaneous pocket 
created on the back of rat. (c, d) Representative photograph of scaffold explant after 
(c) 8 and (d) 16 weeks, with visible blood vessel in growth into the scaffolds. Scale 
bar = 1 cm. 
 
Histological analysis 
The gross morphology of the explanted scaffold was visualised using H & E staining. 
A mixture of fibrous connective tissue and adipose tissue had infiltrated the scaffolds 
in all experimental groups. At experimental end points, no evidence of mature bone 
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was observed. Figures 6.3- 6.6 show tissue sections stained with vWF, which 
specifically stained for the endothelial cells present in blood vessels (figure 6.7).  At 
both time-points, no differences in blood vessel density were found between the 
acellular and cell seeded scaffold group. After 16 weeks of implantation, all explants 
showed reduced blood vessel density compared to that of respective 8 weeks 
explants. Additionally, after 16 weeks of implantation, the density of blood vessels 
was significantly lower for PCL/50-45S5 and PCL/50-SrBG explants compared to 
that of PCL/CaP (figure 6.7).  
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Figure 6.3 Representative (a, d, g) haematoxylin and eosin (H&E) stained images (x10 
maginification) and (b, e, h) immunostaining for Von-Willebrand  factor (vWF) (x20 
magnification)  with the corresponding (c, f, i) isotype control (x20 magnification) images of  
(a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) PCL/50-SrBG cell free scaffolds explanted after 8 
weeks. F-fibrous tissue, A-adipose tissue, red arrow () blood vessel. Scale bars = 100 μm. 
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Figure 6.4 Representative (a, d, g) haematoxylin and eosin stained images (H&E) (x10 
maginification) and (b, e, h) immunostaining for Von-Willebrand  factor (vWF) (x20 
magnification)  with the corresponding (c, f, i) isotype control (x20 magnification) images of  
(a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) PCL/50-SrBG scaffolds pre-seeded with sheep 
bone marrow stromal cells explanted after 8 weeks. F-fibrous tissue, red arrow () blood 
vessel.  Scale bars = 100 μm. 
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Figure 6.5 Representative (a, d, g) haematoxylin and eosin stained images (H&E) (x10 
maginification) and (b, e, h) immunostaining for Von-Willebrand  factor (vWF) (x20 
magnification)  with the corresponding (c, f, i) isotype control (x20 magnification) images of  
(a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) PCL/50-SrBG cell free scaffolds explanted after 16 
weeks. F-fibrous tissue, A-adipose tissue, red arrow () blood vessel. Scale bars = 100 μm. 
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Figure 6.6 Representative (a, d, g) haematoxylin and eosin (H&E) stained images (x10 
maginification) and (b, e, h) immunostaining for Von-Willebrand  factor (vWF) (x20 
magnification)  with the corresponding (c, f, i) isotype control (x20 magnification) images of  
(a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) PCL/50-SrBG scaffolds pre-seeded with sheep 
bone marrow stromal cells explanted after 16 weeks. F-fibrous tissue, A-adipose tissue, red 
arrow () blood vessel.  Scale bars = 100 μm. 
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Figure 6.7 Number of blood vessels per mm2 of tissue area. Mean ± S.D. p= 0.05. #: 
statistically lower compared to that of respective 8 weeks explant group. *: significantly 
lower compared to that of PCL/CaP explants within the same group.  
 
Osteocalcin (OCN) is the most bone specific non-collagenous matrix protein, 
localised at the seam of osteoblasts in the mineralised bone, the osteocyte lacuna and 
the cement line [76]. Therefore it can be used as an indication for the extent of bone 
formation in demineralised tissue sections [7, 76, 273, 274]. As shown in figure 6.9 
to 6.10, negative OCN staining was observed across all groups, except in the 
PCL/50-45S5 cell seeded scaffold, where rare and localised positive OCN tissue 
stain was observed. With extended implantation time (16 weeks) (figure 6.11-6.12), 
the OCN strongly stained across the entire tissue section without any localised 
enhanced staining observed for all groups. 
 
Figure 6.8 Scaffold schematic illustrating the tissue area (red box) imaged and shown 
in figure 6.9-6.12 (a, d, & g). 
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Figure 6.9 Representative (a, d, g) haematoxylin and eosin (H&E) stained images (x4 
magnification, showing tissue area within the central pore of the scaffold) and (b, e, h) 
immunostaining for osteocalcin (OCN) (x10 magnification)  with the corresponding (c, f, i) 
isotype control (x10 magnification) images of  (a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) 
PCL/50-SrBG acellular scaffolds explanted after 8 weeks. Scale bars = 100 μm. Yellow 
boxes represent tissue area shown for the immunostaining for OCN/isotype control of 
respective implant groups.  
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Figure 6.10 Representative (a, d, g) haematoxylin and eosin (H&E) stained images (x4 
magnification, showing tissue area within the central pore of the scaffold) and (b, e, h) 
immunostaining for osteocalcin (OCN) (x10 magnification)  with the corresponding (c, f, i) 
isotype control (x10 magnification) images of  (a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) 
PCL/50-SrBG scaffolds pre-seeded with sheep bone marrow stromal cells explanted after 8 
weeks. Scale bars = 100 μm. Yellow boxes represent tissue area shown for the 
immunostaining for OCN/isotype control of respective implant groups. 
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Figure 6.11 Representative (a, d, g) haematoxylin and eosin (H&E) stained images (x4 
magnification, showing tissue area within the central pore of the scaffold) and (b, e, h) 
immunostaining for osteocalcin (OCN) (x10 magnification)  with the corresponding (c, f, i) 
isotype control (x10 magnification) images of  (a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) 
PCL/50-SrBG acellular scaffolds explanted after 8 weeks. Scale bars = 100 μm. Yellow 
boxes represent tissue area shown for the immunostaining for OCN/isotype control of 
respective implant groups. 
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Figure 6.12 Representative (a, d, g) haematoxylin and eosin (H&E) stained (x4 
magnification, showing tissue area within the central pore of the scaffold) and (b, e, h) 
immunostaining for osteocalcin (OCN) (x10 magnification)  with the corresponding (c, f, i) 
isotype control (x10 magnification) images of  (a-c) PCL/CaP, (d-f) PCL/50-45S5, (g-i) 
PCL/50-SrBG scaffolds pre-seeded with sheep bone marrow stromal cells explanted after 16 
weeks. Scale bars = 100 μm. Yellow boxes represent tissue area shown for the 
immunostaining for OCN/isotype control of respective implant groups. 
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MacNeal’s tetrachrome with von Kossa was utilised for the detection of 
mineralised tissue within the explanted scaffold. During histology processing, xylene 
dissolved the PCL, but BG particles remained in the area corresponding to the 
scaffold struts, and were stained black by von Kossa, which binds to the phosphate 
group present in the BGs (figure 6.13 b & c). The BG can be seen clearly in the 
symmetrical scaffold pattern in figure 6.13 b & c. However, during the staining 
process, dislodging of the BG particles from the resin section was observed. The 
staining of the particles in combination with the dislodging of the BGs particles from 
the PCL scaffolds could potentially create a certain degree of artefact which could 
give false positive results. Thus, to determine the area of mineralised tissue, two 
consecutive sections were viewed for each sample. The mineralised island was 
confirmed if it was observed in both the consecutive sections at the exact same 
location.   
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Figure 6.13 Representative images of (a,b) PCL/CaP, (c,d) PCL/50-45S5 and (e,f) PCL/50-
SrBG cell-free scaffold explanted after 8 weeks, and stained with MacNeal’s tetrachrome 
and von Kossa. The red arrow () in a, c and e points towards the general area previously 
occupied by the scaffold strut. The red box in a, c and e represents area of magnification 
shown in b, d, and f, respectively. It was shown that the BG particles (yellow colour *) 
present within the PCL struts of (d) PCL/50-45S5 and (f) PCL/50-SrBG were stained by von 
Kossa. The area contained with the red dotted line box in (d) showed dislodging BG 
particles.  Blue: soft tissue stained by MacNeal’s tetrachrome, black: BG particles stained by 
von Kossa which binds to the phosphate group present in BG.   
 
Notably, we observed sporadic mineralised islands in the acellular PCL/50-
SrBG scaffold explants after 8 and 16 weeks of implantation as shown in figure 6.14. 
Such mineralised islands were not observed in all other groups.  
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Figure 6.14 MacNeal’s Tetrachrome with von Kossa staining for resin embedded PCL/50-
SrBG scaffold-only group explanted after (a) 8 and (b) 16 weeks. Sporadic mineralised 
tissues were observed within the scaffolds as shown in the x40 magnifications light 
microscopy images. Blue (MacNeal’s tetrachrome): stained for soft tissue; Black (von 
Kossa): stained for mineralised tissue. 
 
6.4 DISCUSSION 
Ectopic implantation (using a soft tissue animal model) of 
scaffolds/biomaterials alone or in combination with cells is an established approach 
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to evaluate the osteoinductive potential of the implants [11, 55]. In this study, such 
an ectopic implantation model in the athymic nude rat was utilised to evaluate the 
osteoinductive capability of PCL/CaP, PCL/50-45S5 and PCL/50-SrBG scaffolds. In 
the past years, there is an accumulation of studies indicating that osteogenic 
differentiated cells along with the mineralised extracellular matrix (ECM) is the main 
driving force for osteoinductivity on resorbable polymeric scaffolds [11, 56]. 
Therefore, to evaluate if the use of cells can improve the scaffold osteoinductivity as 
compared to cell-free scaffold, scaffolds were also seeded with ovine BMSCs and 
subjected to culturing in osteogenic media prior to implantation.  
 For bone TE purposes, it is important that the scaffold/construct utilised can 
permit cell/tissue infiltration, as well as blood vessel ingrowth. The in-growth of 
blood vessels is particularly important as it facilitates the nutrient diffusion between 
cells and biological fluids, thereby establishing a sustainable microenvironment for 
cell survival, proliferation, differentiation and secretion of extracellular matrix 
materials for tissue formation. In this study, all scaffolds or cell/scaffold constructs 
permitted cells/tissues infiltration and blood vessel ingrowth thereby sustaining the 
tissue formed within the pores of the scaffold. From week 8 to week 16 post-
implantation, the number of blood vessels per tissue area decreased (figure 6.7). In 
the 16 weeks explanted samples, the blood vessel network may be undergoing 
remodelling and maturation, whereby blood vessels were undergoing stabilisation or 
regression [275] .  
In this current study, qualitative assessment of demineralised tissue sections 
(paraffin embedded samples) for OCN and evaluation of non-demineralised tissue 
sections (resin embedded samples) with MacNeal’s tetrachrome-von Kossa showed 
no indication of mineralised tissue formation in any of the scaffold groups 
(PCL/CaP, PCL/50-45S5 and PCL/50-SrBG). This indicated that none of the 
scaffolds and cell/scaffold constructs are osteoinductive when implanted for 8 and 16 
weeks.  This may be because the ions released by the CaP coating (Ca2+, P-) or the 
BG particles embedded within the PCL matrix (Ca2+, P-, Si4+, Sr2+) gradually diffuse 
away from the fully interconnected porous scaffold, and did not attain a certain 
threshold to initiate osteogenic differentiation and bone formation [11]. In line with 
this, a study by Vaquette et al. [11] showed no bone formation for cell-free 
PCL/CaP-coated melt electrospun scaffold implanted subcutaneously in rats for 8 
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weeks. Similarly, 8 weeks of subcutaneous implantation of cell-free polymer-
based/BG composite scaffolds has not shown signs of mineralised tissue or mature 
bone formation [56, 182]. The sporadic mineralised nodules observed within the 
pores of PCL/50-SrBG scaffold only group (figure 6.14) do not seem to constitute 
mature bone or viable mineralised tissue. We postulate that this observed 
phenomenon, is similar to the process of CaP-based ceramics or BGs 
biomaterial/bone interface formation process described by Dalcusi et al. [276] and 
Hench et al. [13]. These mineralised islands may have formed due to the dissolution 
of SrBG particles, causing the saturation of the microenvironment with SrBG 
particles dissolution ions which complexes with other ions present in the biological 
fluid. However, the amount of free ions released may not be sufficient to induce cell 
differentiation. This phenomenon was not observed for PCL/50-SrBG cell-seeded 
scaffold group. This may be associated with the duration of pre-culture these 
cell/scaffold constructs were subjected to prior to implantation. The scaffold only 
group was pre-conditioned in serum free culture media for a week prior to 
implantation, while for the cell/scaffold constructs, in addition to the one week pre-
conditioning in serum free-culture media, it was subjected to a further 21 days of cell 
culture prior to implantation. During the extended period of in vitro culture with 
cells, the dissolution of SrBG particles continues, thus, upon implantation, the 
amount of SrBG dissolution ions available on the surface of the PCL/50-SrBG 
scaffolds with cells might be lower compared to PCL/50-SrBG scaffolds without 
cells. Consequently, less SrBG dissolution products were released to the implant 
microenvironment and the quantity was insufficient to surpass the threshold to 
initiate mineralised island formation. These mineralised nodules were not observed 
for PCL/50-45S5 and PCL/CaP, both for the scaffold only and for cell/scaffold 
construct groups. For the PCL/50-45S5 composite scaffold, this may be associated 
with the composite scaffolds inherent properties, such as the composite scaffold 
degradation rate and hydrophilicity and dissolution rate of 45S5, which can all 
contribute towards the overall 45S5 dissolution products available at the implant 
microenvironment, consequently, the formation of mineralised islands. As for the 
PCL/CaP scaffold, the CaP-coating can undergo transformation involving cycles of 
dissolution and reprecipitation mechanisms [98], however, this process is less 
dynamic compared to BGs, thereby the dissolution products may not be sufficient to 
induce the formation of mineralised islands.  
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Pre-culture of cells on scaffolds in osteogenic supplemented media has been 
shown to improve the cell/scaffold osteoinductivity, resulting in ectopic bone 
formation [11]. It was shown that melt-electrospun PCL scaffolds (with or without 
CaP coating), when subjected to pre-culture in osteogenic media for 8 weeks prior to 
implantation can induce bone formation ectopically [11]. On the other hand, Gomide 
et al. [56] showed formation of osteoid-like tissue on a porous polyvinyl alcohol 
(PVA)/BG (50 wt% of 70% SiO2-30%CaO BG) composite scaffold when subjected 
to 21 days of cell culture under osteogenic media prior to subcutaneous implantation. 
However, in our present study, no mineralised tissue was observed in all of the 
cell/scaffold constructs. Currently, the reason behind this is uncertain. However, it 
may be associated with the density of cells on our scaffold system, as it has been 
suggested that cell density plays a major role in the bone formation outcome [11, 
111, 277], whereby a certain threshold cell mass along with mineralised ECM should 
be reached to facilitate bone formation. As seen in figure 6.1, although cell sheet 
bridging across the scaffold pores was observed, the density of cells relative to the 
volume of the scaffold (6 x 6 x 6 mm) utilised may not be sufficient to surpass the 
critical threshold needed to induce bone formation, regardless of the bioactivity of 
the scaffold itself. Consequently, no bone formation was observed in any 
cell/scaffold construct groups. Perhaps a long term in vitro culture period under 
osteogenic media may be required to attain a higher cell density and significant 
deposition of mineralised ECM, which can in turn facilitate in vivo ectopic bone 
formation. However, this may not be ideal for PCL/BG composite scaffolds as 
prolonged in vitro cell culture may significantly reduce the amount of BG dissolution 
products available during implantation.  
Recently, it has been suggested that in testing biomaterial’s osteoinductivity 
using soft tissue animal models (subcutaneous or intramuscular animal model), the 
choice of animal species and implantation site is of large importance [59].  Studies 
have shown that the biomaterials osteoinductive potential differs largely when 
implanted into different animal species [60, 61] and implantation sites [60].  Yang et 
al. [60] showed that both subcutaneous and intramuscular implantation of porous 
CaP ceramic has induced more bone formation in dogs and pigs compared to within 
goats, rabbits and rats [60]. Additionally, it was found that intramuscular 
implantation induced earlier bone formation compared to that of subcutaneous 
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implantation [60]. In another study, Ripamonti [61] has shown that intramuscular 
implantation of coral-derived porous hydroxyapatite into different animal species 
yielded different outcomes, whereby, ectopic bone formation was minimal for 
biomaterials implanted into rabbits (0.5 ± 0.3% bone volume) and dogs (0.75 ± 
0.49% bone volume), while substantially high amounts of bone formation were 
observed in biomaterial implanted into baboons (11.3 ± 3.02% bone volume). 
Therefore, further studies using different animal species of soft tissue animal models 
may be required to determine if the biomaterial possesses species-specific 
osteoinductivity. 
 
6.5 SUMMARY OF STUDY 3 
PCL/CaP, PCL/50-45S5 and PCL/50-SrBG scaffolds with or without pre-
culture with sheep BMSCs under osteogenic media in a dynamic environment were 
implanted subcutaneously into the back of nude rats for the assessment of in vivo 
osteoinductivity for a period of 8 and 16 weeks. All the scaffolds or cell/scaffold 
constructs implanted were able to support host tissue infiltration and blood vessel in 
growth, but were not osteoinductive. To further evaluate if these scaffolds possess 
species specific osteoinductivity, further animal studies using different animal 
species of soft tissue model may be required.   
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7.1 RESEARCH SUMMARY 
Globally, musculoskeletal disease disorders are accounting for 25% of total 
medical expenditure, and in Australia alone, it is costing ~$15 billion per annum [1]. 
However, to date, the treatments for patients with severe open fractures or non-
unions are limited to autografts (transplantation of patient’s own tissue/cells) or 
allografts (transplantation of tissue to another human) [2, 3]. Despite exhibiting high 
healing rates, both autografts and allografts have associated disadvantages; 
approximately 20-30% of autograft patients experience donor site morbidity and 
more than 30% of allograft procedures are complicated by fracture, non-union and 
infection [2]. In cases where bone grafting is not feasible, metallic implants are 
routinely used clinically as a replacement for the “missing” bone. The use of metallic 
implant is not ideal for young patients, as metallic implants are permanent; therefore, 
patients may require further surgeries in their lifetime to keep up with the growing 
body. Therefore, this PhD project focused on the development and fabrication of a 
bioactive composite scaffold made of polycaprolactone (PCL) and bioactive glass 
(BG) using melt extrusion (ME) technique (a form of additive manufacturing (AM) 
technology). It was hypothesised that amalgamation of such fully synthetic and 
bioresorbable composite material and ME technique could yield an osteoinductive 
and patient-specific  scaffold, thereby potentially providing an effective treatment for 
bone defects circumventing the short fall of bone grafting and metallic implants.  
 
7.1.1 Summary of Chapter 4 (study 1)  
Chapter title: Fabrication and in vitro characterisation of PCL, PCL/10-45S5 and 
PCL/10-SrBG scaffolds for bone regeneration potential. 
Chapter 4 demonstrated that the fabrication of PCL scaffolds containing 10 
wt% BG particles of ~38 µm (45S5 and SrBG) via AM technologies with controlled 
pore size and porosity was feasible. The composite scaffolds (PCL/10-45S5 and 
PCL/10-SrBG) were reproducibly manufactured with a scaffold morphology 
resembling that of PCL scaffolds. Additionally, micro-CT analysis revealed that BG 
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particles were homogeneously distributed throughout the scaffolds matrix. 
Mechanical data suggested that PCL/10-45S5 and PCL/10-SrBG composite scaffolds 
had a higher compressive Young’s modulus compared to PCL scaffolds at similar 
porosity (~75%). After 1 day in accelerated degradation conditions, PCL/10-SrBG, 
PCL/10-45S5 and PCL lost 48.6 ±3.8%, 12.1 ±1% and 1.6 ±1% of their original 
mass, respectively. Although dissolution of BG particles occurred when immersed in 
serum-free culture media, it was found that the in vitro bioactivity of the composite 
scaffolds (PCL/10-45S5 and PCL/10-SrBG) was not distinctive, indicated by the lack 
of CaP-like precipitates formation on scaffold surfaces after 28 days.  
In vitro studies were conducted using MC3T3 cells in non-osteogenic or 
osteogenic supplemented culture media to enable assessment of the scaffold 
osteoinductivity. The purpose of this study was to determine whether the scaffolds 
cultured in non-osteogenic media demonstrated cell differentiation behaviour 
compared to cells on scaffolds cultured in osteogenic supplemented media, this 
would mean the scaffolds were osteoinductive in their own right. All scaffolds were 
shown to be able to support cell attachment and proliferation. The results also 
indicated that the inclusion of BGs led to earlier cell differentiation and matrix 
mineralisation when compared to PCL scaffolds under osteogenic conditions. 
However, no significant level of ALP expression was detected for all scaffolds (PCL, 
PCL/10-45S5 and PCL.10-SrBG) cultured in non-osteogenic media. This indicated 
that at 10 wt% loading of BG particles into the PCL bullk, the PCL/BG composite 
scaffolds lacked in vitro osteoinductive capability. This observed phenomena could 
be due to the skinning effect of PCL on the BG bioactivity, as it has been shown that 
the use of BG in isolation (i.e. 100 wt% BG) can release substantial amounts of BG 
dissolution ions into the surrounding environment, leading to the local stimulation of 
osteoblast differentiation in non-osteogenic media [21]. Therefore, in conclusion to 
this study, I decided it was imperative to look at ways to increase the BG 
incorporation to gain a higher wt % of BG in the PCL to increase the potential for the 
BG to exert a stronger bioactive response on the osteoblasts which should in turn 
increase the bone forming potential of the scaffolds. This formed the basis of study 2. 
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7.1.2 Summary of Chapter 5 (study 2) 
Chapter title: Biofabrication, scaffold characterisation and comparison of in vitro 
bone formation potential of PCL, PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG 
scaffolds under static and dynamic culture environment. 
Following on from the findings presented in chapter 4 (study 1), whereby we 
hypothesise that the BG wt% was too low to induce osteogenesis but that 
osteogenesis might be possible with increased BG loading. We next investigated the 
potential of increasing the % BG particle loading into the PCL scaffolds, hence 
increasing the bioactivity of the composite scaffolds. In chapter 5, it was shown that 
the fabrication of PCL scaffolds containing 50 wt% of BGs (45S5 and SrBG, ~ 
20µm) via AM technologies is feasible. The size of the BG particle was initially a 
limiting factor for the fabrication of the composite scaffolds with high BG particle 
loading. To overcome this, the BG particles size was reduced from ~38 µm to ~20 
µm, and the ME melting chamber was modified (described in chapter 5, section 
5.2.2) to enable more efficient transfer of molten material into the extrusion chamber. 
This reduction of BG particles size coupled with modification of the ME melting 
chamber design, enabled us to successfully fabricate PCL/BG composite scaffolds 
containing 50 wt% of BG particles.  
Compared to PCL/BG scaffolds containing just 10 wt% of BG, when we 
increased the BG particles loading to 50 wt%, it resulted in greatly enhanced in vitro 
bioactivity for the composite scaffolds (PCL/50-45S5 and PCL/50-SrBG) with CaP-
like precipitates forming on the surface of the scaffolds after just a week of 
immersion in serum-free media. Additionally, the composite scaffolds showed 
sustained dissolution of BGs up to 10 weeks, which could in turn promote/stimulate 
osteogenesis. Beside the PCL/BG bioactive composite scaffolds, we also investigated 
the osteoinductive potential of PCL scaffold surfaces coated with CaP (PCL/CaP). 
This is because CaP coating is routinely applied on metallic implants to improve host 
bone-to-implants integration [44, 45] and has been adapted onto polymeric-based 
scaffolds to improve its osteoinductivity hence we felt this was a good additional 
“control” group to include in this study. Indeed, many have reported improved 
osteoinductivity of polymeric-based scaffolds coated with CaP [11, 51-54]. From the 
point of view of scaffold production, PCL scaffolds are much easier to fabricate 
compared to PCL/BG composite. Additionally, the procedure of coating PCL 
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scaffold with a layer of CaP was fairly simple. Thus, PCL/CaP-coated scaffold 
osteoinductivity was assessed in comparison to that of PCL/50-45S5 and PCL/50-
SrBG composite scaffolds. When scaffolds were immersed in serum-free culture 
media, PCL/CaP-coated, PCL/50-45S5 and PCL/50-SrBG scaffolds showed 
continuous transformation of the surface coating/precipitates or the dissolution of 
BGs.  The mechanical data suggested that CaP-coating of PCL scaffold did not affect 
the scaffold’s compressive Young’s modulus compared to PCL-only scaffolds. 
However, inclusion of 50 wt% of BG significantly reduced the scaffold’s 
compressive Young’s modulus. In terms of scaffold degradation, when immersed in 
5M NaOH, it was shown that the degradation rate of each scaffold was in the order 
of PCL/50-SrBG > PCL/50-45S5 > PCL/CaP = PCL scaffolds.  
In vitro studies were conducted using sheep BMSCs in non-osteogenic or 
osteogenic culture media under static or dynamic culture environments. Overall, it 
was shown that a dynamic culture environment was advantageous in terms of cell 
proliferation and osteoblast differentiation as compared to a static culture 
environment. All the scaffolds were able to support cell adhesion, growth and 
proliferation. All scaffolds showed the capability to promote osteoblast 
differentiation when cultured in osteogenic media. Additionally, when cultured in 
non-osteogenic media, PCL/CaP scaffolds were shown to upregulate osteopontin 
(OPN, pre-osteoblast marker) gene expression, while PCL/50-45S5 and PCL/50-
SrBG scaffolds were shown to upregulate both OPN and osteocalcin (OCN, mature 
osteoblasts marker) gene expression. These results suggest that PCL/CaP, PCL/50-
45S5 and PCL/50-SrBG composite scaffolds show potential as bioactive and 
osteoinductive bone scaffolds, superior to that of PCL-only scaffolds. 
 
7.1.3 Summary of Chapter 6 (study 3) 
Chapter title: Testing of osteoinductive properties of PCL/CaP-coated, PCL/50-
45S5 and PCL/50-SrBG scaffolds in vivo using a subcutaneous rat model. 
Following the findings in Chapter 5 (study 2), PCL/CaP, PCL/50-45S5 and 
PCL/50-SrBG scaffolds or the respective cell/scaffold constructs, osteoinductive 
capabilities were assessed in vivo using a subcutaneous nude rat model. The scaffolds 
or cell/scaffold constructs implanted were able to support host tissue infiltration and 
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blood vessel in growth. However, the osteoinductivity potential of these scaffolds or 
cell/scaffold constructs was not apparent in a subcutaneous rat model after 8 and 16 
weeks, with no significant new bone formation. To further evaluate if these scaffolds 
possess species specific osteoinductivity, further animal studies using different 
animal species of soft tissue model is required.  
 
7.2 LIMITATIONS AND RECOMMENDATION FOR FUTURE WORK 
Although it was shown that PCL/BG composite scaffolds had osteoinductive 
potential in vitro which may in turn suggest they are able to be used to stimulate 
bone formation, there remain many avenues open for further investigation of BG 
composite scaffolds and more work needs to be done to get a better understanding of 
how to optimise such scaffolds. The limitations of this PhD project along with the 
recommended future work are discussed hereafter. 
 
7.2.1 Scaffold mechanical properties  
During the process of designing a scaffold for tissue engineering, a balance 
must be achieved between the porosity and the mechanical integrity – as increasing 
one invariably decreases the other, and vice versa. Addition of BG introduces a third 
dimension in this balance. Adding high weight percentage of BG into the polymeric 
matrix enhances the composite bioactivity properties; on the other hand, it can easily 
introduce minor imperfections into the bulk polymeric matrix which can significantly 
reduce its mechanical integrity. In this PhD project, in order to achieve highly porous 
(> 75%) and bioactive PCL/BG composite scaffolds, the mechanical properties of the 
composite scaffolds were compromised in favour of porosity and bioactivity. 
Therefore, to further progress such composite scaffolds into real world applications, 
one would need to find a balance between ideal scaffold mechanical properties, 
bioactivity, and porosity. One way to improve the scaffold mechanical strength while 
not compromising the scaffold bioactivity and porosity is to explore the different 
scaffold architectures by varying the scaffold lay-down pattern. It has been shown 
that a change in the scaffold laydown pattern can significantly change the mechanical 
properties of the scaffold owing to a difference in the stress distribution [173, 278, 
279]. Alternatively, one can vary the BG particles size or shapes. For example, nano-
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sized BG particles of spherical shapes will be ideal as it gives the highest surface 
area to volume ratio, providing the larger surface area for dissolution of BG upon 
contact with biological fluids compared to micron-sized irregularly shaped BG. 
Additionally, such uniformly spherical shaped particles also allow the stress to be 
distributed equally in all directions, whereas an irregularly shaped particle may have 
one or more sharp edges where the stress increases considerably compared to other 
regions, leading to non-uniform stress distribution across the entire scaffold 
microfilament. These micron-sized defects, when summed across the entire scaffold, 
may have a detrimental overall effect on the scaffold mechanical integrity. Therefore, 
potentially, by using spherically-shaped nano-sized BG, one can reduce the BG 
loading into the PCL bulk while retaining the composite bioactivity, as well as 
improving the mechanical strength of the composite scaffolds.  
 
7.2.2 Scaffold in vivo degradation behaviour 
In this PhD project, the degradation rate of the various scaffolds were validated 
using an in vitro accelerated degradation model, which only takes into account the 
hydrolytic degradation of the polymer. Conversely, in vivo, when implanted, 
scaffolds not only undergo hydrolytic degradation, but also enzymatic degradation 
facilitated by macrophages [6] under a highly dynamic environment. Therefore, long 
term in vivo studies (1-2 years) would be required to more closely predict the 
scaffold degradation rates. Such a long-term study could employ methods such as 
evaluation of gross morphology and compressive strength of the scaffold as well as 
the crystallinity and molecular weight of the biomaterial as measures of degradation.  
 
7.2.3 Animal species specific scaffold osteoinductivity 
This PhD project evaluated the osteoinductivity of the PCL/BG composite 
scaffolds to form bone using a subcutaneous rat model, as under these conditions, 
any mineralised tissue formed can be directly attributed to the composite scaffold 
inherent properties as opposed to the effect of a local bone environment. Using the 
subcutaneous rat model, the osteoinductivity of the tested scaffolds or cell/scaffold 
constructs was not apparent. One reason for this may be because it has been reported 
that biomaterial osteoinductivity can be species specific [59-61]. Therefore, one can 
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utilise soft tissue models of different animal species (i.e. dogs, goats, pigs, sheep, 
rabbits) to further evaluate if the proposed biomaterials (PCL/CaP, PCL/50-45S5 and 
PCL/50-SrBG) exhibits species-specific osteoinductivity. 
 
7.2.4 Scaffold in vivo bioactivity 
In this PhD project, the in vitro bioactivity of the PCL/BG composite scaffolds 
was validated by the formation of CaP-base precipitates on the scaffold surfaces 
(described in chapter 4 & 5). To further explore the scaffold in vivo bioactivity 
(ability to form a strong and stable bond with host bone), one would have to utilise a 
bone defect animal model. Through this model, one could measure the interfacial 
bonding strength between the PCL/BG composite scaffolds with host bone, 
providing a greater indication of the extent of scaffold bioactivity [189]. 
Furthermore, one can also further explore the bone cell interactions with host bone at 
the biomaterial-bone interface using a number of techniques, such as resin-cast 
scanning electron microscopy (SEM) [280], ultra-high voltage electron microscopy 
tomography (UHVEM) [281], or atomic force microscopy (AFM) [282, 283]. 
 
7.2.5 Scaffold osteoconductivity and bone regeneration capability 
The testing of osteoconductivity and bone regeneration capabilities falls 
beyond the scope of this PhD project. To validate the PCL/BG composite scaffolds 
osteoconductivity and bone regeneration capability, one could implant these 
scaffolds into a bone defect animal model. Moreover, using a bone defect animal 
model, one could study the bone formation and remodelling pattern induced by 
PCL/BG composite scaffold by means of histological and immunohistological 
staining as well as microCT for the evaluation of mineralised tissue formation within 
the scaffold construct. These evaluations would lead to a better understanding of the 
relationship between PCL and different composition of BG which can help scientists 
in predicting its potential clinical performance. To this end, preliminary development 
of an ovine bone defect model has been pursued as an auxiliary goal during the 
course of this PhD (described in detail in Appendix A).   
 152 Chapter 7: Conclusion 
7.3 OVERALL DISCUSSION AND CONCLUSION 
Currently, the leading concept for bone tissue engineering (TE) involves the 
use of a resorbable polymer-based scaffold. These polymeric scaffolds usually lack 
bioactivity and osteoinductivity. Thus, they are often used in combination with 
bioactive and osteoinductive biological factors, such as growth factors and cells, to 
induce bone formation. For example, the clinical use of recombinant human-bone 
morphogenetic protein 2 (rh-BMP2, a potent bone forming growth factor), although 
effective, is expensive due to the complex synthesis/isolation procedures [28], and 
has caused undesirable heterotopic ossification [28-30] due to shortfall in the 
delivery method used which leads to a high-dose, uncontrolled, sub-optimal release 
of the growth factors [31]. On the other hand, the use of cells in combination with 
scaffolds to induce bone formation usually requires a huge number of cells with a 
long period of pre-culture [7, 11], this can be laborious and thus expensive to 
implement for clinical use. To avoid using such biological factors to achieve 
osteoinductive polymeric-based scaffold, one approach is to incorporate bioactive 
materials such as BGs into the polymeric-based scaffolds. These BGs are bioactive, 
that is they are able to promote formation of a strong bond with bone when in close 
proximity [13, 14], and the dissolution ions can promote osteogenesis in a dose 
dependent manner [196]. It has been shown that different composition of BG can 
provide different effects on cell behaviour [15], of which, the incorporation of Sr2+ 
into the BG network have been reported to have beneficial effects on cells by 
promoting bone-forming osteoblast activity while inhibiting bone-resorbing 
osteoclast activity [21]. Therefore, in this PhD project, I aimed to develop a fully 
synthetic and resorbable scaffold made of PCL and BG (45S5 or SrBG) intended for 
the treatment of bone defects by utilising ME techniques. The resultant composite 
scaffold can potentially be highly bioactive and osteoinductive, thereby 
circumventing the use of biologically-derived factors to induce scaffold 
osteoinductivity.  
In this PhD project, PCL scaffolds containing up to 50 wt% of BG were 
successfully fabricated. It was shown in vitro that the composite bioactivity changed 
depending the wt% of BG particles incorporated into the PCL bulk. As expected, 
increasing the wt% of BG improved the composite scaffold bioactivity and hence the 
potential osteoinductivity capability, but conversely, compromised the scaffold 
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strength. Additionally, the composite scaffold degradation rates varied dependent on 
the type of BG incorporated into the PCL bulk. Taking all this into consideration, the 
implications of a PCL/BG composite scaffold are far-reaching. From the point of 
view of degradation rate, we have shown that two different compositions of BGs, 
while providing a similar measure of in vitro bioactivity, underwent in vitro 
degradation at significantly different rates. This finding opens up the possibility of 
designing scaffolds with a tailored degradation profile over time in a clinical setting. 
Every individual patient, based on the clinician’s recommendation, may require a 
scaffold that degrades completely (or partially) in a specific time period. Based on 
this knowledge, tissue engineers can fabricate composites containing different 
measures of polymers and BGs to fine-tune the rate at which the scaffold degrades to 
match the predicted bone regeneration rate of that specific patient. From another 
point of view, this study has shown that mixing different amounts of BGs into a 
polymeric matrix leads to different mechanical properties – giving the clinician and 
the patient another dimension with which to tailor their personalised scaffold. 
Finally, the potential of fabricating truly patient-specific composite scaffold directly 
from the medical imaging scans of the patient has been proven – whereby the 
surgeon takes CT measurements of the diseased/fractured region and a biomedical 
engineer uses such measurements to generate a 3D model of the region of interest. 
The engineer can then, in close consultation with the surgeon, design a scaffold 
perfectly fitting the anatomical site and having the desired mechanical properties and 
pore architecture in order to minimise the risk of necrosis and implant failure. This 
ME technique has been demonstrated as feasible within our research team, hence the 
production of patient specific, bioactive composite scaffolds containing BGs is one 
step closer to the clinic as a result of this PhD research project and is a valuable 
contribution to the field. 
However, to make PCL/BG composite scaffolds a clinically viable product, 
more research is required to better understand the relationship between PCL and the 
different compositions of BG which can help predict its potential clinical 
performance. One of the logical steps to bring it closer to the bedside is testing it 
using a bone defect animal model, which can enable the assessment of scaffolds’ 
bone regeneration potential at the intended application site. As described earlier in 
“future work”, to this end, preliminary development of an ovine bone defect model 
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has been pursued as an auxiliary goal during the course of this PhD (described in 
detail in Appendix A).  If successful, this animal model will enable new insights into 
biomaterial regeneration potential and pattern in two skeletally distinct sites which 
has never been explored previously. It is our belief that this additional body of work 
will act as a catalyst for further research into the field of biomaterials for bone 
regeneration.  
In conclusion, the combination of PCL/BG composite material with AM 
technology can potentially provide a custom-made osteoinductive scaffold. However, 
more research is required to further understand the relationship between PCL and 
different composition of BG. Nonetheless, the body of work presented in this PhD 
project shows the first successful steps for the potential of PCL/BG composite 
scaffold to move towards a cell-free, fully synthetic scaffold for treating bone 
defects. 
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Appendices 
Appendix (A) 
 
Establishment of a large animal model for the study of bone regeneration 
potential of composite material in two skeletally distinct sites 
 
This appendix describes an auxiliary project which was undertaken as part of 
the final year of my PhD, however, complications in the model (the pilot sheep 
suffered a femur fracture) meant that it was not fully established in the time frame of 
the PhD to the extent that scaffolds were able to be implanted and analysed. Hence 
the model establishment is described in the appendix rather than as a full chapter. As 
the leader of this project, I would like to acknowledge Dr. Siamak Saifzadeh, Dr. 
Mostyn Yong and Dr. Jan Henkel for their guidance and assistance.  
The aim of this phase of the PhD project was to establish a bi-defect ovine 
model which could permit (1) the assessment of a scaffold’s bone regeneration 
capability when implanted in a bone defect site. Owing to 8 identical small defects 
being created, it was the purpose of this model to ultimately act as a screening model 
for the selection of biomaterials with most promising clinical performance for 
downstream assessment, and (2) direct comparison of the bone regeneration 
capabilities of the same biomaterials when implanted into two skeletally distinct sites 
with different developmental pathway, namely endochondral and intramembraneous 
ossification (detail description in Chapter 3, section  3.2.1 and 3.2.2) . 
In the screening and selection of biomaterials for clinical applications, it is 
inevitable that the biomaterials have to be investigated in the intended application 
sites. In our case, the biomaterial has to be implanted into a bone defect sites to 
determine its osteoconductivity and bone regeneration capability. The conventional 
method is to implant the fabricated scaffolds into a small/medium animal model with 
either cranial/femoral/tibial defects. Here, we decided to establish a bi-defect ovine 
model for the selection of biomaterials, and to further study and compare the bone 
regeneration potential of the same biomaterials in two skeletally distinct sites. 
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A.1 LITERATURE REVIEW 
A.1.1 Bone regeneration pathway using bioresorbable materials 
Although it is widely accepted that bone regeneration involves callus formation 
through a combination of intramembranous and endochondral ossification as 
previously described (Chapter 3: Literature review) [284, 285], recent studies have 
shown that the bone regeneration may be directed to follow either intramembranous 
or endochondral ossification pathways, dependent on the defect microenvironment. 
Tortelli et al. [286] seeded HA scaffolds with 2.5 x 106 rat mesenchymal stem cells 
(MSC) or rat osteoblasts, and then subcutaneously implanted them into nude mice. 
They found that implants containing MSCs led to bone formation through an 
endochondral ossification pathway, while bone formation on implants containing 
osteoblasts followed an intramembranous ossification pathway [286]. In another 
study by Hwang et al. [287], PLGA/PLLA or PLGA/PLLA/HA scaffolds seeded 
with   3 x 106 human embryonic stem cells (hESCs) were implanted subcutaneously 
into nude mice [287]. It was reported that bone formation on PLGA/PLLA scaffolds 
were through endochondral ossification while PLGA/PLLA/HA scaffolds resulted in 
faster bone formation through intramembranous ossification [287]. Recently, Kuhn et 
al. [288] reported that collagen/HA scaffolds seeded with 1 x 106 hESCs induced 
bone formation through an endochondral ossification pathway when implanted into a 
rat calvarial defect. For all the aforementioned studies, all authors attributed the 
different bone formation pathway observed to the cell type seeded on the implanted 
scaffold. Due to different experimental setups (i.e. scaffold type, cell type, 
implantation sites and etc.), the study outcomes of [286], [287] and [288] were not 
easily/directly comparable. Nevertheless, the collective outcomes of the studies do 
indicate that the defect microenvironment can direct/cue the bone formation either 
through endochondral or intramembranous ossification pathways. Moreover,  Clarke 
et al. [289] reported that osteoblasts from the appendicular and axial skeletal respond 
differently to various hormonal, mechanical or cytokine signals. Thus, we 
hypothesised that bone regeneration capabilities of the same bioresorbable 
biomaterial will be significantly different when implanted in two skeletally distinct 
sites with different developmental pathways.  
 
 157 
Appendix A                      157  
A.1.2 In vivo model for bioresorbable materials 
Currently, there exist various animal models successfully established for the 
purpose of biomaterial research, as detailed in [290]. Thus, dependent on the research 
question, one model may be more suitable over another. However, to date, there is no 
existing animal model that can enable the direct comparison of multiple 
bioresorbable biomaterials’ bone regeneration potential in two skeletally distinct sites 
with different developmental pathways (i.e. long bone versus flat bone).  
Thus, alongside with the development of biodegradable synthetic polymer/BG 
composite intended for bone TE, during this PhD I also aimed to establish a sheep 
model which could enable the direct comparison of bioresorbable biomaterials’ bone 
regeneration potential in flat bone versus long bone by utilising the same model and 
the same implants, at different anatomical defect sites. The intention was to be able 
to implant the scaffolds into the defects; however unforeseen circumstances meant 
that this was not possible within the time frame. The model is continuing to be 
established in the group. 
 
A.1.3 Animal selection 
To determine a suitable animal model, one would have to consider the study 
aims, implants design, accessibility to resources and costs involved. Moreover, the 
animal model chosen must be manageable to operate and post-surgery care must be 
possible with a multiplicity of study objects over a relatively short period of time [55, 
217, 291-293]. For the proposed hypothesis, it is of utmost importance to select an 
animal model which can enable the direct comparison of bone regeneration potential 
using the same biomaterial in flat bone versus long bone; whilst taking into account 
the physiological and pathological resemblance of the animal bone to human bone as 
well as the above mentioned factors.  
Small/medium animal models such as mouse, rat, and rabbit are not suitable for 
the proposed aim as having multiple surgical sites in small/medium animals require 
high surgical precision and scaffolds could not be reproducibly produced on that 
scale; hence this could become unmanageable. It is also reported that the bone 
healing capacity is higher in rodents and rabbits than in other species [273] and 
rodents do not show Harversian type remodelling in cortical bone [274]. Therefore, 
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both rodent and rabbit do not accurately reflect the bone healing capacity/pattern of 
human, making them less ideal for the study of bone regeneration capacity/pattern of 
biomaterials. Among large animal models, the bone composition of canine was 
reported to be the closest to human [55, 87, 97] although the bone microstructure and 
bone remodelling pattern was reported to be different compared to human bone [55, 
291]. However, canine as an experimental model has raised ethical consideration due 
to the negative public perception of using companion animals for medical research.  
Mature sheep have a body weight more comparable to human, and show no 
evidence of major differences in bone mineral composition [280] to humans. 
Furthermore, it was reported that sheep have metabolic and bone remodelling rates 
similar to human [281, 291]. However, bone histology revealed that sheep bone 
consists principally of primary bone structure in comparison with the predominantly 
secondary, Harvesian bone composition of human [283]. In sheep, the secondary, 
osteonal remodelling only occurs at an average age of 7-9 years old [282]. Therefore, 
when using sheep as an animal model, one would have to be very careful with age 
selection to enable valid comparison between experimental groups.  
As an animal model for biomaterial research for bone, like sheep, goat has a 
comparable body weight to human [294]. Goat also has comparable bone healing 
capacity and tibial blood supply with that of human [295]. However, it was reported 
that the rate at which bone graft revascularises was found to be faster in the goat, 
occurring approximately 3 months in comparison to 8 months in human [296]. To 
date, there is little comparison studies on the suitability if goats versus sheep for bone 
implant-related studies. However, in comparison to sheep, goats tend to have a more 
interactive/social nature, which may make confinement for long duration more 
challenging [294].  
Pigs have been described as a representative model of human bone 
regeneration processes as they have very similar anatomical and morphological 
features, healing and remodelling capacity, and bone mineral density to human bone 
[87]. However, pigs are often not favourable to researchers as they are difficult to 
handle with their aggressive behaviour [55].  
Considering the aforementioned factors and the readily available resources of 
our research group, sheep have been chosen over other animal models in this 
instance. Sheep as an experimental model enables the creation of small multiple 
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surgical sites for the direct comparison of bone regeneration potential and pattern of 
several of the same biomaterial scaffolds in long bone and flat bone. The following 
section will review established sheep models with drill hole defects for the study of 
bone regeneration potential of bioresorbable implants.  
 
A.1.4 Established sheep models with drill hole defect for bone-biomaterials 
research 
A mature sheep is considered a valuable model for orthopaedic research as it 
has similar body weight to an adult human. Moreover, sheep have similar bone 
mineral composition, bone metabolism and bone remodelling rates to human. To 
date, there are only a handful of sheep drill hole defect models established for the 
study of bone regeneration potential of biomaterials.  
 
Calvarial drill hole defects model  
A summary of the following studies is detailed in table A1. Lindholm et al. 
[89], Viljanen et al. [297],  Shang et al. [298], and Kuemmerle et al. [299] created a 
unilateral/bilateral full thickness cylindrical defect measuring 18-23 mm in the 
parietal bone of sheep skull (figure A.1b) for the evaluation of different biomaterial 
scaffolds’ bone regeneration potential (table A.1). Postoperatively, only one 
reversible complication was reported by Kuemmerle et al. [299], and no 
complications were reported in all other studies. 
Schmidmaier et al.[300] created six cylindrical 15 mm (diameter), full-
thickness-critical size defects in the parietal and occipital bone on the sheep skull 
(figure A.1c). Custom-made round membrane (diameter = 2 cm) of different 
biomaterials (table A.1) were randomly assigned into the defect sites and fixed on the 
bone with three resorbable polylactide pins for 12 or 24 weeks. Ten days 
postoperatively, one of the eight operated sheep developed a superficial suture 
infection which was completely cured after local antibiotics treatments.  
Zins et al.[301]  created unilateral/bilateral full thickness rectangular defects 
measuring 15 x 30 mm (width x length) in the parietal bone of sheep skull (figure 
A.1d). In a bilateral defect model, either the Norain craniofacial repair system (CRS) 
or Norain craniofacial repair system fast set putty (FSP) were compared with a full 
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thickness cranial bone graft harvested from the opposite parietal bone. In the 
unilateral model, the CRS or FSP was compared with the opposite intact bone. 
Postoperatively, two complications were reported, where one animal was euthanized 
due to overt extrusion of bone cement (CRS group) and another was euthanized due 
to fragmentation and brain abscess. Both animals were replaced as the events 
occurred in the early phase of studies.  
 
Figure A.1 (a) Anatomy of sheep skull bone (frontal view). (b - d) Schematic of 
defect sites used for established sheep cranial defect model (membranous bone 
model). Red areas represent the defect site. (b) = [89, 297-299] , (c) = [300] , and (d) 
= [301]. All schematics were not drawn to scale. 
 
Femur, tibia or pelvic drill hole defects model  
Cortez et al. [302, 303] created 4 or 5 cylindrical 5 mm (diameter), full 
thickness unicortical defects on the lateral diaphysis of sheep femur on both hind 
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limbs (figure A.2a). Defects were kept at least 10 mm apart from each other to 
minimise risk of fracture. In their studies, the experimental group listed in table A.1 
was compacted into the defect sites. No postoperative complications were reported. 
Griffon et al. [304] created circular defects measuring 15 x 15 mm (diameter x 
depth) in the tibia and femur of sheep (figure A.2b). The experimental groups listed 
in table A.1 were randomly assigned to the defect sites, and each defect was sealed 
with polymethylmethacrylate. In phase 1 of the studies, four out of the twenty one 
sheep fractured one femur a week postoperatively. Following that, in phase 2 of the 
studies, the surgical intervention was refined by decreasing the number of drill holes 
from three to two in each hind limb (figure A.2b). No postoperative complication 
occurred in phase 2 of the studies. In a further study by Griffon et al. [305], the 
defects were created following the unrefined surgical procedures as described in 
[304]. Postoperatively, of the twenty two operated sheep, one sheep died of 
anaesthetic complications and four sheep fractured their femur. The refined surgical 
approach as described in [304] was utilised by Pratt et al. [306], and no 
complications were observed post-operatively. 
Flautre et al. [307] investigated the biological properties of calcium phosphate 
hydraulic cement (CPHC). The CPHC in the form of paste/ moulded block was 
injected/ implanted into a defect measuring 10 x 20 mm (diameter x depth) created 
bilaterally in the distal femur condyles of sheep. Postoperatively, no adverse events 
were reported. However, in their studies, details of surgical procedures, exact 
anatomical defect sites and number of defects created in each femur was not 
reported. In a study by Bodde et al. [308], bilateral two partial thickness cylindrical 
defects measuring 6 x 9 mm (diameter x depth) were created on the femoral medial 
condyles of sheep (figure A.2c). The defects were kept at least 10 mm apart. 
Experimental groups listed in table A.1 were packed into defect sites. No 
postoperative complications were observed.  
Van der Pol et al. [89] investigated the biocompatibility and osteoconductivity 
of poly(L-lactic acid)/β-tricalcium phosphate biocomposites using a sheep model 
with partial thickness, cylindrical defects measuring 5.1 x 15 mm (diameter x depth) 
in the cancellous region of the distal femora and proximal tibial. However, the exact 
position of defects in the distal femora and proximal tibial, as well as the surgical 
procedures were not described in detail. No postoperative complications were 
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observed, except in one sheep which developed pneumonia after one month, which 
was excluded and replaced in the studies.    
Beck et al.  [297] investigated the effect of reamer bone graft for bone 
regeneration using sheep with bilateral full thickness iliac wing defects measuring 17 
mm (diameter) (figure 6d). Details of the experimental groups are listed in table A.1. 
Postoperatively, two of the eighteen operated sheep were reported with mild 
complications which were treated and recovered during the course of the studies.    
 
Figure A.2 Schematic of defect sites on established sheep hind limb drill hole defect 
model. Red or purple areas represent the defect site. (a) = cortical bone defect model 
[302, 303], (b-d) = trabecular bone model, (b) = [304-306], three defect sites (red + 
purple dot) were created in the initial approach. In their refined model, only two 
defect sites (red dot) were created., (c) = [308] and (d) = [297]. All schematics were 
not drawn to scale.  
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Defect site(s) Type of defect Experimental group (biomaterials tested) 
 Cranial model 
  
[89, 297-299] Skull 
Parietal bone 
Unilateral/ bilateral 
cylindrical full thickness 
defects 
 
Defect size (diameter): 
[89] 18- 20 mm 
[297] 22 mm 
[298] 20 mm 
[299] 23 mm 
[89]  1: BMP/insoluble bone matrix noncollageneous proteins in gelatine capsule 
      2: Serum bovine albumin in gelatine capsule 
 
[297]  1: BMP/Collagen type IV 
      2: Collagen type IV 
      3: Autologous bone marrow 
 
[298] 1: Calcium alginate gel containing autologous bone marrow stromal cells 
     2: Calcium alginate gel only 
     3: Empty defect 
 
[299] 1: New brushite cement chronOSTM inject 
     2: Apatite cement Biobon® 
[300] Skull 
Parietal and occipital bone 
Defect size (diameter): 15 
mm 
 
Six cylindrical full thickness 
defects 
[300]1: Defect filled with spongiosa 
    2: Empty defect covered with custom-made 70/30 PL/DLLA membrane 
 3: Defect filled with spongiosa, covered with custom-made 70/30 PL/DLLA 
membrane 
    4: Empty defect covered with custom-made PDLLA membrane 
       5: Defect filled with spongiosa, covered with custom-made PDLLA    membrane 
    6: Empty defect 
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[301] Skull 
Parietal bone 
Defect sixe (width x length) 
= 15 x 30 mm 
 
Unilateral/ bilateral 
rectangular full thickness 
defects 
[301] 1: Norain craniofacial repair system 
     2: Norain craniofacial repair system fast set putty 
     3: Autologous bone graft 
Femur/ tibia/ pelvic model 
  
[302, 303] Hind limbs (femur) 
Lateral diaphysis of femur 
Defect size (diameter): 5 
mm 
 
Four or five cylindrical full 
thickness unicortical drill 
holes in each femur. 10mm 
distance was kept between 
each drill hole. 
[302] 1: Bonelike® pellet (500 – 1000 µm) 
     2: Bonelike® polygonal granules (500 – 1000 µm) 
     3: Empty defect 
 
[303] 1: Bonelike® 
     2: New Osteo® 
    3: Bonelike®: New Osteo® (80:20 wt%) 
    4: Bonelike®: New Osteo® (70:30 wt%) 
    5: Bonelike®: New Osteo® (50:50 wt%) 
    6: Empty defect 
[304-306] Hind limbs (femur + tibia) 
Proximal subchanteric region of  femur, 
Lateral aspect of distal femoral       
metaphysis, proximal medial tibial 
metaphysis 
 
Defect size (diameter x 
depth): 
15 x 15 mm 
 
Two or three partial 
thickness drill holes on each 
hind limb 
 
[304] Phase 1 
     1 to 3 (A1-A3): New silicate-free bioactive glass 
     4: Autogenous cancellous graft 
     5: Sterile, “idealised”, morselised allograft 
     6: Empty defect 
     Phase 2 
    7: Sterile morselised impacted allograft 
    8 to 10: (B1-B3): Mixtures of TCP/HA 
 
[305] 1: Autogenous corticocancellous graft 
     2: Idealised allograft 
     3: Allograft idealised with Corglaes® 
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     4: 50/50 mixture of allograft and Corglaes® 
     5: Idealised Corglaes® 
     6: Empty defect 
 
[306] 1: Sterile morselised impacted allograft 
     2: Allograft + HA/TCP (80:20wt%) mixture, prepared with 8 particles sizes 
     3: Allograft + HA/TCP (20:80wt%) mixture, prepared with 8 particles sizes 
     4: Allograft + HA/TCP (80:20wt%) mixture, prepared with 3 particles sizes 
[307] Hind limbs (femur) 
Femoral condyles – exact defect sites 
not reported 
Defect size (diameter x 
depth): 
10 x 20 mm 
 
Defects were created 
bilaterally. However, 
number of defects on each 
femur was not reported. 
[307] 1: Calcium phosphate hydraulic cement paste 
     2: Calcium phosphate hydraulic cement moulded block 
     3: Empty defect 
[308] Hind limbs (femur) 
Femoral medial condyles 
Defect size (diameter x 
depth): 
6 x 9 mm 
 
Two cylindrical partial 
thickness drill holes in each 
hind limb. 10 mm distance 
was kept between each drill 
hole. 
[308] 1: ConduitTM TCP 
     2: Biosel® 
[89] Hind limbs (femur + tibia) 
Distal femoral, proximal tibial 
Defect size (diameter x 
depth): 
5.1 x 15 mm 
 
Three cylindrical partial 
[89] 1: PLA/β-TCP biocomposite 
     2: ChronOSTM 
     3: Empty defect 
 166 Appendix A 
 
 
 
 
 
 
 
 
 
 
thickness drill holes in distal 
femoral, two cylindrical 
partial thickness drill holes 
in proximal tibial of each 
hind limb. 
[297] Pelvis (iliac wing) 
Os Ilium 
Defect size (diameter): 17 
mm 
 
One cylindrical full 
thickness drill holes on each 
iliac wing. 8 mm space was 
kept on the dorsal and 
lateral side of the defect. 
[297] 1: Freshly harvested RIA bone graft 
     2: RIA bone graft incubated in dexamethasone 
     3: RIA bone graft reconstituted with cellular fraction of irrigation fluid 
     4: RIA bone graft reconstituted with cellular fraction of irrigation fluid  incubated 
in   dexamethosone 
     5: RIA bone graft collected through β-TCP filter system 
     6: Autologous iliac wing bone graft 
Note: All RIA is harvested from operated sheep tibia. 
Table A.1  List of established drill hole defect sheep model with corresponding experimental group.  
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A.1.5 Summary 
To date, the bone regeneration potential of bioresorbable biomaterials has been 
investigated in sequential steps, from small animal to large animal models, and from 
subcutaneous modes through to clinically relevant bone defect models. With recent 
studies suggesting that bone regeneration may follow either intramembranous or 
endochondral ossification pathways, dependent on the defect microenvironment; it 
has sparked our interest in studying the bone regeneration potential of the same 
biomaterial scaffolds when implanted into flat bone (cranial) compared with long 
bone (femur or tibia). However, there is no existing animal model that can enable the 
direct comparison of multiple bioresorbable biomaterial scaffolds’ bone regeneration 
capabilities in two skeletally distinct sites. Therefore, I aimed to establish a sheep 
model which could enable the direct comparison of bioresorbable biomaterials’ bone 
regeneration potential in flat bone versus long bone by utilising the same sheep 
model and identical sized and composition implants, at different anatomical defect 
sites, at the femur or tibia (long bone) and the cranial (flat bone). 
 
A.2 METHODS AND MATERIALS 
A.2.1 Surgeries 
The study was performed with the approval of the animal research ethics 
committee of Queensland University of Technology, Australia (ethics number: 12-
108). The establishment of the animal model was done in two phases as listed in 
table A.2. Experiment was undertaken using male sheep (Ovis Aries) of 7-8 years old. 
 
Table A.2 List of study phases. 
 
A.2.2 Anaesthesia 
For both phases, anaesthesia was induced using lidocaine with adrenaline (4 
mg/kg) after premedication and analgesia with buprenorphine (0.01 mg/kg). Prior to 
surgery, the sheep were given prophylactic antibiotics coverage consisting of 
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cephalothin (100 mg/kg, I.V.), gentamicin (1 mg/kg, I.M.), and Cefazolin (25 mg/kg, 
I.V.). Throughout the surgery, anaesthesia was maintained with 5% isoflurane, 
ventilated with oxygen using a Campbell anaesthetic ventilator, and hydrated with 
Hartmann’s solution (10 ml/kg/hr). The sheep heart rate, oxygen saturation and end-
tidal carbon dioxide levels were monitored continuously throughout the surgery.  
 
A.2.3 Preparation of surgical sites 
For both phases, the surgical sites were prepared by shaving the wool from mid 
nasal bone (nose area) to the occipital bone (neck area) for cranial surgery and the 
entire region around the femur (phase 1)  or tibia (phase 2) for  femur/tibia surgery. 
To create a sterile surgical environment, the surgical incision sites were scrubbed 
with disinfectant solution (Providone/Chlorhexidine), covered with op-site (Smith & 
Nephew) and draped accordingly.    
 
A.2.4 Cranial defect surgery  
The surgical procedures for the creation of defects in the cranial bone remained 
the same for phase 1 and 2. Using the animal’s horn as a guide, an imaginary line 
was drawn between the two horns. Then, a midline incision (10 ± 2 cm) was created 
3 cm below the imaginary line (figure A.3a). Then, the covering periosteal tissue was 
removed, exposing the surface of the parietal bone. Following that, eight defect sites 
were identified and marked using a surgical pen (figure A.3b). Using a 6 mm 
trephine with laser marked depth, impressions of defect sites were created. Then, 
partial thickness defects measuring 6 x 2.5 mm (diameter x depth) were created using 
a drill piece. The depth of defect was checked using a custom-made template. Sterile 
PCL-based scaffolds fabricated via melt extrusion (ME) as previously described in 
chapter 4, section 4.2.2 were press-fit into the created defect sites.   
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Figure A.3 (a) Schematic of the surgical incision sites on the sheep skull and (b) the 
eight partial-thickness defects created on the parietal bone. 
 
A.2.5 Femur/tibia defect surgery  
1st phase: femoral defect model  
A lateral skin incision (15 ± 2 cm) was made within an imaginary line drawn 
from the greater trochanter to the lateral condyle. Then, dissection was made through 
the intramuscular planes of tension fascia lata and vastus lateralis, exposing the 
underlying periosteal tissue which was removed to expose the surface of the femoral 
bone. Provisional drill hole sites were identified and marked using a surgical pen 
(figure A.4), ensuring >10 mm spacing between drill holes. Using a 6 mm trephine 
drill, four unicortical drill holes were made on the lateral side of each femur. Sterile 
scaffolds were press-fit into the created defect sites. The procedures were repeated on 
the contralateral hindlimb. 
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Figure A.4  Schematic of femur model with four 6 mm defects, created at the lateral 
side of the femur along the diaphysis region. 
 
2nd phase: tibial defect model 
A medial skin incision (15 ± 2 cm) was made within the diaphysis region of the 
tibia. The periosteal tissue covering the tibia was removed, exposing the surface of 
the tibial bone. A bone plate was fixed on the medial side of the tibial using cortical 
screws. Provisional drill hole sites were identified and marked using a surgical pen, 
ensuring >10 mm spacing between drill holes. Using a 6 mm trephine drill, four 
unicortical drill holes were created on the posterior and anterior side of the tibia 
(figure A.5). Sterile scaffolds were then press-fitted into the created defect sites. Two 
1 mm drill holes were made in close proximity to the defect site to securely hold the 
scaffold in place using 6/0 novofil sutures.   
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Figure A.5 Schematic of tibia model with four defects created in of the anterior and 
posterior side of the tibia on the diaphysis region. 
 
A.2.6 Closing of surgical sites and post-operative care 
The muscle layers were closed with 1 vicryl absorbable suture, and the 
subcutaneous layer with 2/0 vicryl absorbable sutures. The skin incisions were closed 
using 2/0 novofil sutures. Then, the wounds were sprayed with tetramycin antibiotic, 
and bandaged. For phase 2, the sheep tibia was cement casted. For the first 72 hours 
post-operation, all animals were under the multi-model pain management care (one 
dose of NSAID and two doses of Buprenorphine/day). Furthermore, animals were 
spot monitored at 8-hourly intervals for the initial 72 hours. 
Immediately post-operation, animals were placed in a custom-made sling for 
24 hours (phase 1), or up to a week (phase 2) in an enclosed floor pen. Thereafter, 
the post-operative care varied in phase 1 and 2 of the study, and will be further 
detailed in the section A.3.2. 
 
A.3 RESULTS 
A.3.1 Phase 1: cranial + femoral defect model 
Figure A.6 (a-e) shows the cranial defect surgery. During phases 1 and 2 of the 
study, the same surgery procedures were employed. The cranial defect creation was 
relatively simple and the post-operative care of the cranial surgical site was 
manageable. 
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Figure A.6 (a-e) Pictures of cranial defect surgery procedures. (a) Mid-line incision 
on sheep skull. (b) Opening of the incision using a retractor and marking of the 
defect sites using surgical pen. (c) Impression made on the marked defect sites using 
trephine drill. (d) Defect sites were drilled to 2.5 mm depth using drill. (e) Scaffolds 
press-fit into defect sites.  
 
Figure A.7 (a-d) shows the femoral defect surgery. During surgery, no 
complications arose and both operated animals recovered from anaesthesia without 
complications.  
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Figure A.7 (a) Incision of the subcutaneous layer. (b) Retraction of the muscle 
covering the femur. (c) Marking of the defect sites using surgical pen. (d) Defects 
created using trephine drill.    
 
Post-operatively, after the initial 24 hours immobilisation on a custom made 
sling, the animals were released but confined in an enclosed small pen. However, one 
of the two animals experienced femur fracture at day 3. Two weeks post-operatively, 
similar adverse event happened on the second operated animal. As shown in figure 
A.8, the animals experienced spiral fracture on the femur which originated from one 
of the created drill hole defects.  
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Figure A.8 Post-operative x-ray image of sheep femur fracture. 
 
A.3.2 Phase 2: cranial + tibial defect model 
Figure A.9 (a-b) shows the tibial defect created during surgery. During surgery, 
no complications arose. Of the two operated animals, one animal recovered from 
anaesthesia without any complications. The second animal did not recover from 
anaesthesia. After post-mortem, it was found that cause of death was unrelated to the 
surgical procedure, as the sheep was found to have caseous lymphadenitis (CLA). 
 
Figure A.9 (a) The 10 holes bone plate was fixed medially on the tibia with four 
screws each on the distal and proximal end. (b) Scaffolds were press-fit into the 
defect site and secured in place. 
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Due to the adverse events in phase 1; the post-operative care of phase 2 was 
amended. The animal was immobilised in an improved version of the custom-made 
sling, where the operated limb can be elevated from the ground, mimicking the post-
operative care of humans after an orthopaedic surgery. After a week, the animal was 
released from the sling, but confined in an indoor floor pen for up to a month. Then, 
the animal was transferred to an outdoor confined yard. However, 2 days after the 
transfer, the animal experienced tibia fracture as shown in figure A.10. The pilot 
study was thus stopped and the sheep was euthanised. 
 
Figure A.10 Post-operative x-ray image of sheep tibia fracture. 
  
From both phase 1 and 2 of the study, no complications arose from the cranial 
defect throughout the lifetime of the animals.  
 
A.4 DISCUSSIONS  
The aim of this study is to establish a bi-defect sheep model to enable the direct 
comparison of the same biomaterials’ bone regeneration potential and pattern in flat 
bone versus long bone. During this initial establishment stage, many challenges have 
been encountered; especially the occurrence of adverse events associated with 
fractured femur or tibia post-operatively.  
In phase 1 of the study, the operated sheep experienced femur fracture post-
operatively. A similar surgical approach for creating cortical defect on sheep femur 
was employed by [302, 303], with no reported post-operative complications. In their 
studies, five drill holes with diameter of 5 mm were created on the lateral diaphysis 
of sheep femur. Post-operatively, the sheep were caged individually for 3 weeks 
post-operatively [302, 303]. In our study, four drill holes measuring 6 mm were 
created on the lateral diaphysis of sheep femur. Post-operatively, the sheep were 
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immobilised for the first 24 hours and subsequently released to an indoor confined 
yard and housed in a group of two. Both the different drill hole size and post-
operation care procedures may have contributed to the adverse events that happened. 
As reported by Edgerton et al. [301] and Hipp et al. [309], a slight increase of 
circular defect diameter on cortical bone of the femur can have detrimental effects on 
the bone’s mechanical strength, although it was not anticipated in this study to be so 
prevalent given that only 4 drill holes were made as opposed to the published 5 of 
[302, 303]. Additionally, when housed in groups, behaviour and movement of sheep 
can be unpredictable. Although spot monitoring on sheep were carried out by 
investigators to ensure the wellness of the sheep, the movements of the sheep were 
not restricted. Additionally, when housed together, the sheep behaviour can be 
unpredictable, thus leading to the fracture of the femur.  
In phase 2 of the study, a tibia fixation plate was utilised with the aim to 
provide additional support to the operated limb. However, after two days in the 
outdoor yard, the sheep experienced a tibial fracture. By distant observation, the 
sheep was seen to run and jump to approximately 2.5 feet high several times.  This 
hyperactive behaviour of sheep may have inflicted the fracture. The fixation plate did 
not perform as well as in our previous studies, whereby the fixation plate was used to 
stabilise a 3 cm tibia segmental defect [7, 207]. This may be because there is no 
physical barrier that prevents load bearing through the tibia. During load bearing, 
stress was concentrated around the periphery of the drill holes as reported by Zioupos 
et al. [310], this is in line with the fracture line observed in figure A.10, which 
indicated that the fracture had originated from the drill hole. In order to avoid load 
transfer through the tibia, perhaps a 3 mm osteotomy line can be created to act as a 
physical barrier, thereby redirecting the applied load to transfer through the fixation 
plate.  
Collectively, from this initial establishment stage of bi-defect sheep model, 
further refinement on the surgical approach and post-operative care utilised in phase 
2 of the study is required to successfully establish the model. Perhaps, for the next 
phase of the study, the reduction in number of drill holes on the tibia should be 
consider to minimised the number of weak points introduces to the tibia. The 
successful establishment of this propose bi-defect sheep model, will enable new 
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insights into biomaterial regeneration potential and pattern which has never been 
explored previously.  
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